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26 Abstract
27 Infections of antibiotic-resistant pathogens pose an ever-increasing threat to mankind. The 
28 investigation of novel approaches for tackling the antimicrobial resistance (AMR) crisis must be part 
29 of any global response to this problem if an untimely reversion to the pre-penicillin era of medicine is 
30 to be avoided. One such promising avenue of research involves so-called antibiotic resistance 
31 breakers (ARBs), capable of re-sensitising resistant bacteria to antibiotics. Although some ARBs have 
32 previously been employed in the clinical setting, such as the β-lactam inhibitors, we posit that the 
33 broader field of ARB research can yet yield a greater diversity of more effective therapeutic agents 
34 than have been previously achieved. This review introduces the area of ARB research, summarises the 
35 current state of ARB development with emphasis on the various major classes of ARBs currently 
36 being investigated and their modes of action, and offers a perspective on the future direction of the 
37 field.
Page 2 of 123
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
3
38 1. Introduction
39 Since their discovery more than 70 years ago, antibacterial drugs have become an essential part of the 
40 modern healthcare landscape, allowing treatment of previously life-threatening bacterial infections. 
41 However, ever-increasing levels of antimicrobial resistance (AMR) threaten the health benefits 
42 achieved with antibiotics and this phenomenon is recognised as a global crisis (Ventola, 2015). Over 
43 the period of 2011-2014, the percentage of Klebsiella pneumoniae infections resistant to 
44 fluoroquinolones, third-generation cephalosporins or aminoglycosides, as well as combined resistance 
45 to all three antibiotic groups, has increased significantly in Europe, with a similar trend also observed 
46 for Escherichia coli infections (ECDC, 2015). With AMR currently estimated to be responsible for 
47 50,000 deaths annually across the US and Europe, urgent action needs to be taken on an international 
48 scale if the modern antibiotic treatment paradigm is to survive (O'Neil, 2014). It should be noted that 
49 this review will discuss approaches to overcome bacterial resistance, but AMR refers to resistance 
50 caused by all microbes against their respective drugs.
51 While figures vary between different regions, the general trend is that poorer countries are 
52 experiencing much higher levels of resistance. This is likely due to several factors, including greater 
53 availability of second- and third-line treatments in ‘First World’ countries compared to their ‘Third 
54 World’ counterparts. Additionally, regional instances of higher resistance levels can have a global 
55 effect, with the advent of rapid intercontinental travel allowing the dissemination of resistant bacterial 
56 strains globally. It has been suggested that regional resistance levels could affect international travel 
57 and commerce, with people less likely to be willing to travel to areas where they could develop 
58 problematic bacterial infections. That AMR levels are only rising, despite implementation of 
59 additional healthcare measures in the more economically developed countries of the world, highlights 
60 the need for novel approaches to tackling the AMR problem (O'Neil, 2014).
61
62 The effects of antibacterial resistance are not limited to those patients who develop bacterial 
63 infections; wider medical procedures stand to be impacted. Antibiotic prophylaxis is commonly 
64 employed, both preoperatively for a variety of surgical procedures and for immunocompromised 
Page 3 of 123
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
4
65 patients undergoing chemotherapy, to avoid the development of infections (Wenzel, 1992, Teillant et 
66 al., 2015, Crader & Bhimji, 2018). Such prophylactic measures will no longer be possible if AMR 
67 spreads at its current rate, which could in turn impact the scope of surgical procedures available to 
68 clinicians and the quality of patients’ lives (O'Neil, 2014.).
69 The ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella 
70 pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species), whilst 
71 not the only problematic pathogens, have been identified as requiring special attention since they are 
72 responsible for the majority of hospital-acquired infections per annum and show high incidences of 
73 AMR (Rice, 2008). With recent observations of strains of Gram-negative ESKAPE bacteria 
74 possessing multiple mechanisms of resistance to carbapenems, the drugs of last resort used to treat 
75 such infections, the need for new classes of antibiotics with novel modes of action is greater than ever 
76 (Limansky et al., 2002, Mena et al., 2006, Rodriguez-Martinez et al., 2009, Papp-Wallace et al., 
77 2011). However, since the 1960s only two new antibiotic classes have been released and the scientific 
78 community has been unable to keep pace with the emergence of resistance (Coates et al., 2011).
79 Investment in antibiotic research by major pharmaceutical companies has declined sharply in 
80 recent years, mainly because of the lack of return in investments. Besides a long and difficult 
81 regulatory process for new drugs to navigate (Ventola, 2015), antibiotics are typically short term 
82 treatments meaning such drugs bring in less revenue for pharmaceutical companies when compared to 
83 drugs that are intended to treat long term conditions. In addition, the rise of other infectious diseases 
84 with different causative agents, such as acquired immune deficiency syndrome, has caused a shift in 
85 focus within the industry, often resulting in reduced budgets available for antibiotics research and 
86 development (Alanis, 2005). With healthcare policy increasingly inclined towards the saving of new 
87 antimicrobials for treatment of resistant infections, change is required to make antibiotic development 
88 more attractive. Solutions include research incentives, such as the Innovative Medicines Initiative 
89 “New Drugs for Bad Bugs” workstream which funds antimicrobial discovery research between 
90 academics/small enterprises and large companies, simplification of the regulatory landscape, such as 
91 the proposed FDA rapid antibacterial approval pathway LPAD (Limited Population Antibacterial 
92 Drug), and re-evaluation of the prices of antibiotics in order to provide companies with a better return 
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93 on their investments (Sukkar, 2013). Until the implementation of such incentives results in an 
94 increased volume of new antibiotic candidates reaching and passing the clinical trial hurdle, interim 
95 strategies must be explored to preserve the current clinical arsenal of antibiotics.
96
97 2. Antimicrobial Resistance
98 There are four main molecular mechanisms by which bacteria may resist the effects of antibiotics; 
99 modification of the target site, modification or destruction of the antibiotic, antibiotic efflux via efflux 
100 transporters and reduced antibiotic influx through decreased membrane permeability (Figure 1) 
101 (Munita & Arias, 2016). These resistance mechanisms can be present together in different 
102 combinations in one bacterial cell, potentially allowing high level resistance to multiple antibiotic 
103 compounds simultaneously (Nikaido, 2009). Some bacteria possess an innate insensitivity towards 
104 certain classes of antibiotics (intrinsic resistance), either through naturally possessing any of the above 
105 mechanisms in the absence of artificial antibacterial selection pressure (ampicillin resistance in 
106 Klebsiella spp.), lack of the antibiotic target (vancomycin resistance in lactobacilli) or lack of a 
107 metabolic pathway or enzyme necessary for the activation of the drug (metronidazole resistance in 
108 aerobic bacteria) (Bryan & Kwan, 1981, Schaechter et al., 2007).
109 Resistance towards antibiotics is acquired by bacteria through either vertical evolution 
110 (endogenous) or horizontal evolution (exogenous). Vertical evolution involves the occurrence of a 
111 spontaneous mutation within the bacterial genome that confers on the bacterium (and subsequently its 
112 progeny) increased resistance to a given compound. The process to achieve high level resistance is 
113 often stepwise, wherein the selection pressure of antibiotic treatment causes an initial mutation that 
114 allows domination of the pathogen population by the mutant bacteria, followed by subsequent 
115 additional mutations that confer an additional survival advantage during further antibiotic therapy. 
116 Though mutation frequencies can often be as low as 10-8, this is offset by the vast numbers of cells in 
117 bacterial colonies (Drlica & Perlin, 2011). Work by Santos Costa et al. into fluoroquinolone resistance 
118 in S. aureus showed that, in this case at least, an intermediate resistance phenotype (via upregulation 
119 of efflux pump expression) is first to appear and acts as a platform from which higher level resistance 
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120 mutations can occur by ensuring a sub-lethal intracellular fluoroquinolone concentration (Santos 
121 Costa et al., 2015).
122 Horizontal evolution involves the transfer of a resistance gene from a resistant bacterium to a 
123 susceptible bacterium. The mechanisms through which it can occur are conjugation, transduction and 
124 transformation. Conjugation involves the transfer of resistance (R) plasmids containing antibiotic 
125 resistance genes between bacteria through a conjugative pilus, whilst transformation refers to the 
126 alteration of the bacterial genome through the uptake and incorporation of exogenous DNA and 
127 transduction involves transfer of bacterial DNA as facilitated by a viral vector. Such transfer 
128 mechanisms potentially allow a mechanism acquired by less problematic bacterial strains to spread to 
129 a more dangerous bacterial species, with potentially devastating consequences (Alanis, 2005).
130 The genes encoding different resistance mechanisms are often located on transposons, which 
131 makes it easier for them to be transmitted between different bacteria, and some transposons may 
132 contain specialised regions called integrons able to include different resistant genes, thereby making a 
133 bacterial species resistant to multiple different antibiotics (Alanis, 2005). In addition, bacteria can also 
134 have physical states which aid in resisting antibacterial pressure. A variety of both Gram-positive and 
135 Gram-negative bacterial species are known assemble in biofilms (Abee et al., 2011), hydrated 
136 matrices of extracellular polymeric substance in which the bacterial cells are embedded allowing 
137 adherence to both each other and external surfaces. Such structures become problematic when located 
138 in urinary catheters or on medical implants; since biofilms are harder for antibiotics to penetrate at 
139 lethal concentrations, the biofilm provides resistance to antibiotic action (Donlan, 2002). The bacterial 
140 population within the biofilm can also enter into a dormant state where they are not actively growing, 
141 and this can also contribute to antibiotic resistance(Gilbert et al., 1990, Wood et al., 2013). 
142
143 3. Antibiotic Resistance Breakers
144 To tackle the increasing emergence of AMR, alternative treatment strategies have been designed with 
145 the collective aim of reducing the number of antibiotics used and preserving the current classes of 
146 antibiotic for further clinical use. This review aims to showcase the potential of one such strategy, the 
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147 use of antibiotic resistance breakers (ARBs). These are compounds that can increase the effectiveness 
148 of current antibiotics by combatting the resistance mechanisms employed against them. ARBs may or 
149 may not have direct antibacterial effects and can either be co-administered with or conjugated to 
150 failing antibiotics. Though ARBs have previously been referred to as antibiotic adjuvants, the latter 
151 also refers to alternative treatments such as drugs which stimulate host defence mechanisms to aid the 
152 eradication of bacterial infections (Gill et al., 2015); as such, this review will be restricted to the 
153 discussion of compounds that are used to reverse bacterial resistance mechanisms. The major classes 
154 of ARBs currently under investigation include modifying-enzyme inhibitors, membrane 
155 permeabilisers and efflux pump inhibitors.
156 The idea of co-administering ARBs with conventional antibiotics stems from dual antibiotic 
157 therapy, which has enjoyed success in the past through either synergistic or additive effects of the 
158 individual antibiotic agents (Kalan & Wright, 2011), and several ARBs have enjoyed lengthy clinical 
159 use including the β-lactamase inhibitors (Drawz & Bonomo, 2010). Successful co-administered ARBs 
160 should enhance the effects of antibiotics by combatting the bacterial resistance mechanisms employed 
161 against the latter, allowing lower doses of antibiotics to be used. The minimum inhibitory 
162 concentration (MIC), the minimal concentration required of a compound to prevent visible growth of 
163 the pathogenic species under defined conditions (Wiegand et al., 2008), is a useful term in this regard; 
164 the more successful ARBs achieve greater reductions in the MICs of antibiotics versus antibiotic 
165 monotherapy. Such potentiation is an attractive prospect, both because reduced antibiotic selection 
166 pressure could slow the onset of resistance and because widening of the therapeutic window may 
167 allow for the alleviation of side effects experienced by patients on antibiotic monotherapy.
168
169 3.1. Modifying Enzyme Inhibitors
170 Bacteria employ a diverse range of enzymes to modify or destroy antibiotics in order to render them 
171 ineffective and achieve a resistant phenotype. These enzymes can be categorised by both their 
172 mechanisms of action and their substrate antibiotics. Hydrolysis of certain susceptible bonds within 
173 the antibiotic molecule, transfer of a functional group to the antibiotic and (less commonly) the 
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174 actions of redox and lyase enzymes are all examples of detoxification mechanisms (Wright, 2005). 
175 This led to the development of antibiotics that would tolerate their actions, such as the β-lactam 
176 flucloxacillin which was designed to tolerate the action of the penicillinases (Sutherland et al., 1970). 
177 A method which has found more success is the design of modifying enzyme inhibitors, a term which 
178 encompasses the wide variety of chemical compounds that target bacterial enzymes involved in 
179 antibiotic modification and destruction. Modifying enzyme inhibitors are used to disrupt bacterial 
180 detoxification enzymes, increasing the effectiveness of a co-administered antibiotic. Two major 
181 classes are the β-lactamase inhibitors and aminoglycoside-modifying enzymes.
182
183 3.1.1. Β-Lactamase Inhibitors
184 The most successful class of ARBs is arguably the β-lactamase inhibitors (BLIs). β-lactam antibiotics 
185 function by interfering with bacterial cell-wall synthesis, binding to and inactivating the C-terminal 
186 transpeptidase domain of penicillin-binding proteins which are responsible for the cross-linking of the 
187 peptidoglycan chains in the cell wall (Fisher et al., 2005). The β-lactams include several frequently 
188 prescribed families of antibiotics such as the penicillins and cephalosporins. They remain the most 
189 widely used class of antibiotics, reported to comprise 65% of the global antibiotic market in 2004 
190 (Elander, 2003), while broad-spectrum penicillins and cephalosporins were reported to be the two 
191 most consumed drug classes globally in 2010 (Van Boeckel et al., 2014). β-lactamases (EC 3.5.2.6) 
192 are bacterial enzymes that hydrolyse the β-lactam rings such drugs possess, inactivating them. 
193 Modification of β-lactam drugs is the major defence mechanism for Gram-negative pathogenic 
194 bacteria, with β-lactamases differing in their mechanisms and their substrate specificities (Wilke et 
195 al., 2005). Of note, carbapenemases can often act on carbapenem drugs and a wide range of other β-
196 lactams, including penicillins, cephalosporins and monobactams (Queenan & Bush, 2007). These 
197 enzymes are of special concern, since carbapenems are generally reserved as a last resort for many 
198 complicated infections, both Gram-positive and Gram-negative (Papp-Wallace et al., 2011).
199 There are two widely accepted classification systems for β-lactamases. The Ambler molecular 
200 classification divides them into classes A-D based on sequence homology, each of which function via 
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201 slightly different mechanisms. All four classes hydrolyse the β-lactam ring, but enzymes of classes A, 
202 C and D do so through use of a serine nucleophile, whereas those of class B require a metal cofactor, 
203 usually a zinc atom, to achieve the same effect. Because of the need for the metal cofactor, class B β-
204 lactamases may also be referred to as metallo-β-lactamases (MBLs) (Ambler, 1980). An alternative 
205 classification, known as the Bush-Jacoby-Medeiros functional classification, is based on substrate 
206 specificity and includes four main groups based on inhibitor profile, with group 2 further divided into 
207 several subgroups (Bush & Jacoby, 2010). The extended spectrum β-lactamases (ESBLs), often 
208 loosely defined as β-lactamases which confer resistance against penicillins, aztreonam and first, 
209 second and third generation cephalosporins, are recognised as particularly problematic. ESBLs may 
210 be regarded as members of class A of the Ambler molecular classification; with the OXA-type β-
211 lactamases being an exception, named after their ability to hydrolyse oxacillin and members of class 
212 D. Carbapenems are usually regarded as the drugs of choice to eradicate strains possessing ESBLs. 
213 However, several ESBL-producing clinical isolates have been identified which are resistant to 
214 carbapenems (Paterson & Bonomo, 2005). For example, a P. aeruginosa strain has been identified 
215 which produces both the ESBL PER-1 and the carbapenemase VIM-2 (Docquier et al., 2001).
216 Several BLIs widely used in the clinical setting are themselves β-lactam compounds. One 
217 well documented example is clavulanic acid (Figure 2), commonly sold as the combination products 
218 co-amoxiclav (combined with the β-lactam amoxicillin; marketed by GlaxoSmithKline as 
219 Augmentin®) and co-ticarclav (combined with ticarcillin; marketed by GlaxoSmithKline as 
220 Timentin®). While clavulanic acid displays poor antimicrobial activity in vivo (Reading et al., 1983), 
221 its β-lactamase inhibitory activity affords the co-administered β-lactam protection from enzymatic 
222 degradation (Bush, 1988). Predominantly active against Ambler class A β-lactamases, clavulanic acid 
223 irreversibly acylates the catalytic serine residue, resulting in an inactive acyl-enzyme complex. 
224 Clavulanic acid has been shown to inhibit the plasmid-encoded β-lactamases of E. coli and S. aureus, 
225 but not the chromosomally-encoded versions found in Pseudomonas and Enterobacter strains 
226 (Wright, 1999). Thus, co-amoxiclav has activity against both amoxicillin-sensitive and select 
227 amoxicillin–resistant strains of clinically-relevant pathogenic microorganisms. However, Leflon-
228 Guibout et al. studied co-amoxiclav resistance in E. coli clinical isolates, defined by an MIC greater 
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229 than 16 μg mL-1, in 14 French hospitals from 1996 to 1998 and found that the overall resistance rate 
230 was 5% with most resistant isolates identified in patients with respiratory tract infections (Leflon-
231 Guibout et al., 2000). Such reports of resistance to the established BLIs (Drawz & Bonomo, 2010) 
232 have driven fresh efforts into finding novel alternatives.
233 Sulbactam (CP-45,899; developed by Pfizer (English et al., 1978)) and tazobactam (YTR 830 
234 H; developed by Taiho Pharmaceutical Co. (Aronoff et al., 1984)) are both penicillanic acid sulfones 
235 with β-lactamase inhibitory activity (Figure 2). Both compounds inhibit TEM-type β-lactamases 
236 (IC50s of 0.03 and 0.01 against TEM-3, respectively), though sulbactam is far less effective against 
237 SHV- and OXA-type β-lactamases (Payne et al., 1994). Available combinations of sulbactam with β-
238 lactam antibiotics include ampicillin-sulbactam, which shows limited activity against ESBL-
239 producers including strains of E. coli and K. pneumoniae (Rafailidis et al., 2007), and cefoperazone-
240 sulbactam, effective against ESBL-positive strains of Pseudomonas spp., Acinetobacter spp., 
241 Klebsiella spp. and E. coli (Bodey et al., 1989, Mohanty et al., 2005). Sulbactam has also been shown 
242 to inhibit penicillin binding protein 3 in Acinetobacter spp., granting it direct antibacterial activity 
243 against this genus (Penwell et al., 2015).
244 Combinations of β-lactams and tazobactam currently in clinical use include ceftolozane-
245 tazobactam and piperacillin-tazobactam. Ceftolozane-tazobactam was approved in December 2014 by 
246 the FDA for treatment of complicated intra-abdominal and urinary tract infections and shows activity 
247 against multidrug-resistant (MDR) P. aeruginosa (MIC50 2 μg mL-1; MIC90 8 μg mL-1), ESBL-
248 negative K. pneumoniae (MIC50 0.25 μg mL-1; MIC90 0.5 μg mL-1) and ESBL-positive E. coli (MIC50 
249 0.5 μg mL-1; MIC90 4 μg mL-1), among others. A dose reduction is required for patients with renal 
250 impairment, depending on creatinine clearance (Cho et al., 2015). In comparison, work by Mohanty et 
251 al. demonstrated the piperacillin-tazobactam combination, approved by the FDA in 1993 (Shlaes, 
252 2013), to have superior percentage coverage of ESBL-positive strains of Pseudomonas spp., 
253 Klebsiella spp., E. coli, Enterobacter spp. and Citrobacter spp. versus cefoperazone-sulbactam and 
254 ticarcillin-clavulanic acid (Mohanty et al., 2005). In India, the cephalosporin cefepime has been used 
255 with tazobactam and this combination is gaining ground as an attractive new prospect for the 
256 treatment of MDR Gram-negative pathogens (Bush, 2015, Livermore et al., 2018).
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257 Brobactam (BRL 25214; Figure 2), structurally similar to sulbactam and tazobactam, was 
258 developed by LEO Pharma A/S as another β-lactamase inhibitor (Wise et al., 1992). The work of 
259 Melchior and Keilding demonstrated that brobactam alone possessed 8-50 fold higher potency than 
260 clavulanic acid against chromosomally-encoded cephalosporinase enzymes in Enterobacteriaceae and 
261 that an ampicillin-brobactam combination held superior activity in vitro to co-amoxiclav against 
262 Proteus vulgaris, Morganella morganii, Citrobacter freundii and Yersinia enterocolitica (Melchior & 
263 Keiding, 1991). However, despite favourable results for a combination of brobactam and the β-lactam 
264 prodrug pivampicillin from an eight-person tolerability study (Wise et al., 1992), development of 
265 brobactam appears to have been discontinued and it is not available for use in the clinic.
266 AAI101 (Figure 2), a novel penicillanic acid sulfone similar in structure to tazobactam, is an 
267 ESBL inhibitor active against some class A and D carbapenemases (Mushtaq, 2014, Nordmann, 2014) 
268 that is being developed by Allecra Therapeutics as a combination therapy with cefepime. Crandon and 
269 Nicolau reported that the combination (using 8 μg mL-1 of AAI101) was effective against a panel of 
270 223 cefepime-resistant Enterobacteriaceae isolates, improving on the MIC50 of cefepime by over 512-
271 fold (Crandon, 2014, Crandon & Nicolau, 2015). They subsequently demonstrated a strong 
272 correlation between increasing AAI101 concentration and MICs for the cefepime-AAI101 
273 combination in K. pneumoniae-infected female ICR mice between 1 and 16 μg mL-1 (Crandon & 
274 Nicolau, 2015). As of 2017, the combination is in phase II clinical trials (Papp-Wallace, 2017).
275 As early as the late 1980s, nosocomial isolates resistant to combination therapies involving 
276 the aforementioned β-lactam-based BLIs were being reported (Legrand et al., 1988, Ling et al., 1988, 
277 Eliopoulos et al., 1989, Cullmann & Stieglitz, 1990). New BLIs were required for the next generation 
278 of combination treatments, and to this end classes of structurally divergent compounds with BLI 
279 activity were investigated. One such class of newer, non-β-lactam BLIs is the diazabicyclooctanes 
280 (DABCOs), based on a (5R)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl sulphate core (Figure 3). The 
281 strained nature of this core, further activated towards nucleophilic attack through the incorporation of 
282 a sulphate group on one nitrogen of the urea functionality, underlies the β-lactamase inhibitory 
283 activities of the DABCOs (Mangion et al., 2011). Figure 3 and Table 1 list the structures of the 
284 compounds in this class either approved for clinical use or currently in development.
Page 11 of 123
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
12
285 Avibactam (NXL104; developed by Actavis and AstraZeneca; Table 1), when approved for 
286 clinical use in the US in 2015, was both the first DABCO brought to market and the first new BLI 
287 approved in 22 years (Garber, 2015). A comparison by Stachyra et al. of avibactam with clavulanic 
288 acid, sulbactam and tazobactam showed the former to be superior in inhibitory activity for all Ambler 
289 class A and C β-lactamases tested, including TEM-1, KPC-2 and SHV-4; investigation of the mode of 
290 action revealed that avibactam covalently modifies a catalytic serine residue in the β-lactamase active 
291 site in the same manner as the penicillanic sulfones, but that the highly stable nature of the carbamyl-
292 enzyme complex underpins its enhanced inhibitory activity (Stachyra et al., 2010). In combination 
293 with the third-generation cephalosporin ceftazidime (marketed as Avycaz® in the US by Allergan and 
294 as Zavicefta® in Europe by Pfizer), it is approved by the FDA for the treatment of complicated intra-
295 abdominal infections in combination with metronidazole and for the treatment of complicated urinary 
296 tract infections (Mosley et al., 2016, Wright, 2016). The combination has broad Gram-negative 
297 activity, including Enterobacteriaceae and P. aeruginosa (Crandon et al., 2012, Flamm et al., 2014, 
298 Chalhoub et al., 2015, Sader et al., 2015), and was found to be superior to ceftazidime alone against 
299 120 KPC-producing carbapenem-resistant Enterobacteriaceae clinical isolates in a study by 
300 Castanheira and co-workers in 2015 (Castanheira et al., 2015). However, while a subsequent study by 
301 Castanheira et al. found 99.3% of Enterobacteriaceae isolates from US hospitals between 2012 and 
302 2015 were be susceptible to ceftazidime-avibactam (Castanheira et al., 2017), Shields et al. have since 
303 detailed the first instances of K. pneumoniae ceftazidime-avibactam resistance in patients treated with 
304 the combination for 10-19 days. They identified the causes of said resistance to be mutations (chiefly 
305 a D179Y/T243M double mutation) in the plasmid-located blaKPC-3 gene (Shields et al., 2017). As with 
306 ceftolozane-tazobactam, patients with renal impairment require a dose reduction according to 
307 creatinine clearance levels (Mosley et al., 2016). The separate combinations of avibactam and both 
308 ceftaroline and aztreonam are in late-stage clinical trials (ClinicalTrials.gov, NCT03329092) (Wright, 
309 2016).
310 Another DABCO in late stage development is relebactam (MK-7655; Merck & Company, 
311 Inc.; Table 1), currently being investigated for combination with the carbapenem imipenem and the 
312 dehydropeptidase I inhibitor cilastatin (the latter employed to prevent degradation of imipenem in the 
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313 kidneys). The structure of relebactam is similar to that of avibactam, with a piperazine ring added to 
314 the nitrogen of the C2 amide substituent (Mangion et al., 2011). Zhanel et al. have recently compiled 
315 a series of modal MIC50 and MIC90 values for both imipenem and imipenem-relebactam based on a 
316 review of available in vitro studies; they report that relebactam enhances the activity of imipenem 
317 versus the majority of Enterobacteriaceae, including KPC-producing K. pneumoniae (>16 fold 
318 reduction in MIC90), and imipenem-resistant P. aeruginosa (8-fold reduction), though no 
319 enhancement was observed against KPC-producing P. aeruginosa or A. baumannii (Zhanel et al., 
320 2018). As of September 2017, Merck have completed a phase III trial for evaluation of the safety and 
321 efficacy of the imipenem-cilastatin-relebactam combination versus imipenem-cilastatin-colistimethate 
322 sodium in treatment of imipenem-resistant bacterial infections (ClinicalTrials.gov, NCT02452047). A 
323 number of clinical trials are currently underway involving imipenem-cilastatin-relebactam, including 
324 a phase III trial in Japan investigating treatment of complicated intra-abdominal infections and 
325 complicated urinary tract infections (ClinicalTrials.gov, NCT03293485), a phase III noninferiority 
326 trial versus piperacillin-tazobactam for treatment of hospital-acquired and ventilator-associated 
327 bacterial pneumonia (ClinicalTrials.gov, NCT02493764) and a phase I trial investigating the 
328 individual pharmacokinetic profiles of the three drugs following administration (ClinicalTrials.gov, 
329 NCT03230916).
330 In August 2013, Naeja Pharmaceutical Inc. were granted a patent for a promising series of 
331 novel C2 N-(hydroxy)amide and hydrazide DABCOs (Maiti, 2013), subsequently in-licensed to 
332 Fedora Pharmaceuticals (Inc., 2012). Lead compounds identified within this series included FPI-1459, 
333 FPI-1465, FPI-1523 and FPI-1602 and, unlike previous DABCOs, they were found to have multiple 
334 modes of action; in addition to their BLI activities, they act directly as antibacterial agents through 
335 inhibiting penicillin-binding protein 2 and also as potentiators of their accompanying antibiotics in the 
336 absence of β-lactamases (Morinaka et al., 2015, King et al., 2016, Bush & Page, 2017, Bush, 2018). 
337 Meiji Seika Pharma and Fedora Pharmaceuticals partnered with F. Hoffmann la Roche in January 
338 2015 (Philippidis, 2015) to further develop FPI-1459, renamed nacubactam (RO7079901, previously 
339 OP0595, RG6080). In separate papers, Morinaka and co-workers investigated the ability of 
340 nacubactam to resensitise CTX-M-15 positive E. coli, KPC-positive K. pneumoniae and AmpC-
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341 derepressed P. aeruginosa to piperacillin, meropenem and cefepime both in vitro and in vivo; they 
342 found 4 μg mL-1 of nacubactam sufficient to achieve mean MICs of <0.03 in vitro for all three β-
343 lactams in the E. coli and K. pneumoniae strains tested (Morinaka et al., 2016). At this concentration, 
344 only the cefepime combination achieved a mean MIC below 2 μg mL-1 in the P. aeruginosa strains 
345 tested, indicating cefepime to be the optimal β-lactam partner for nacubactam (Morinaka et al., 2017). 
346 Nacubactam was also observed to retain its β-lactam enhancer effect in Enterobacteriaceae possessing 
347 nacubactam-resistant metallo-β-lactamases (Livermore et al., 2016). Having completed a phase I trial 
348 in 2014 to assess safety and tolerability in adult Caucasian males (ClinicalTrials.gov, NCT02134834), 
349 nacubactam (Table 1) has since been involved in a number of other phase I trials and appears to be in  
350 development in combination with meropenem for the treatment of meropenem-resistant Gram-
351 negative infections (ClinicalTrials.gov, NCT03182504, NCT03174795, NCT02972255 & 
352 NCT02975388).
353 Previously known as WCK 5107, zidebactam (Table 1) is in development by Wockhardt Ltd 
354 (Bush & Page, 2017) and was originally patented in 2013 (Patel, 2013). Zidebactam inhibits class A, 
355 C and select class D β-lactamases (Khande, 2016) and, like nacubactam, possesses both direct activity 
356 against MDR Gram-negative bacteria (Deshpande, 2016) and the capability to augment the activity of 
357 β-lactams in the absence of β-lactamases (Livermore, 2016) in a number of species including A. 
358 baumannii (Moya et al., 2017) and P. aeruginosa (Moya et al., 2017). A combination with cefepime, 
359 also known as WCK 5222 and FED-ZID, was shown to be effective in vitro against a global 
360 collection of 7,876 clinical isolates from 2015, consisting of Enterobacteriaceae, P. aeruginosa and 
361 Acinetobacter spp.; in a 1:1 ratio, the combination achieved MICs below or equal to 4 μg mL-1 in 
362 99.9% of Enterobacteriaceae isolates and MICs below or equal to 8 μg mL-1 in 99.5% of P. 
363 aeruginosa isolates (Sader et al., 2017). These results are in concurrence with a subsequent, smaller 
364 scale study conducted by Sader and co-workers (Sader et al., 2017). However, a separate study by 
365 Livermore and co-workers found cefepime-zidebactam to be ineffective (over 32 μg mL-1) against 
366 Proteeae, Serratia spp. and select strains of E. coli, Klebsiella spp., Enterobacter spp. and Citrobacter 
367 spp. (Livermore et al., 2017). A number of phase I clinical trials have been completed investigating 
368 the safety, tolerability and pharmacokinetics of zidebactam, both alone (ClinicalTrials.gov, 
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369 NCT02674347) and in combination with cefepime (ClinicalTrials.gov, NCT02532140 & 
370 NCT02707107) (Preston et al., 2019).
371 Also in development by Wockhardt Ltd is WCK 5153 (Table 1), a close structural analogue 
372 of WCK 5107 differing only in the nature of the aliphatic ring of the side arm moiety (a 3-subsituted 
373 piperidine in WCK 5107, a 3-subsituted pyrrolidine in WCK 5153). WCK 5153 inhibits class A, C 
374 and some class D β-lactamases, with increased potency versus class C enzymes compared to both 
375 avibactam and relebactam (Papp-Wallace et al., 2018). As for WCK 5107, WCK 5153 shows a β-
376 lactam enhancer effect against A. baumannii (Moya et al., 2017) and P. aeruginosa (Moya et al., 
377 2017), with the combination of cefepime and WCK 5107 achieving MICs of 0.06-4 μg mL-1 in a 
378 panel of P. aeruginosa strains including porin mutants (Moya et al., 2017).
379 Another DABCO in development by Wockhardt Ltd. is WCK 4234 (Table 1). Like 
380 zidebactam, it is active against class A, C and some class D β-lactamases (Patil, 2016). A combination 
381 with meropenem, known as WCK 5999, has been shown to be superior to meropenem monotherapy 
382 against MDR clinical isolates of A. baumannii (Huband, 2016), including OXA-23- and OXA-24-
383 producing strains (Castanheira, 2016, Mushtaq et al., 2017), K. pneumoniae (Castanheira, 2016) and 
384 P. aeruginosa (Huband, 2016).
385 An effort by Entasis Therapeutics towards the rational design of analogues of avibactam with 
386 improved Gram-negative penetration and better activity against class D β-lactamases led to the 
387 discovery of ETX2514 (Figure 3), a DABCO analogue with class A, C and broad class D β-lactamase 
388 inhibitory activity (Durand-Reville et al., 2017). In particular, activity against the class D enzymes 
389 OXA-10, OXA-23 and OXA-24 is significantly improved in ETX2514 versus avibactam (Shapiro et 
390 al., 2017). Rate constants of time-dependent β-lactamase inhibition for ETX2514 (compared to 
391 avibactam) were approximately 100-fold higher for class A and C enzymes and approximately 1000-
392 fold higher for class D β-lactamases. ETX2514 was also observed to be an inhibitor of penicillin 
393 binding protein 2 in E. coli and A. baumannii, helping explain its direct antibacterial activity against 
394 wider Enterobacteriaceae including mcr-1-positive E. coli (MIC90 1 μg mL-1, 10 strains), K. 
395 pneumoniae (MIC90 4 μg mL-1, 20 strains), Enterobacter cloacae (MIC90 1 μg mL-1, 10 strains), 
396 Stenotrophomonas maltophilia (MIC90 16 μg mL-1, 18 strains), Citrobacter spp. (MIC90 2 μg mL-1, 55 
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397 strains) and class B β-lactamase-positive and -negative CRE (MIC90 8 μg mL-1, 32 strains). The 
398 compound was well tolerated up to 2 g kg-1 in both rats and dogs in separate 14-day toxicological 
399 studies (Durand-Reville et al., 2017).
400 Imipenem, meropenem, ceftazidime and aztreonam were combined individually with 
401 ETX2514 (4 μg mL-1) against panels of 202 random E. coli clinical isolates and 202 random P. 
402 aeruginosa clinical isolates, respectively; MIC90 values for all four combinations against the E. coli 
403 panel were below 0.06 μg mL-1, whereas imipenem was the most effective β-lactam partner versus P. 
404 aeruginosa (MIC90 2 μg mL-1). In a similar manner, the same four β-lactams and sulbactam were 
405 trialled with ETX2514 against 198 random K. pneumoniae clinical isolates; in this case, sulbactam 
406 was the most effective partner (MIC90 4 μg mL-1). The sulbactam-ETX2514 combination was further 
407 tested against 1,131 A. baumannii clinical isolates, including MDR, meropenem-resistant and colistin-
408 resistant phenotypes, and improved upon sulbactam monotherapy 16-fold (64 – 4 μg mL-1) (Durand-
409 Reville et al., 2017). McLeod et al. investigated the frequency of spontaneous resistance to 
410 sulbactam-ETX2514 in four different A. baumannii clinical isolates and found it to be low (<9.0 × 
411 10−10 frequency at 4x MIC of combination) with no ETX2514-resistant β-lactamases detected in 
412 resistant mutants (McLeod et al., 2018). ETX2514 has completed an open-label, phase I study 
413 (Rodvold et al., 2018) in 30 healthy adults in combination with sulbactam and a 124-person trial both 
414 alone and in combination with sulbactam compared with imipenem/cilastatin and a placebo to 
415 evaluate its safety, tolerability and pharmacokinetic profile (ClinicalTrials.gov, NCT02971423). As of 
416 April 2018, the combination is undergoing a phase I trial in 30 patients with varying degrees of renal 
417 impairment (ClinicalTrials.gov, NCT03310463) and phase II trial in 80 patients with complicated 
418 urinary tract infections (ClinicalTrials.gov, NCT03445195).
419 Also in development by Entasis Therapeutics is the DABCO ETX0282, an oral prodrug of 
420 ETX1317 (structures not yet disclosed). ETX1317, in line with other members of this class of BLI, 
421 enjoys activity against class A, C and D β-lactamases. Like ETX2514, it is an inhibitor of penicillin 
422 binding protein 2 in E. coli, affording the compound intrinsic antimicrobial activity. Based on testing 
423 in combination against a SHV-18, OXA-2 and OKP-6 positive strain of K. pneumoniae, cefpodoxime 
424 was selected as the optimal partner for ETX1317 at 4 μg mL-1 of the latter (Durand-Réville, 2017). 
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425 Pharmacokinetic studies in both rats and dogs showed both the prodrug and active form to have high 
426 bioavailabilities (>90%) and similar elimination half-lives to cefpodoxime. The combination of 
427 ETX0282 and cefpodoxime was effective at the three concentrations of BLI tested (10, 25 and 100 mg 
428 kg-1; cefpodoxime proxetil fixed at 50 mg kg-1) against E. coli ARC2687 in a neutropenic murine 
429 thigh infection model and against CRE K. pneumoniae ARC5118 at 200 and 400 mg kg-1 BLI 
430 concentrations (O’Donnell, 2017). In addition, the combination of cefpodoxime and 4 μg mL-1 
431 ETX1317 was active against 33 of a 35 isolate panel of KPC and/or MBL-positive Enterobacteriaceae 
432 (MICs <0.5 μg mL-1), outperforming ceftazidime and 4 μg mL-1 avibactam (McLeod, 2017). 
433 ETX0282 is currently undergoing a phase I clinical trial in healthy volunteers to evaluate 
434 pharmacokinetics and safety (ClinicalTrials.gov, NCT03491748).
435 Originally developed by LegoChem Biosciences (South Korea) as LCB18 0055, as of 
436 September 2017 Geom Therapeutics have secured a worldwide license excluding South Korea to 
437 further develop this DABCO, renamed GT-055 (Table 1), in combination with the novel siderophore-
438 conjugated cephalosporin GT-1 (also developed by LegoChem Biosciences and subsequently licensed 
439 to Geom Therapeutics) (AdisInsight, 2017). GT-055 is active against class A, C, D and some class B 
440 β-lactamases, has intrinsic activity against some Enterobacteriaceae and is reported to potentiate GT-1 
441 against MDR strains of A. baumannii and P. aeruginosa (Thye, 2018). Against a panel of 334 
442 Enterobacteriaceae clinical isolates, GT-055 was observed to increase GT-1 activity against MBL-
443 positive E. coli and K. pneumoniae strains (MIC50/90 4/8 μg mL-1 for both), including porin/efflux 
444 mutant strains (16-fold lower MIC90, from 64 μg mL-1 to 4 μg mL-1) (Sader, 2018). The combination 
445 was found to improve upon GT-1 alone in a K. pneumoniae murine infection model (Oh, 2018). The 
446 combination showed activity against the biothreat pathogen Yersinia pestis, both in vitro (MIC range 
447 <0.03-2 μg mL-1) and in mice (90% survival at 30 days post-challenge, dosing 200 mg kg-1 GT-1 and 
448 300 mg kg-1 GT-055) (Zumbrun, 2018). GT-055 has also been shown to potentiate GT-1 in strains of 
449 E. coli with ESBLs that afford greater protection against the latter, such as CTX-M-15, and in strains 
450 of K. pneumoniae with DHA-1 AmpC (Phuong, 2018).
451 Boronic acid transition state inhibitors (BATSIs) are a novel class of BLIs with activity 
452 against serine β-lactamases. BATSIs are characterised by the presence of a boronic acid functionality, 
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453 cyclic or acyclic, within the molecule; the electrophilic nature of the boron atom imitates the 
454 electrophilic carbonyl centre of a β-lactam ring, but nucleophilic attack by the catalytic serine residue 
455 of a β-lactamase generates a tetrahedral enzyme-BATSI adduct, inhibiting the enzyme in a 
456 competitive, reversible manner (Rojas et al., 2016).
457 Of the BATSIs, vaborbactam (RPX7009; developed by Rempex Pharmaceuticals, Inc., A 
458 Subsidiary of The Medicines Company; Figure 4) is currently the furthest advanced with respect to 
459 clinical development. Hecker et al. report that it shows inhibition of a broad spectrum of class A, C 
460 and D enzymes, including KPC, CTX-M, SHV, and CMY, and improves upon both clavulanic acid 
461 and tazobactam against KPC-2, P99 and CMY-2 (Hecker et al., 2015). Originally partnered with the 
462 carbapenem biapenem (RPX2003, also developed by Rempex Pharmaceuticals) (Livermore & 
463 Mushtaq, 2013), Goldstein and co-workers found the combination improved upon biapenem 
464 monotherapy against select anaerobic Gram-negative bacteria (Bacteroides fragilis, Bacteroides 
465 ovatus and Fusobacterium mortiferum) but not significantly for any anaerobic Gram-positive bacteria 
466 tested (Goldstein et al., 2013). Livermore and Mushtaq found vaborbactam itself to lack any direct 
467 antibacterial activity, but found the biapenem-vaborbactam combination to improve upon biapenem 
468 alone against a panel of 145 KPC-positive Enterobacteriaceae isolates (94.4% of isolate MICs below 
469 1 μg mL-1 for combination vs. 5.5% for biapenem alone) at a vaborbactam concentration of 8 μg mL-1 
470 (Livermore & Mushtaq, 2013). A combination with the cephalosporin cefepime at 4 μg mL-1 
471 vaborbactam was active in vitro against a panel of 13 Enterobacteriaceae expressing class A, C and D 
472 β-lactamases, showing 2 - 256-fold potentiation of cefepime across the panel, and vaborbactam also 
473 potentiated the carbapenems biapenem, meropenem, ertapenem and imipenem up to 512-fold versus a 
474 panel of 11 Enterobacteriaceae expressing class A carbapenemases (Hecker et al., 2015).
475 Lapuebla and co-workers evaluated the meropenem-vaborbactam combination 
476 (Carbavance®) at 8 μg mL-1 vaborbactam in vitro against a collection of 4,500 Gram-negative clinical 
477 isolates from 11 New York City hospitals and found it to be highly active against KPC-producing 
478 Enterobacteriaceae including E. coli, Enterobacter spp. and K. pneumoniae. 98.5% of KPC-producing 
479 Enterobacteriaceae strains showed MICs below 1 μg mL-1, but vaborbactam did not potentiate 
480 meropenem against A. baumannii and P. aeruginosa. In addition, K. pneumoniae isolates with 
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481 reduced expression of genes ompK35 and ompK36 were less susceptible to the combination (Lapuebla 
482 et al., 2015). A number of subsequent studies (Castanheira et al., 2016, Castanheira et al., 2017, 
483 Lomovskaya et al., 2017, Hackel et al., 2018, Pfaller et al., 2018) were in agreement with these 
484 findings; together, they note a number of additional factors that contribute to increased MICs for 
485 meropenem-vaborbactam in K. pneumoniae isolates, including possession of metallo-β-lactamases, 
486 reduced expression of ompK37, increased expression of the AcrAB-TolC efflux system (Castanheira 
487 et al., 2016) and possession of class B or D carbapenemases (Lomovskaya et al., 2017). Sun and co-
488 workers found the frequency of spontaneous resistance to the combination to be <1 × 10-8 in 77.8% of 
489 a panel of KPC-producing K. pneumoniae strains at 8 μg mL-1 of both meropenem and vaborbactam 
490 (Sun et al., 2017). Reports by Weiss et al. and Sabet et al. demonstrated that the combination is active 
491 in a murine pyelonephritis model (Weiss et al., 2018), an in vitro hollow fibre model (Sabet et al., 
492 2018) and murine thigh and lung infection models (Sabet et al., 2018), respectively.
493 Vaborbactam has completed a number of phase I clinical trials alone (Griffith et al., 2016) 
494 and in combination with biapenem (ClinicalTrials.gov, NCT01772836) and meropenem 
495 (ClinicalTrials.gov, NCT02073812) (Rubino et al., 2018, Rubino et al., 2018). The meropenem-
496 vaborbactam has completed two phase III trials, evaluating its use against complicated urinary tract 
497 infections (Kaye et al., 2018) and infections of carbapenem-resistant Enterobacteriaceae (Wunderink 
498 et al., 2018), and the FDA approved the combination for the former indication in August 2017 
499 (McCarthy & Walsh, 2017). Meropenem-vaborbactam is currently being evaluated for treatment of 
500 hospital-acquired and ventilator-associated bacterial pneumonia in a TANGO III trial 
501 (ClinicalTrials.gov, NCT03006679).
502 Other notable work in the field of BATSIs includes that of VenatoRx Pharmaceuticals, who 
503 are developing the BATSI VNRX-5133 (Figure 4) (Docquier, 2018). Patented in 2016 (Burns, 2016), 
504 VNRX-5133 inhibits class A, C and D serine β-lactamases and VIM/NDM class B metallo-β-
505 lactamases in both carbapenem-resistant Enterobacteriaceae and P. aeruginosa. X-ray crystallography 
506 conducted on VNRX-5133 bound to the class A serine ESBL CTX-M-15 found the compound to bind 
507 the enzyme at the catalytic serine residue via the boron atom, which was sp3 hybridised. Similar 
508 experiments with VIM-2 found that the boron adopted the same hybridisation state, with its hydroxyl 
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509 group interacting with Zn1 and the Asn233 residue and the cyclic oxygen atom interacting with Zn2 
510 (Docquier, 2018). Steady state inhibition studies confirmed VNRX-5133 to be a potent competitive 
511 VIM-2 inhibitor (Daigle, 2018). A combination with cefepime appears promising; of two panels, one 
512 of 1,120 recent Enterobacteriaceae isolates and another of 155 NDM- or OXA-positive 
513 Enterobacteriaceae isolates, 99% and 81% were inhibited at or below the cefepime breakpoint, 
514 respectively (Hackel, 2018, Kazmierczak, 2018). Cefepime activity was also restored to below 
515 breakpoint (8 μg mL-1) in 93.1% of 245 clinical CRE isolates (Tyrrell, 2018), 70% of 817 isolates of 
516 P. aeruginosa resistant to cefepime, meropenem or both (Estabrook, 2018) and 90% of 29 ESBL- and 
517 carbapenemase-producing P. aeruginosa isolates (Donnelly, 2018). 98.3% of 1,066 
518 Enterobacteriaceae urinary tract infection isolates resistant to co-amoxiclav and levofloxacin were 
519 susceptible to the combination (Hackel, 2018). Potentiation of cefepime between 8 and over 2048-fold 
520 by VNRX-5133 against individual Enterobacteriaceae strains possessing CTX-M-15, KPC, VIM-1, 
521 NDM-1 and OXA-48 enzymes has also been reported (C. Hamrick, 2018). The combination has 
522 proved effective in murine bacteremia (Weiss, 2018), lung (Weiss, 2018), urinary tract (Weiss, 2018) 
523 and neutropenic thigh infection models (Georgiou, 2018), has completed a phase I study in healthy 
524 volunteers (ClinicalTrials.gov, NCT02955459) and is currently undergoing a phase I drug-drug 
525 interaction study (ClinicalTrials.gov, NCT03332732).
526 Very few effective inhibitors of metallo-β-lactamases (MBLs) have been discovered to date, 
527 with none in clinical use currently. Unlike the serine β-lactamases, MBLs achieve hydrolysis of β-
528 lactam antibiotics via a divalent metal cofactor, often zinc (Davies & Abraham, 1974, Wommer et al., 
529 2002). These enzymes are of special concern because of their activity against penicillins, 
530 cephalosporins and carbapenems (covering both widely used and last-resort antibiotics) and their 
531 resistance to the actions of all BLIs in current clinical use (Palzkill, 2013).
532 A potential clinically useful MBL inhibitor is aspergillomarasmine A, a natural fungal 
533 product that has shown efficacy against the MBLs NDM-1 and VIM-2 and has been shown to 
534 resensitise MBL-positive strains of Pseudomonas spp., Acinetobacter spp. and Enterobacteriaceae to 
535 meropenem. Aspergillomarasmine A restored meropenem activity in CD1 mice infected with NDM-
536 1-producing K. pneumoniae (>95% survival rate after 5 days, single dose of aspergillomarasmine A 
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537 and meropenem combination). It is thought to act as a Zn2+ ion chelator, achieving demetallation and 
538 thus inactivation of MBLs (King et al., 2014).
539 Discovered in Japan by Meiji Seika Kaisha Ltd., ME1071 is a maleic acid derivative 
540 (Yamada et al., 2013) and selective MBL inhibitor capable of potentiating carbapenems and 
541 ceftazidime against MBL-positive P. aeruginosa (Ishii et al., 2010). Work by Livermore et al. 
542 demonstrates that, regardless of partner carbapenem, ME1071 achieved its greatest levels of 
543 potentiation against strains possessing IMP-type MBLs and its lowest levels against NDM-type MBLs 
544 (Livermore et al., 2013). Combined with biapenem, ME1071 significantly prolonged the survival of 
545 mice infected with MBL-positive P. aeruginosa compared with both control and biapenem 
546 monotherapy groups (P < 0.05) (Yamada et al., 2013).
547 The metal chelating agents 1,4,7-triazacyclononane-1,4,7-triacetic acid and 1,4,7,10-
548 tetraazacyclod-odecane-1,4,7,10-tetraacetic acid have been reported by Somboro et al. to inhibit 
549 NDM, VIM, and IMP-type MBLs (Somboro et al., 2015, Zhang et al., 2018).
550 Wang et al. have reported that a number of Bi(III)-containing compounds, including colloidal 
551 bismuth subcitrate (CBS), inhibit a large variety of B1 MBLs (at 32 μg mL-1, CBS potentiated 
552 meropenem 16-fold against NDM-1-positive Citrobacter freundii, 64-fold against VIM-2-positive E. 
553 coli BL21 and 8-fold against IMP-4-positive E. coli BL21). IC50 values against NDM-1, VIM-2 and 
554 IMP-4 for CBS were 2.81 ± 0.34 μM, 3.55 ± 0.78 μM and 0.70 ± 0.08 μM, respectively. The study 
555 concluded that such compounds achieve MBL (NDM-1) inhibition through binding to a cysteine 
556 residue (shown to be Cys208 in NDM-1 via a C208A mutant), leading to release of Zn(II) from the 
557 enzyme. CBS was also observed to suppress resistance mutations in NDM-1-positive bacteria; when 
558 added to meropenem (½ MIC concentration) against the NDM-1-positive E. coli strains NDM-HK, 
559 CBS reduced the mutation frequency from approximately 4 × 10−7 (no CBS) to 1 × 10−10 (256 μg mL-1 
560 CBS) (Wang et al., 2018).
561 Recent studies by Spyrakis et al. and Cain et al. have demonstrated in silico screening as a 
562 possible method of MBL inhibitory discovery and development. Spyrakis and co-workers docked a 
563 commercially available library of compounds with available crystal structures for NDM-1 (protein 
564 data bank ID 3Q6X and 3SPU) to identify a number of non-β-lactam compounds with MBL-
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565 inhibitory activity (compound 1 Ki 0.72 ± 0.014 μM) (Spyrakis et al., 2018). In contrast, Cain et al. 
566 used the de novo molecular design program SPROUT to generate possible ligands for a crystal 
567 structure of NDM-1 (protein data bank ID 3Q6X) and found 2-(mercaptomethyl)benzoic acid as a 
568 putative NDM-1 substrate-competitive inhibitor. Further modification of this scaffold resulted in a 
569 number of analogues with potent B1 MBL inhibitory activities (compound 5; NDM-1 IC50 0.31 ± 0.05 
570 μM, VIM-2 IC50 0.07 ± 0.05 μM, IMP-1 IC50 0.14 ± 0.05 μM) (Cain et al., 2018).
571 Two other novel classes of BLI being developed are O-acyl and O-phosphyl hydroxamates. 
572 Tilvawala and Pratt assessed the effectiveness of N-phenylcarbonyl and N-tertbutoxycarbonyl 
573 derivatives of the cyclic O-acyl-hydroxamic acid, 3H-benzo[d][1,2]oxazine-1,4-dione. These 
574 compounds are prodrugs with no BLI activity which spontaneously hydrolyse in aqueous solution to 
575 produce O-phthaloyl hydroxamic acids with serine-β-lactamase inhibitor activity, and both can 
576 subsequently and reversibly cyclise in solution to form phthalic anhydride, another BLI. For both 
577 derivatives, both the O-phthaloyl hydroxamic acid and phthalic anhydride forms can react to form 
578 covalent phthaloyl-enzyme complexes and it was found that incubation of either compound with P99 
579 β-lactamase resulted in inhibition of the enzyme (t1/2 for turnover of CENTA™ (50 µM) by enzyme 
580 (1.0 nM) alone (100s), in presence of phthalic anhydride (500s at 30 mM) and in presence of O-
581 phthaloyl hydroxamic acids (>1500s for both at 10 mM phthalic anhydride, 10 mM hydroxamic 
582 acid)). Inhibition was observed to be transient; this was ascribed to hydrolysis of the phthaloyl-
583 enzyme complexes leading to reactivation of the β-lactamase (Tilvawala & Pratt, 2013).
584 Cyclobutanone derivatives of β-lactams have received attention as potential serine- and 
585 metallo-β-lactamase inhibitory compounds (Johnson et al., 2008, Devi & Rutledge, 2017). Johnson 
586 and co-workers tested a number of such compounds against representative β-lactamases from classes 
587 A-D (KPC-2, IMP-1, GC1 and OXA-10, respectively); micromolar inhibitory activity was observed 
588 against KPC-2 and GC1, with activity against IMP-1 and OXA-10 less pronounced (Johnson et al., 
589 2010).
590
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591 3.1.2. Aminoglycoside-Modifying Enzyme Inhibitors
592 The aminoglycosides are a family of bacterial protein synthesis inhibitors that bind to the A site of the 
593 prokaryotic 70S ribosome and possess bactericidal activity (Doi & Arakawa, 2007). Aminoglycoside 
594 resistance is a major concern because of the several important uses of aminoglycoside antibiotics, 
595 including treatment of infections of Mycobacterium tuberculosis. While the initial treatment for M. 
596 tuberculosis infections usually consists of a combination regimen including rifampicin, ethambutol, 
597 pyrazinamide and isoniazid, streptomycin is a suitable alternative when isoniazid resistance has been 
598 established or if the patient has any tolerability issues with the initial regimen. Amikacin is a suitable 
599 second-line option when there are further issues with resistance or side effects caused by the first-line 
600 drugs (Rojano et al., 2019).
601 Resistance to aminoglycosides may arise through several different mechanisms, including 
602 extrusion by efflux pumps, reduced outer membrane permeability, target modification and enzymatic 
603 inactivation. Target modification may occur by methylation of specific nucleotides within the 16S 
604 rRNA. This resistance mechanism was initially identified in aminoglycoside-producing species such 
605 as Streptomyces spp., providing them with intrinsic resistance against the antibiotics they produce. 
606 This mechanism was subsequently identified in several strains of clinically relevant bacteria such as 
607 P. aeruginosa (Doi & Arakawa, 2007). However, the most prevalent aminoglycoside resistance 
608 mechanism is enzymatic inactivation. As with the β-lactamases, these modifying enzymes may be 
609 further subdivided into several groups, members of which achieve the same effects through slightly 
610 different mechanisms. The three groups of aminoglycoside modifying enzymes are the 
611 aminoglycoside acetyltransferases (AACs), aminoglycoside nucleotidyltransferases (ANTs) and 
612 aminoglycoside phosphotransferases (APHs). AACs function by catalysing the acetylation of primary 
613 amine groups within the aminoglycoside molecules, using acetyl coenzyme A as a donor substrate. 
614 ANTs are responsible for mediating the transfer of an adenosine monophosphate group to a hydroxyl 
615 group in the aminoglycoside molecule, using ATP as a donor substrate, while APHs catalyse the 
616 transfer of a phosphate group to the aminoglycoside molecule (Ramirez & Tolmasky, 2010). Several 
617 promising inhibitors of these enzymes have been developed, but none have yet entered clinical use.
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618 In 1997, Hon and co-workers reported that APH(3’) enzymes (EC 2.3.1.81) show unusually 
619 high structural similarity to eukaryotic protein kinases despite minimal sequence homology (Hon et 
620 al., 1997). This inspired the testing of protein kinase inhibitors as inhibitors of APHs. Selective 
621 inhibition is an important requirement for any such repurposed compound, since the inhibitor must be 
622 able to distinguish between eukaryotic protein kinases and APHs. Stogios et al. identified 
623 pyrazolopyrimidine compounds with selective inhibitory activity against the enzyme APH(3’)-Ia, 
624 which plays a large role in Gram-negative resistance against aminoglycoside antibiotics, and 
625 suggested that these can be further developed to provide a new option for combatting aminoglycoside 
626 resistance (Stogios et al., 2013).
627 Another strategy is the use of bisubstrate analogues, consisting of the aminoglycoside 
628 antibiotic and coenzyme A (CoA). This strategy was successfully carried out with gentamicin; the 
629 bisubstrate showed inhibitory activity in vitro (but not in vivo) towards the enzyme AAC(3)-I. It was 
630 suggested that this was due to poor compound influx into Gram-negative bacterial cells (Williams & 
631 Northrop, 1979). Since this discovery, several aminoglycoside-CoA conjugates have been 
632 synthesised, with varying functional groups. It was found that amide-linked bisubstrates that 
633 contained sulfoxide and sulfone functionalities showed effective inhibition of AAC(6)-Ii (EC 
634 2.3.1.82) at nanomolar concentrations (Gao et al., 2008).
635 Boehr et al. screened several antimicrobial peptides against the aminoglycoside-modifying 
636 enzymes APH(3’)-IIIa (EC 2.7.1.95), AAC(6’)-Ii and AAC(6’)-APH(2″) (EC 2.3.1.81). The bovine 
637 peptide indolicidin (primary sequence H-ILPWKWPWWPWRR-NH2) and its analogues CP11CN (H-
638 ILKKWPWWPWRRK-NH2) and CP10A (H- ILAWKWAWWAWRR-NH2) were all demonstrated to 
639 inhibit AAC(6’)-Ii, with IC50 values of 13, 23 and 4.4 μM respectively, and APH(3’)-IIIa, with IC50 
640 values of 11, 51 and 11 μM respectively (Boehr et al., 2003).
641
642 3.2. Membrane Permeabilisers
643 Gram-negative bacteria are intrinsically resistant to several antibiotic classes because of the presence 
644 of a second, outer membrane compared to Gram-positive bacteria which these antibiotics cannot 
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645 penetrate. The Gram-negative bacterial envelope consists of three components; an inner membrane 
646 which surrounds the organelles, an outer membrane (OM) and a periplasmic region between the two 
647 membranes containing a peptidoglycan layer (Silhavy et al., 2010). The OM consists mainly of 
648 lipopolysaccharides (LPS), which are made up of three parts; a polysaccharide referred to as the O-
649 antigen, a core domain consisting of an oligosaccharide component and a lipid region referred to as 
650 lipid A (Raetz & Whitfield, 2002). This LPS layer is stabilised by cross-linking, enabled by divalent 
651 cations such as Mg2+ and Ca2+ (Zabawa et al., 2016). The OM contains porins, water-filled protein 
652 channels that facilitate entry of hydrophilic molecules into the bacterial cell; mutations in Gram-
653 negative bacteria resulting in reduced porin expression can reduce influx of hydrophilic drugs into 
654 these bacteria. This method of antibacterial resistance has been confirmed in several clinically 
655 relevant bacterial species, such as P. aeruginosa (Fernandez & Hancock, 2012).
656 Besides directly damaging the cell membrane, various other methods have been suggested to 
657 increase rates of antibiotic influx in bacterial cells, such as the use of liposomal drug preparations 
658 (Torres et al., 2012). However, it is the use of membrane permeabilisers, compounds that make the 
659 Gram-negative outer membrane more permeable to facilitate increased antibiotic influx, that will be 
660 reviewed herein. Membrane permeabilisers can function by chelating and removing divalent cations 
661 from the OM and/or (in the case of permeabilisers with a net cationic charge) associating with the 
662 negatively charged OM to disrupt it, causing a breakdown of OM structure (Zabawa et al., 2016). The 
663 effectiveness of putative membrane permeabilisers can be assessed by measuring the level of uptake 
664 of substances that would not normally be able to penetrate the Gram-negative outer membrane, such 
665 as a hydrophobic probe. The fluorescent dye N-phenyl-1-napthylamine (NPN) is used for this 
666 purpose; an increase in fluorescence indicates increased incorporation of NPN into the outer 
667 membrane of the pathogen and thus increased outer membrane permeability (Lee et al., 2004). 
668 Besides enabling increased influx of antibiotics, membrane permeabilisation alone can be sufficient to 
669 cause bacterial lysis; as such, several of the compounds mentioned in this section also have direct 
670 antibacterial activity (Zabawa et al., 2016).
671
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672 3.2.1. The Polymyxins
673 Polymyxins (see Figure 5 and Table 2), including polymyxin B and polymyxin E (colistin), are 
674 antibiotics that function through disruption of the Gram-negative OM. First reported in 1947 
675 (Ainsworth et al., 1947, Benedict & Langlykke, 1947, Stansly et al., 1947), the polymyxins are 
676 pentacationic lipopeptides consisting of a cyclic peptide attached to a long fatty acid chain. Colistin 
677 itself was available for treatment of Gram-negative bacterial infections from 1959 (Ross et al., 1959), 
678 though clinical use decreased from the 1970s to the 1990s because of reports of neurotoxicity and 
679 nephrotoxicity (Vaara, 1992, Li et al., 2005, Falagas & Kasiakou, 2006). While Falagas and Kasiakou 
680 report that adverse events related to current polymyxin use are less frequent than reported in older 
681 literature, possibly due to better understanding of appropriate dosing regimen and the avoidance of 
682 simultaneous administration of nephrotoxic and/or neurotoxic drugs (Falagas & Kasiakou, 2006), 
683 increased colistin use in recent years has been primarily driven by the onset of resistance to β-lactams, 
684 aminoglycosides and quinolones in Gram-negatives (Livermore, 2002). Polymyxins interact 
685 electrostatically with the OM to displace Mg2+ and Ca2+ cations from their binding sites to disrupt 
686 membrane integrity, causing cell damage and also facilitating the influx of other molecules, including 
687 other antibiotics (Landman et al., 2008). Lin et al. found that azithromycin, ineffective against Gram-
688 negative rods, showed synergy with colistin; the combination was effective against MDR-isolates of 
689 P. aeruginosa, K. pneumoniae and A. baumannii (Lin et al., 2015). Synergistic combinations of 
690 colistin with other drugs have also been reported; Lee and co-workers found that the combination of 
691 colistin and rifampicin at clinically-relevant concentrations was additive or synergistic against MDR 
692 strains of A. baumannii and suppressed the emergence of colistin resistance (Lee et al., 2013).
693 The membrane permeabilising effects of colistin towards pandrug-resistant Gram-negative 
694 bacteria have been investigated. Pandrug-resistant bacteria refers to bacteria that are resistant to all 
695 anti-pseudomonal drugs (penicillins, cephalosporins, carbapenems, monobactams, quinolones, 
696 aminoglycosides) except the polymyxins, although some commentators include the polymyxins in this 
697 definition. Mohamed et al. measured the effect of 50 μg mL-1 of colistin on the cytoplasmic 
698 membranes of four pandrug-resistant clinical isolates (A. baumannii A182, P. aeruginosa P103, K. 
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699 pneumoniae K103 and E. coli E9). This concentration of colistin was far in excess of the MICs for the 
700 isolates (range 0.625-1.25 μg mL-1) and resulted in net membrane leakage in all four isolates. The 
701 haemolytic effect of colistin on human red blood cells was also assessed; at a concentration of 12.5 μg 
702 mL-1, colistin caused approximately 1.3% haemolysis, confirming its selectivity towards bacterial 
703 membranes (Mohamed et al., 2016).
704
705 3.2.2. Polymyxin Derivatives
706 Increasing levels of polymyxin resistance globally (Cannatelli et al., 2016, Lee et al., 2016, Liu et al., 
707 2016, Rapoport et al., 2016, Skov & Monnet, 2016, Kluytmans, 2017, Haeili et al., 2018) necessitate 
708 the development of novel alternatives. Efforts to develop polymyxin derivatives as ARBs to potentiate 
709 the actions of antibiotics have been spearheaded in recent decades by Prof. Martti Vaara and co-
710 workers. Chihara et al. first described in 1972 the production of a novel, truncated form of polymyxin 
711 B, later termed polymyxin B nonapeptide (PMBN; Table 2) (Vaara, 1988). PMBN lacks the fatty acid 
712 and terminal diaminobutyric acid moieties of polymyxin B required for bactericidal activity (Vaara, 
713 1988), but it does retain the OM permeabilising character of the latter, a fact first demonstrated by 
714 Vaara in 1983 (Vaara & Vaara, 1983). Together with subsequent work, they showed it capable of 
715 enhancing penetration of hydrophobic antibiotics, including erythromycin, clindamycin, rifampicin, 
716 fusidic acid, novobiocin and cloxacillin, in most polymyxin-susceptible Gram-negative bacteria, 
717 including MDR E. coli, K. pneumoniae and P. aeruginosa (Viljanen & Vaara, 1984). Ofek et al. 
718 tested several polymyxin-susceptible strains of E. coli, K. pneumoniae, P. aeruginosa and Salmonella 
719 typhimurium with PMBN and found that it sensitised the majority of them to six different antibiotics 
720 (ampicillin, erythromycin, lincomycin, nafcillin, novobiocin and vancomycin). The exceptions were a 
721 single strain of P. aeruginosa resistant to nafcillin, one E. coli strain and two K. pneumoniae strains 
722 resistant to vancomycin; it was suggested that these strains possess resistance mechanisms unrelated 
723 to permeability (Ofek et al., 1994). Zabawa et al. posit that development of PMBN ultimately stalled 
724 because of similar levels of nephrotoxicity to polymyxin B in rats (Zabawa et al., 2016).
725 Many membrane permeabilising agents require a net positive charge to exert their effects. 
726 However, in a second generation of polymyxin B derivatives, Vaara et al. showed that analogues with 
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727 a reduced number of positive charges display a concomitant reduction in nephrotoxicity. The 
728 derivatives, which contain only three positive charges at physiological conditions instead of the usual 
729 five, had a lower affinity for rat kidney border brush membranes than polymyxin B. Antibacterial 
730 activity was not necessarily compromised; MICs of one derivative, NAB739, were comparable to 
731 those of polymyxin B against 17 different E. coli strains (range 0.5-1 μg mL-1 for NAB739, range 
732 0.25-1 μg mL-1 for polymyxin B) and were 2-8 fold higher than the corresponding polymyxin B MICs 
733 for strains of Klebsiella oxytoca, K. pneumoniae, E. cloacae, C. freundii, A. baumannii and P. 
734 aeruginosa. Furthermore, at sub-MIC concentrations, NAB739 potentiated the activity of several 
735 antibiotic drugs against A. baumannii, including rifampicin, vancomycin and clarithromycin (Vaara et 
736 al., 2008).
737 Another second generation derivative, NAB741 (Table 2), showed strong synergism with 
738 rifampin and clarithromycin against resistant strains of E. coli, K. pneumoniae, E. cloacae and A. 
739 baumannii and sensitised E. coli and E. cloacae strains to azithromycin, mupirocin, fusidic acid and 
740 vancomycin (Vaara et al., 2010). Further studies detailed reduced cytotoxicity in NAB741 versus 
741 polymyxin B, with the former found to have 32-fold cytotoxicity towards LLC-PK1 cells than the 
742 latter (Mingeot-Leclercq et al., 2012). These second generation derivatives were patented by Vaara, 
743 Vaara and Northern Antibiotic Ltd (Vaara & Vaara, 2009) in 2009 and subsequently licensed to Spero 
744 Therapeutics, where NAB741 was given the code SPR741. Corbett et al. reported that 8 μg mL-1 of 
745 SPR741 was sufficient to potentiate thirteen antibiotics (azithromycin, clarithromycin, dalfopristin, 
746 erythromycin, fidaxomicin, fosfomycin, fusidic acid, mupirocin, novobiocin, ramoplanin, 
747 retapamulin, rifampicin and telithromycin) between 32 and 8,192-fold against E. coli ATCC 25922 
748 (Corbett et al., 2017). At 16 μg mL-1, SPR741 potentiated ten antibiotics (azithromycin, 
749 clarithromycin, erythromycin, fusidic acid, mupirocin, novobiocin, retapamulin, rifampicin, 
750 telithromycin and vancomycin) between 32 and 128-fold against K. pneumoniae ATCC 43816, and 
751 eight antibiotics (clarithromycin, dalfopristin, erythromycin, fusidic acid, ramoplanin, retapamulin, 
752 rifampicin and teicoplanin) between 32 and 128-fold against A. baumannii NCTC 12156 (Corbett et 
753 al., 2017). Further work by Zurawski and co-workers using a panel of 28 extensively drug-resistant 
754 strains of A. baumannii found that a combination of 1 μg mL-1 rifampicin combined with 4 μg mL-1 
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755 SPR741 was sufficient to inhibit growth in 27 of the strains (96%). The exception, strain AB3927, 
756 was significantly more resistant to rifampicin (MIC >256 μg mL-1) compared to the other strains 
757 (MIC range 2-16 μg mL-1) (Zurawski et al., 2017). As of December 2017, SPR741 has completed two 
758 phase I clinical trials; a 64-person, first-in-man study to assess safety and tolerability 
759 (ClinicalTrials.gov, NCT03022175) and a 27-person trial evaluating separate combinations of 
760 SPR741 and ceftazidime, piperacillin/tazobactam and aztreonam (ClinicalTrials.gov, NCT03376529).
761
762 3.2.3. Other Permeabilisers
763 Antimicrobial peptides (AMPs), an umbrella term encompassing a diverse array of compounds 
764 produced by a variety of organisms to combat infections of pathogenic microorganisms, have been 
765 investigated for use as ARBs. The temporins, the first 10 members of which were isolated from the 
766 skins secretions of the European common frog Rana temporaria, are a notable example; Giacometti et 
767 al. investigated the activity of temporin A against Enterococcus faecalis and reported both direct 
768 activity and synergism with imipenem and co-amoxiclav (Simmaco et al., 1996, Giacometti et al., 
769 2005). LL-37, a cathelicidin class antimicrobial peptide found in humans, was found by Lin and 
770 colleagues to potentiate the macrolide antibiotic azithromycin and the combination to be synergistic at 
771 sub-MIC concentrations against MDR strains of P. aeruginosa, K. pneumoniae and A. baumannii (Lin 
772 et al., 2015). Synthetic AMPs appear equally attractive ARB candidates; Lainson et al. have described 
773 synergy between a novel bivalent peptide, ASU014, and the narrow spectrum β-lactam oxacillin 
774 against MRSA at sub-MIC concentrations of both compounds both in vitro and in a skin infection 
775 model (Lainson et al., 2017). A more thorough discussion of antimicrobial peptides in this capacity 
776 can be found in previous summaries (Kosikowska & Lesner, 2016).
777 Peptidomimetics are synthetic compounds that mimic the membrane permeabilization 
778 mechanism of action of antimicrobial peptides, but are stable to enzymatic degradation. A 
779 peptidomimetic library was designed by Radzishevsky et al. with alternating acyl chains and cationic 
780 amino acids, called oligo-acyl-lysyls, with the purpose of avoiding the formation of undesirable 
781 secondary structures. Compound C12K-7α8 exhibited significant antimicrobial activity against several 
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782 Gram-negative bacteria, including Klebsiella spp. and Pseudomonas spp., and showed no increase in 
783 MICs after several subcultures, indicating a low probability of resistance emerging. Furthermore, 
784 C12K-7α8 showed minimal haemolytic activity up to at least 156 μM, a concentration 100-fold higher 
785 than its MIC for several bacteria (Radzishevsky et al., 2007). A subsequent study from the same 
786 group found that C12K-7α8 at ½ MIC concentration was capable of potentiating several cytoplasm-
787 targeting antibiotics (erythromycin, clarithromycin and tetracycline) up to 256-fold versus four MDR 
788 E. coli clinical isolates, but was far less efficient at potentiating periplasm-targeting compounds such 
789 as β-lactams. The authors concluded that C12K-7α8 synergises with efflux-afflicted antibiotics to 
790 increase their influx into the bacterial cell, thereby circumventing this resistance mechanism (Livne et 
791 al., 2010). Further work has established the ability of macromolecular assemblies of C12K-7α8 to 
792 potentiate erythromycin in male ICR mice infected with MDR E. coli (Sarig et al., 2011). Another 
793 oligo-acyl-lysyl, C12(ω7)X, has been demonstrated to reduce the MIC of rifampicin against E. coli, K. 
794 pneumoniae, P. aeruginosa and Salmonella enterica (Jammal et al., 2015).
795 Li and co-workers have demonstrated that cholic acid derivatives are suitable alternatives to 
796 polymyxins as ARBs. The derivatives were designed to include structural elements present in the 
797 polymyxins, including three primary amine groups and associated hydrophobic chains. Of the 
798 derivatives assessed, compound 5 showed particular promise for use as an ARB; while it showed 
799 weak direct antibiotic activity against P. aeruginosa, E. coli and K. pneumoniae strains (MIC range 
800 20-50 μg mL-1), it showed synergism with erythromycin, novobiocin and rifampicin at concentrations 
801 as low as 0.16-5.3 μg mL-1 against the aforementioned strains (strains were resistant to all three 
802 antibiotics in monotherapy) (Li et al., 1999). A further advantage of cholic acid derivatives is their 
803 activity against Gram-positive cocci and fungi. Compound 5 had MICs of 3.3, 2.0 and 4.2 μg mL-1 
804 against E. faecalis, S. aureus, and Streptococcus pyogenes, respectively, and had an MIC of 14 μg 
805 mL-1 against Candida albicans, improving on polymyxin B by over four-fold in all cases. However, 
806 commercial development of this compound may be complicated because of its significant haemolytic 
807 activity (100 μg mL-1) (Li et al., 1999).
808 Another example of a permeabiliser is ethylenediaminetetraacetic acid, a chaotropic agent 
809 that has been shown to release a large proportion of LPS from the OM. It functions by chelating the 
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810 divalent cations present in the LPS layer, thereby compromising the integrity and stability of the OM 
811 (Vaara, 1992). Polyethyleneimine, a cationic polymer, has also shown membrane permeabilising 
812 effects. However, instead of releasing LPS, it functions by intercalating into the OM (Helander et al., 
813 1997, Helander et al., 1998). Alakomi et al. assessed NPN uptake for several membrane 
814 permeabilisers, including ethylenediaminetetraacetic acid and polyethyleneimine, and found that both 
815 caused increased NPN uptake in Pseudomonas sp. and Stenotrophomonas nitritireducens strains. The 
816 clinical benefits of polyethyleneimine have been investigated; it was shown in a susceptibility study to 
817 induce an increased susceptibility of a Pseudomonas sp. strain to erythromycin, novobiocin and 
818 fusidin. However, susceptibilities of S. nitritireducens and Sinorhizobium morelense strains to the 
819 same antibiotics did not show similar improvements (Alakomi et al., 2006).
820 Plant-derived phenolic compounds, a group of secondary metabolites abundant in fruit, 
821 vegetables and berries, have been shown to possess membrane permeabilising activity. The effect of 
822 berry-derived phenolic compounds on the OM permeability of Salmonella species was studied by 
823 Alakomi et al. It was shown that several of these compounds, such as 3-phenylpropionic acid, 
824 efficiently permeabilised the membrane as indicated by an increased NPN uptake. Their destabilising 
825 effect on the OM, acting on the divalent cations, was confirmed by the addition of MgCl2 which 
826 partially abolished this effect. The same study also found that the use of organic acids present in 
827 berries, such as sorbic and benzoic acid, also resulted in an increased NPN uptake and LPS release 
828 (Alakomi et al., 2007).
829
830 3.3. Efflux Pump Inhibitors
831 Bacterial efflux pumps act to decrease intracellular concentrations of antibiotics by pumping 
832 antibiotics out of bacterial cells, thereby reducing their effectiveness. The presence of efflux systems 
833 has been confirmed in prokaryotic species, archaea and both inferior and superior eukaryotic species 
834 (Van Bambeke et al., 2003). Their main function is the extrusion of undesirable compounds from 
835 cells; these include heavy metals (Nies, 2003), organic solvents (Ramos et al., 2002), dyes such as 
836 ethidium bromide (Kaatz et al., 1993), amphiphilic detergents (Ma et al., 1994), biocides (Costa et al., 
837 2013), quorum sensing molecules (Pearson et al., 1999) and metabolites (Van Dyk et al., 2004) in 
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838 addition to antibiotics. The presence of efflux pumps and their clinical significance in contributing 
839 towards AMR has been confirmed in many bacteria, including M. tuberculosis (Ainsa et al., 1998) 
840 and P. aeruginosa. The latter species possesses the tripartite RND systems MexAB-OprM, MexXY-
841 OprM, MexCD-OprJ and MexEF-OprN, which together can extrude fluoroquinolones, tetracycline, 
842 chloramphenicol and some β-lactams to achieve a multidrug resistant phenotype (Piddock, 2006). 
843 Efflux systems have also been implicated in biofilm formation in a number of different bacterial 
844 species; a more detailed discussion of this area can be found in previous reviews on the subject (Alav 
845 et al., 2018).
846 Prokaryotic efflux systems can be categorised into a number of superfamilies according to 
847 their energy source, substrates they can act on, composition and membrane-spanning regions. These 
848 include the resistance-nodulation-division (RND) family, the major facilitator superfamily (MFS), the 
849 ATP-binding cassette (ABC) superfamily, the small multidrug resistance (SMR) family and the 
850 multidrug and toxic compound extrusion (MATE) family (Sun et al., 2014). Substrate specificity 
851 varies between different pumps; some are drug-specific while others act on multiple drugs. Genes for 
852 multidrug-extruding pumps are usually found on chromosomes, while drug-specific efflux systems 
853 are located on mobile gene elements which can be transferred between different bacteria via 
854 horizontal gene transfer (Poole, 2007).
855 A popular approach to combatting bacterial efflux systems has been the development of 
856 efflux pump inhibitor (EPI) compounds. A diverse array of EPI compounds have been reported to 
857 date (Stavri et al., 2007, Mahmood et al., 2016), both from natural product screening, de novo 
858 synthetic efforts and in the form of repurposed previously-approved drugs, and these are detailed in 
859 Table 3. However, at the time of writing no discrete EPI compound has been approved for clinical 
860 use. While unacceptable toxicities would appear to be the most touted explanation, this position may 
861 not be unilaterally correct (Lomovskaya, 2018, Opperman, 2018). Most EPIs investigated thus far 
862 adhere to a ‘cork-in-bottle’ method of blocking pumps, serving to physically obstruct passage of 
863 substrate molecules through the transporter. But in the absence of compounds able to covalently 
864 modify their target pumps, this approach allows for a degree of competition for pump binding 
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865 between the substrate antibiotic and the inhibitor, with the result that levels of potentiation observed 
866 are typically modest (Figure 6).
867 Two alternative interpretations of the EPI paradigm could address this problem. The design of 
868 agents, either small molecule or biologic in nature, capable of selectively binding the promoter 
869 regions of the genes encoding efflux transporters could allow for the efflux problem to be 
870 circumvented entirely by preventing pump expression. Jeon and Zhang employed peptide nucleic 
871 acids, synthetic DNA-mimicking polymers, to this end and achieved decreased expression of the 
872 RND-type CmeABC efflux pump in Campylobacter jejuni, sensitising it to ciprofloxacin and 
873 erythromycin. Addition of the peptide nucleic acid, CmeA-PNA, at a concentration of 1 µM resulted 
874 in a 2-fold reduction of the MICs of both antibiotics, while at a concentration of 2 µM it caused 8- and 
875 4-fold reductions in the MICs of ciprofloxacin and erythromycin, respectively (Jeon & Zhang, 2009). 
876 Alternatively, covalently modified antibiotics with EPI character could provide a conventional pump 
877 blocking agent free of the aforementioned competitive binding disadvantage and thus be better able to 
878 improve upon the parent antibiotic (Laws et al., 2017).
879
880 4. Future Perspective and Conclusion
881 Antibiotic resistance is increasing at an alarming rate and is now widely recognised as a global issue 
882 that requires urgent attention. Despite several strategies being deployed, resistance levels are still of 
883 huge concern, and antibiotic resistance breakers (ARBs) represent a promising avenue of research to 
884 counter this. Yet as things stand, the only class of ARBs to make a significant impact in the clinic is 
885 the β-lactamase inhibitors; factors underpinning both the successes of enzyme inhibitors and the 
886 failures of efflux pump inhibitors and membrane permeabilisers as adjunct therapies must be 
887 appreciated if a more complete suite of clinically-approved ARBs is to be realised.
888 The conventional ARB approach – that of using discrete antibiotic and ARB compounds in 
889 combination to enhance the action of the former – deserves re-examining. Undoubtedly it has 
890 advantages, chiefly an inherent flexibility in the nature of the combined agents and the possibility of 
891 synergy between the two drugs. But these are offset by a number of problems, including the increased 
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892 regulatory burden resulting from combining two drugs and a caveat that the pharmacokinetic profiles 
893 of the combined drugs be similar (Gonzalez-Bello, 2017). The latter has suited development of β-
894 lactam-BLI combinations since BLIs necessarily resemble β-lactam antibiotics in structure, but likely 
895 poses more of a challenge in the cases of membrane permeabilisers and efflux pump inhibitors where 
896 the ARBs will likely not structurally resemble the antibiotic they potentiate. This hurdle may be 
897 circumvented by embracing other methodologies, such as covalent modification of substrate 
898 antibiotics to introduce additional ARB character (Laws et al., 2017).
899 Further research within the field must aim for derivatives with improved toxicological 
900 profiles, since several of the compounds mentioned herein are unsuitable for further clinical 
901 development for this reason (Zabawa et al., 2016, Lomovskaya, 2018). In this regard, the 
902 investigation of less nephrotoxic derivatives of polymyxin B (Corbett et al., 2017, Zurawski et al., 
903 2017) (ClinicalTrials.gov, NCT03022175 & NCT03376529) and continued refinement of existing 
904 efflux pump inhibitor scaffolds (Opperman et al., 2014, Vargiu et al., 2014, Aron & Opperman, 2016, 
905 Opperman, 2018) is encouraging. Another option here, as noted by David Brown in his 2015 review 
906 on the subject, is the repurposing of previously-approved drugs for use as ARBs or their use as hit 
907 scaffolds in ARB development (Brown, 2015). This would presumably serve to expedite the market 
908 entry of any resulting therapies and is an attractive option.
909 De novo techniques must play a role in ARB development; an area which will likely drive 
910 development of future ARBs through enhancing understanding of ARB mechanisms of action is 
911 computational modelling of specific biological targets and systems. This is particularly true in the 
912 case of efflux inhibition, where in the absence of crystal structures (due to the complex, 
913 transmembrane nature of prokaryotic efflux transporters), use of computer processing power to 
914 develop a mechanistic understanding of efflux inhibition is critical (Ramaswamy et al., 2016, 
915 Jamshidi et al., 2018). The current state of technology necessitates a compromise between accuracy 
916 and computational burden; systems on the protein scale are modelled using coarse grain molecular 
917 dynamics simulations, with more accurate and resource-intensive quantum mechanical simulations 
918 reserved only for small areas therein (Chaskar et al., 2017). However, with increasing interest and 
919 investment in much-vaunted quantum computing technology (Preskill, 2018), the gains in processor 
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920 power required for quantum mechanical simulations to be applied to protein-sized systems may soon 
921 be within reach. Such advances could conceivably allow a more accurate suite of in silico modelling 
922 tools to drive new generations of both antibiotic and ARB compounds towards the clinic.
923 The scientific community can also look beyond small-molecules to biologics and related 
924 technologies in order to realise the next generation of ARBs. Researchers need to further explore the 
925 use of biologics in targeted delivery to overcome resistance and reduce the selection pressure 
926 associated with non-targeting broad-spectrum antibiotics. The success of antibody-drug conjugates as 
927 cancer therapies has led to research into antibiotic-antibody conjugates using bacteria-specific 
928 antibodies (Mariathasan & Tan, 2017) and there has been some early success at the pre-clinical level 
929 to treat intracellular S. aureus (Lehar et al., 2015). Phage therapy, which uses viruses that specifically 
930 infect bacterial cells, also deserves mention; though its discovery and first use predates that of modern 
931 antibiotics, doubts surrounding the efficacy of phage preparations led to their supersession by the 
932 latter (Sulakvelidze et al., 2001). Phage therapy is not widely used currently and is approved in few 
933 countries (Sulakvelidze et al., 2001), but previous data shows its potential for treating infections of E. 
934 coli (Smith & Huggins, 1982), P. aeruginosa, A. baumannii (Soothill, 1992) and K. pneumoniae 
935 (Bogovazova et al., 1991) in mice and several phage preparations have undergone phase I/II clinical 
936 trials, including a topical preparation for E. coli and P. aeruginosa infections in burn wounds (Gill et 
937 al., 2015).
938 The use of nucleic acid-based aptamers is another promising direction and can be used for the 
939 specific recognition of infectious agents as well as for blocking their functions. Systematic evolution 
940 of ligands by exponential enrichment (SELEX) technologies are being employed to identify aptamers 
941 that can detect specific pathogens (Alizadeh et al., 2017). Aptamers could be used to develop nucleic 
942 acid-based detection systems that can detect bacteria directly in a real complex matrix without 
943 preliminary concentration, which is often a limiting factor in developing rapid diagnostics. Aptamers 
944 able to detect and often block critical function have already been reported for S. enterica, S. aureus 
945 and M. tuberculosis and this represents an important development towards the realisation of such 
946 diagnostic platforms (Alizadeh et al., 2017).
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947 A novel delivery platform using nanocarriers could be used to overcome the permeability 
948 barrier encountered in Gram-negative bacteria. Nanocarriers can also be used to selectively deliver 
949 high concentrations of antibiotics locally, thus avoiding systemic side effects. Several strategies have 
950 been studied in order to deliver antibiotics such as the use of antimicrobial polymers, nanoparticles 
951 and liposomes. Success with these strategies has been limited, but it is expected that with more 
952 research and advancement of technology, nanodelivery can become an important tool to overcome 
953 bacterial resistance (Gao et al., 2014).
954 The BLIs in the clinic today were, by their very nature, developed after their partner 
955 antibiotics. However, the fact that the majority of BLIs have arrived on the clinical scene many 
956 decades after their partner β-lactams were first approved (Drawz & Bonomo, 2010) likely reflects the 
957 relatively recent drive to address the problem of antimicrobial resistance. This typifies the current 
958 reactive nature of antibiotic research and development, ‘patching up’ a failing arsenal as it declines. 
959 Going forward, we hope that a new wave of funding schemes such as non-profit private-public 
960 partnerships (such as CARB-X) and government-funded programmes (such as the EU-backed 
961 Innovative Medicines Initiative) can drive a change in this methodology. A more proactive, 
962 diagnostics-driven approach to ARB development would allow the lifespans of current antibiotics to 
963 be maximised when practised in combination with wider efforts such as antimicrobial stewardship and 
964 increased public awareness of AMR.
965
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26 Abstract
27 Infections of antibiotic-resistant pathogens pose an ever-increasing threat to mankind. The 
28 investigation of novel approaches for tackling the antimicrobial resistance (AMR) crisis must be part 
29 of any global response to this problem if an untimely reversion to the pre-penicillin era of medicine is 
30 to be avoided. One such promising avenue of research involves so-called antibiotic resistance 
31 breakers (ARBs), capable of re-sensitising resistant bacteria to antibiotics. Although some ARBs have 
32 previously been employed in the clinical setting, such as the β-lactam inhibitors, we posit that the 
33 broader field of ARB research can yet yield a greater diversity of more effective therapeutic agents 
34 than have been previously achieved. This review introduces the area of ARB research, summarises the 
35 current state of ARB development with emphasis on the various major classes of ARBs currently 
36 being investigated and their modes of action, and offers a perspective on the future direction of the 
37 field.
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38 1. Introduction
39 Since their discovery more than 70 years ago, antibacterial drugs have become an essential part of the 
40 modern healthcare landscape, allowing treatment of previously life-threatening bacterial infections. 
41 However, ever-increasing levels of antimicrobial resistance (AMR) threaten the health benefits 
42 achieved with antibiotics and this phenomenon is recognised as a global crisis (Ventola, 2015). Over 
43 the period of 2011-2014, the percentage of Klebsiella pneumoniae infections resistant to 
44 fluoroquinolones, third-generation cephalosporins or aminoglycosides, as well as combined resistance 
45 to all three antibiotic groups, has increased significantly in Europe, with a similar trend also observed 
46 for Escherichia coli infections (ECDC, 2015). With AMR currently estimated to be responsible for 
47 50,000 deaths annually across the US and Europe, urgent action needs to be taken on an international 
48 scale if the modern antibiotic treatment paradigm is to survive (O’Neill, 2014). It should be noted that 
49 this review will discuss approaches to overcome bacterial resistance, but AMR refers to resistance 
50 caused by all microbes against their respective drugs.
51 While figures vary between different regions, the general trend is that poorer countries are 
52 experiencing much higher levels of resistance. This is likely due to several factors, including greater 
53 availability of second- and third-line treatments in ‘First World’ countries compared to their ‘Third 
54 World’ counterparts. Additionally, regional instances of higher resistance levels can have a global 
55 effect, with the advent of rapid intercontinental travel allowing the dissemination of resistant bacterial 
56 strains globally. It has been suggested that regional resistance levels could affect international travel 
57 and commerce, with people less likely to be willing to travel to areas where they could develop 
58 problematic bacterial infections. That AMR levels are only rising, despite implementation of 
59 additional healthcare measures in the more economically developed countries of the world, highlights 
60 the need for novel approaches to tackling the AMR problem (O' Neil, 2014.).
61 The effects of antibacterial resistance are not limited to those patients who develop bacterial 
62 infections; wider medical procedures stand to be impacted. Antibiotic prophylaxis is commonly 
63 employed, both preoperatively for a variety of surgical procedures and for immunocompromised 
64 patients undergoing chemotherapy, to avoid the development of infections (Wenzel, 1992, Teillant et 
Page 54 of 123
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
4
65 al., 2015, Crader & Bhimji, 2018). Such prophylactic measures will no longer be possible if AMR 
66 spreads at its current rate, which could in turn impact the scope of surgical procedures available to 
67 clinicians and the quality of patients’ lives (O'Neil, 2014).
68 The ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella 
69 pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species), whilst 
70 not the only problematic pathogens, have been identified as requiring special attention since they are 
71 responsible for the majority of hospital-acquired infections per annum and show high incidences of 
72 AMR (Rice, 2008). With recent observations of strains of Gram-negative ESKAPE bacteria 
73 possessing multiple mechanisms of resistance to carbapenems, the drugs of last resort used to treat 
74 such infections, the need for new classes of antibiotics with novel modes of action is greater than ever 
75 (Limansky et al., 2002, Mena et al., 2006, Rodriguez-Martinez et al., 2009, Papp-Wallace et al., 
76 2011). However, since the 1960s only two new antibiotic classes have been released and the scientific 
77 community has been unable to keep pace with the emergence of resistance (Coates et al., 2011).
78 Investment in antibiotic research by major pharmaceutical companies has declined sharply in 
79 recent years, mainly because of the lack of return in investments. Besides a long and difficult 
80 regulatory process for new drugs to navigate (Ventola, 2015), antibiotics are typically short term 
81 treatments meaning such drugs bring in less revenue for pharmaceutical companies when compared to 
82 drugs that are intended to treat long term conditions. In addition, the rise of other infectious diseases 
83 with different causative agents, such as acquired immune deficiency syndrome, has caused a shift in 
84 focus within the industry, often resulting in reduced budgets available for antibiotics research and 
85 development (Alanis, 2005). With healthcare policy increasingly inclined towards the saving of new 
86 antimicrobials for treatment of resistant infections, change is required to make antibiotic development 
87 more attractive. Solutions include research incentives, such as the Innovative Medicines Initiative 
88 “New Drugs for Bad Bugs” workstream which funds antimicrobial discovery research between 
89 academics/small enterprises and large companies, simplification of the regulatory landscape, such as 
90 the proposed FDA rapid antibacterial approval pathway LPAD (Limited Population Antibacterial 
91 Drug), and re-evaluation of the prices of antibiotics in order to provide companies with a better return 
92 on their investments (Sukkar, 2013). Until the implementation of such incentives results in an 
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93 increased volume of new antibiotic candidates reaching and passing the clinical trial hurdle, interim 
94 strategies must be explored to preserve the current clinical arsenal of antibiotics.
95
96 2. Antimicrobial Resistance
97 There are four main molecular mechanisms by which bacteria may resist the effects of antibiotics; 
98 modification of the target site, modification or destruction of the antibiotic, antibiotic efflux via efflux 
99 transporters and reduced antibiotic influx through decreased membrane permeability (Figure 1) 
100 (Munita & Arias, 2016). These resistance mechanisms can be present together in different 
101 combinations in one bacterial cell, potentially allowing high level resistance to multiple antibiotic 
102 compounds simultaneously (Nikaido, 2009). Some bacteria possess an innate insensitivity towards 
103 certain classes of antibiotics (intrinsic resistance), either through naturally possessing any of the above 
104 mechanisms in the absence of artificial antibacterial selection pressure (ampicillin resistance in 
105 Klebsiella spp.), lack of the antibiotic target (vancomycin resistance in lactobacilli) or lack of a 
106 metabolic pathway or enzyme necessary for the activation of the drug (metronidazole resistance in 
107 aerobic bacteria) (Bryan & Kwan, 1981, Schaechter et al., 2007).
108 Resistance towards antibiotics is acquired by bacteria through either vertical evolution 
109 (endogenous) or horizontal evolution (exogenous). Vertical evolution involves the occurrence of a 
110 spontaneous mutation within the bacterial genome that confers on the bacterium (and subsequently its 
111 progeny) increased resistance to a given compound. HighThe process to achieve high level resistance 
112 is rarely correlated with single mutations; the process is more often stepwise, wherein the selection 
113 pressure of antibiotic treatment causes an initial mutation that allows domination of the pathogen 
114 population by the mutant bacteria, followed by subsequent additional mutations that confer an 
115 additional survival advantage during further antibiotic therapy. Though mutation frequencies can 
116 often be as low as 10-8, this is offset by the vast numbers of cells in bacterial colonies (Drlica & 
117 Perlin, 2011). Work by Santos Costa et al. into fluoroquinolone resistance in S. aureus showed that, in 
118 this case at least, an intermediate resistance phenotype (via upregulation of efflux pump expression) is 
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119 first to appear and acts as a platform from which higher level resistance mutations can occur by 
120 ensuring a sub-lethal intracellular fluoroquinolone concentration (Santos Costa et al., 2015).
121 Horizontal evolution involves the transfer of a resistance gene from a resistant bacterium to a 
122 susceptible bacterium. The mechanisms through which it can occur are conjugation, transduction and 
123 transformation. Conjugation involves the transfer of resistance (R) plasmids containing antibiotic 
124 resistance genes between bacteria through a conjugative pilus, whilst transformation refers to the 
125 alteration of the bacterial genome through the uptake and incorporation of exogenous DNA and 
126 transduction involves transfer of bacterial DNA as facilitated by a viral vector. Such transfer 
127 mechanisms potentially allow a mechanism acquired by less problematic bacterial strains to spread to 
128 a more dangerous bacterial species, with potentially devastating consequences (Alanis, 2005).
129 The genes encoding different resistance mechanisms are often located on transposons, which 
130 makes it easier for them to be transmitted between different bacteria, and some transposons may 
131 contain specialised regions called integrons able to include different resistant genes, thereby making a 
132 bacterial species resistant to multiple different antibiotics (Alanis, 2005). In addition, bacteria can also 
133 have physical states which aid in resisting antibacterial pressure. A variety of both Gram-positive and 
134 Gram-negative bacterial species are known assemble in biofilms (Abee et al., 2011), hydrated 
135 matrices of extracellular polymeric substance in which the bacterial cells are embedded allowing 
136 adherence to both each other and external surfaces. Such structures become problematic when located 
137 in urinary catheters or on medical implants; since biofilms are harder for antibiotics to penetrate at 
138 lethal concentrations, the biofilm provides resistance to antibiotic action (Donlan, 2002).The bacterial 
139 population within the biofilm can also enter into a dormant state where they are not actively growing, 
140 and this can also contribute to antibiotic resistance(Gilbert et al., 1990, Wood et al., 2013). 
141
142 3. Antibiotic Resistance Breakers
143 To tackle the increasing emergence of AMR, alternative treatment strategies have been designed with 
144 the collective aim of reducing the number of antibiotics used and preserving the current classes of 
145 antibiotic for further clinical use. This review aims to showcase the potential of one such strategy, the 
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146 use of antibiotic resistance breakers (ARBs). These are compounds that can increase the effectiveness 
147 of current antibiotics by combatting the resistance mechanisms employed against them. ARBs may or 
148 may not have direct antibacterial effects and can either be co-administered with or conjugated to 
149 failing antibiotics. Though ARBs have previously been referred to as antibiotic adjuvants, the latter 
150 also refers to alternative treatments such as drugs which stimulate host defence mechanisms to aid the 
151 eradication of bacterial infections (Gill et al., 2015); as such, this review will be restricted to the 
152 discussion of compounds that are used to reverse bacterial resistance mechanisms. The major classes 
153 of ARBs currently under investigation include modifying-enzyme inhibitors, membrane 
154 permeabilisers and efflux pump inhibitors.
155 The idea of co-administering ARBs with conventional antibiotics stems from dual antibiotic 
156 therapy, which has enjoyed success in the past through either synergistic or additive effects of the 
157 individual antibiotic agents (Kalan & Wright, 2011), and several ARBs have enjoyed lengthy clinical 
158 use including the β-lactamase inhibitors (Drawz & Bonomo, 2010). Successful co-administered ARBs 
159 should enhance the effects of antibiotics by combatting the bacterial resistance mechanisms employed 
160 against the latter, allowing lower doses of antibiotics to be used. The minimum inhibitory 
161 concentration (MIC), the minimal concentration required of a compound to prevent visible growth of 
162 the pathogenic species under defined conditions (Wiegand et al., 2008), is a useful term in this regard; 
163 the more successful ARBs achieve greater reductions in the MICs of antibiotics versus antibiotic 
164 monotherapy. Such potentiation is an attractive prospect, both because reduced antibiotic selection 
165 pressure could slow the onset of resistance and because widening of the therapeutic window may 
166 allow for the alleviation of side effects experienced by patients on antibiotic monotherapy.
167
168 3.1. Modifying Enzyme Inhibitors
169 Bacteria employ a diverse range of enzymes to modify or destroy antibiotics in order to render them 
170 ineffective and achieve a resistant phenotype. These enzymes can be categorised by both their 
171 mechanisms of action and their substrate antibiotics. Hydrolysis of certain susceptible bonds within 
172 the antibiotic molecule, transfer of a functional group to the antibiotic and (less commonly) the 
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173 actions of redox and lyase enzymes are all examples of detoxification mechanisms (Wright, 2005). 
174 This led to the development of antibiotics that would tolerate their actions, such as the β-lactam 
175 flucloxacillin which was designed to tolerate the action of the penicillinases (Sutherland et al., 1970). 
176 A method which has found more success is the design of modifying enzyme inhibitors, a term which 
177 encompasses the wide variety of chemical compounds that target bacterial enzymes involved in 
178 antibiotic modification and destruction. Modifying enzyme inhibitors are used to disrupt bacterial 
179 detoxification enzymes, increasing the effectiveness of a co-administered antibiotic. Two major 
180 classes are the β-lactamase inhibitors and aminoglycoside-modifying enzymes.
181
182 3.1.1. Β-Lactamase Inhibitors
183 The most successful class of ARBs is arguably the β-lactamase inhibitors (BLIs). β-lactam antibiotics 
184 function by interfering with bacterial cell-wall synthesis, binding to and inactivating the C-terminal 
185 transpeptidase domain of penicillin-binding proteins which are responsible for the cross-linking of the 
186 peptidoglycan chains in the cell wall (Fisher et al., 2005). The β-lactams include several frequently 
187 prescribed families of antibiotics such as the penicillins and cephalosporins. They remain the most 
188 widely used class of antibiotics, reported to comprise 65% of the global antibiotic market in 2004 
189 (Elander, 2003), while broad-spectrum penicillins and cephalosporins were reported to be the two 
190 most consumed drug classes globally in 2010 (Van Boeckel et al., 2014). β-lactamases (EC 3.5.2.6) 
191 are bacterial enzymes that hydrolyse the β-lactam rings such drugs possess, inactivating them. 
192 Modification of β-lactam drugs is the major defence mechanism for Gram-negative pathogenic 
193 bacteria, with β-lactamases differing in their mechanisms and their substrate specificities (Wilke et 
194 al., 2005). Of note, carbapenemases can often act on carbapenem drugs and a wide range of other β-
195 lactams, including penicillins, cephalosporins and monobactams (Queenan & Bush, 2007). These 
196 enzymes are of special concern, since carbapenems are generally reserved as a last resort for many 
197 complicated infections, both Gram-positive and Gram-negative (Papp-Wallace et al., 2011).
198 There are two widely accepted classification systems for β-lactamases. The Ambler molecular 
199 classification divides them into classes A-D based on sequence homology, each of which function via 
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200 slightly different mechanisms. All four classes hydrolyse the β-lactam ring, but enzymes of classes A, 
201 C and D do so through use of a serine nucleophile, whereas those of class B require a metal cofactor, 
202 usually a zinc atom, to achieve the same effect. Because of the need for the metal cofactor, class B β-
203 lactamases may also be referred to as metallo-β-lactamases (MBLs) (Ambler, 1980). An alternative 
204 classification, known as the Bush-Jacoby-Medeiros functional classification, is based on substrate 
205 specificity and includes four main groups based on inhibitor profile, with group 2 further divided into 
206 several subgroups (Bush & Jacoby, 2010). The extended spectrum β-lactamases (ESBLs), often 
207 loosely defined as β-lactamases which confer resistance against penicillins, aztreonam and first, 
208 second and third generation cephalosporins, are recognised as particularly problematic. ESBLs may 
209 be regarded as members of class A of the Ambler molecular classification; with the OXA-type β-
210 lactamases being an exception, named after their ability to hydrolyse oxacillin and members of class 
211 D. Carbapenems are usually regarded as the drugs of choice to eradicate strains possessing ESBLs. 
212 However, several ESBL-producing clinical isolates have been identified which are resistant to 
213 carbapenems (Paterson & Bonomo, 2005). For example, a P. aeruginosa strain has been identified 
214 which produces both the ESBL PER-1 and the carbapenemase VIM-2 (Docquier et al., 2001).
215 Several BLIs widely used in the clinical setting are themselves β-lactam compounds. One 
216 well documented example is clavulanic acid (Figure 2), commonly sold as the combination products 
217 co-amoxiclav (combined with the β-lactam amoxicillin; marketed by GlaxoSmithKline as 
218 Augmentin®) and co-ticarclav (combined with ticarcillin; marketed by GlaxoSmithKline as 
219 Timentin®). While clavulanic acid displays poor antimicrobial activity in vivo (Reading et al., 1983), 
220 its β-lactamase inhibitory activity affords the co-administered β-lactam protection from enzymatic 
221 degradation (Bush, 1988). Predominantly active against Ambler class A β-lactamases, clavulanic acid 
222 irreversibly acylates the catalytic serine residue, resulting in an inactive acyl-enzyme complex. 
223 Clavulanic acid has been shown to inhibit the plasmid-encoded β-lactamases of E. coli and S. aureus, 
224 but not the chromosomally-encoded versions found in Pseudomonas and Enterobacter strains 
225 (Wright, 1999). Thus, co-amoxiclav has activity against both amoxicillin-sensitive and select 
226 amoxicillin–resistant strains of clinically-relevant pathogenic microorganisms. However, Leflon-
227 Guibout et al. studied co-amoxiclav resistance in E. coli clinical isolates, defined by an MIC greater 
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228 than 16 μg mL-1, in 14 French hospitals from 1996 to 1998 and found that the overall resistance rate 
229 was 5% with most resistant isolates identified in patients with respiratory tract infections (Leflon-
230 Guibout et al., 2000). Such reports of resistance to the established BLIs  (Drawz & Bonomo, 2010) 
231 have driven fresh efforts into finding novel alternatives.
232 Sulbactam (CP-45,899; developed by Pfizer (English et al., 1978)) and tazobactam (YTR 830 
233 H; developed by Taiho Pharmaceutical Co. (Aronoff et al., 1984)) are both penicillanic acid sulfones 
234 with β-lactamase inhibitory activity (Figure 2). Both compounds inhibit TEM-type β-lactamases 
235 (IC50s of 0.03 and 0.01 against TEM-3, respectively), though sulbactam is far less effective against 
236 SHV- and OXA-type β-lactamases (Payne et al., 1994). Available combinations of sulbactam with β-
237 lactam antibiotics include ampicillin-sulbactam, which shows limited activity against ESBL-
238 producers including strains of E. coli and K. pneumoniae (Rafailidis et al., 2007), and cefoperazone-
239 sulbactam, effective against ESBL-positive strains of Pseudomonas spp., Acinetobacter spp., 
240 Klebsiella spp. and E. coli (Bodey et al., 1989, Mohanty et al., 2005). Sulbactam has also been shown 
241 to inhibit penicillin binding protein 3 in Acinetobacter spp., granting it direct antibacterial activity 
242 against this genus (Penwell et al., 2015).
243 Combinations of β-lactams and tazobactam currently in clinical use include ceftolozane-
244 tazobactam and piperacillin-tazobactam. Ceftolozane-tazobactam was approved in December 2014 by 
245 the FDA for treatment of complicated intra-abdominal and urinary tract infections and shows activity 
246 against multidrug-resistant (MDR) P. aeruginosa (MIC50 2 μg mL-1; MIC90 8 μg mL-1), ESBL-
247 negative K. pneumoniae (MIC50 0.25 μg mL-1; MIC90 0.5 μg mL-1) and ESBL-positive E. coli (MIC50 
248 0.5 μg mL-1; MIC90 4 μg mL-1), among others. A dose reduction is required for patients with renal 
249 impairment, depending on creatinine clearance (Cho et al., 2015). In comparison, work by Mohanty et 
250 al. demonstrated the piperacillin-tazobactam combination, approved by the FDA in 1993 (Shlaes, 
251 2013), to have superior percentage coverage of ESBL-positive strains of Pseudomonas spp., 
252 Klebsiella spp., E. coli, Enterobacter spp. and Citrobacter spp. versus cefoperazone-sulbactam and 
253 ticarcillin-clavulanic acid.  In India, the cephalosporin cefepime has been used with tazobactam and 
254 this combination is gaining ground as an attractive new prospect for the treatment of MDR Gram-
255 negative pathogens (Bush, 2015, Livermore et al., 2018).
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256 Brobactam (BRL 25214; Figure 2), structurally similar to sulbactam and tazobactam, was 
257 developed by LEO Pharma A/S as another β-lactamase inhibitor (Wise et al., 1992). The work of 
258 Melchior and Keilding demonstrated that brobactam alone possessed 8-50 fold higher potency than 
259 clavulanic acid against chromosomally-encoded cephalosporinase enzymes in Enterobacteriaceae and 
260 that an ampicillin-brobactam combination held superior activity in vitro to co-amoxiclav against 
261 Proteus vulgaris, Morganella morganii, Citrobacter freundii and Yersinia enterocolitica (Melchior & 
262 Keiding, 1991). However, despite favourable results for a combination of brobactam and the β-lactam 
263 prodrug pivampicillin from an eight-person tolerability study (Wise et al., 1992), development of 
264 brobactam appears to have been discontinued and it is not available for use in the clinic.
265
266 AAI101 (Figure 2), a novel penicillanic acid sulfone similar in structure to tazobactam, is an 
267 ESBL inhibitor active against some class A and D carbapenemases (Mushtaq, 2014, Nordmann, 2014) 
268 that is being developed by Allecra Therapeutics as a combination therapy with cefepime. Crandon and 
269 Nicolau reported that the combination (using 8 μg mL-1 of AAI101) was effective against a panel of 
270 223 cefepime-resistant Enterobacteriaceae isolates, improving on the MIC50 of cefepime by over 512-
271 fold (Crandon, 2014, Crandon & Nicolau, 2015). They subsequently demonstrated a strong 
272 correlation between increasing AAI101 concentration and MICs for the cefepime-AAI101 
273 combination in K. pneumoniae-infected female ICR mice between 1 and 16 μg mL-1 (Crandon & 
274 Nicolau, 2015). As of 2017, the combination is in phase II clinical trials (Papp-Wallace, 2017).
275 As early as the late 1980s, nosocomial isolates resistant to combination therapies involving 
276 the aforementioned β-lactam-based BLIs were being reported (Legrand et al., 1988, Ling et al., 1988, 
277 Eliopoulos et al., 1989, Cullmann & Stieglitz, 1990). New BLIs were required for the next generation 
278 of combination treatments, and to this end classes of structurally divergent compounds with BLI 
279 activity were investigated. One such class of newer, non-β-lactam BLIs is the diazabicyclooctanes 
280 (DABCOs), based on a (5R)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl sulphate core (Figure 3). The 
281 strained nature of this core, further activated towards nucleophilic attack through the incorporation of 
282 a sulphate group on one nitrogen of the urea functionality, underlies the β-lactamase inhibitory 
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283 activities of the DABCOs. Figure 3 and Table 1 list the structures of the compounds in this class 
284 either approved for clinical use or currently in development.
285 Avibactam (NXL104; developed by Actavis and AstraZeneca; Table 1), when approved for 
286 clinical use in the US in 2015, was both the first DABCO brought to market and the first new BLI to 
287 be approved in 22 years (Garber, 2015). A comparison by Stachyra et al. of avibactam with clavulanic 
288 acid, sulbactam and tazobactam showed the former to be superior in inhibitory activity for all Ambler 
289 class A and C β-lactamases tested, including TEM-1, KPC-2 and SHV-4; investigation of the mode of 
290 action revealed that avibactam covalently modifies a catalytic serine residue in the β-lactamase active 
291 site in the same manner as the penicillanic sulfones, but that the highly stable nature of the carbamyl-
292 enzyme complex underpins its enhanced inhibitory activity (Stachyra et al., 2010). In combination 
293 with the third-generation cephalosporin ceftazidime (marketed as Avycaz® in the US by Allergan and 
294 as Zavicefta® in Europe by Pfizer), it is approved by the FDA for the treatment of complicated intra-
295 abdominal infections in combination with metronidazole and for the treatment of complicated urinary 
296 tract infections (Mosley et al., 2016, Wright, 2016). The combination has broad Gram-negative 
297 activity, including Enterobacteriaceae and P. aeruginosa (Crandon et al., 2012, Flamm et al., 2014, 
298 Chalhoub et al., 2015, Sader et al., 2015), and was found to be superior to ceftazidime alone against 
299 120 KPC-producing carbapenem-resistant Enterobacteriaceae clinical isolates in a study by 
300 Castanheira and co-workers in 2015 (Castanheira et al., 2015). However, while a subsequent study by 
301 Castanheira et al. found 99.3% of Enterobacteriaceae isolates from US hospitals between 2012 and 
302 2015 were be susceptible to ceftazidime-avibactam (Castanheira et al., 2017), Shields et al. have since 
303 detailed the first instances of K. pneumoniae ceftazidime-avibactam resistance in patients treated with 
304 the combination for 10-19 days. They identified the causes of said resistance to be mutations (chiefly 
305 a D179Y/T243M double mutation) in the plasmid-located blaKPC-3 gene (Shields et al., 2017). As with 
306 ceftolozane-tazobactam, patients with renal impairment require a dose reduction according to 
307 creatinine clearance levels (Mosley et al., 2016). The separate combinations of avibactam and both 
308 ceftaroline and aztreonam are in late-stage clinical trials (ClinicalTrials.gov, NCT03329092) (Wright, 
309 2016).
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310 Another DABCO in late stage development is relebactam (MK-7655; Merck & Company, 
311 Inc.; Table 1), currently being investigated for combination with the carbapenem imipenem and the 
312 dehydropeptidase I inhibitor cilastatin (the latter employed to prevent degradation of imipenem in the 
313 kidneys). The structure of relebactam is similar to that of avibactam, with a piperazine ring added to 
314 the nitrogen of the C2 amide substituent (Mangion et al., 2011). Zhanel et al. have recently compiled 
315 a series of modal MIC50 and MIC90 values for both imipenem and imipenem-relebactam based on a 
316 review of available in vitro studies; they report that relebactam enhances the activity of imipenem 
317 versus the majority of Enterobacteriaceae, including KPC-producing K. pneumoniae (>16 fold 
318 reduction in MIC90), and imipenem-resistant P. aeruginosa (8-fold reduction), though no 
319 enhancement was observed against KPC-producing P. aeruginosa or A. baumannii (Zhanel et al., 
320 2018). As of September 2017, Merck have completed a phase III trial for evaluation of the safety and 
321 efficacy of the imipenem-cilastatin-relebactam combination versus imipenem-cilastatin-colistimethate 
322 sodium in treatment of imipenem-resistant bacterial infections (ClinicalTrials.gov, NCT02452047). A 
323 number of clinical trials are currently underway involving imipenem-cilastatin-relebactam, including 
324 a phase III trial in Japan investigating treatment of complicated intra-abdominal infections and 
325 complicated urinary tract infections (ClinicalTrials.gov, NCT03293485), a phase III noninferiority 
326 trial versus piperacillin-tazobactam for treatment of hospital-acquired and ventilator-associated 
327 bacterial pneumonia (ClinicalTrials.gov, NCT02493764) and a phase I trial investigating the 
328 individual pharmacokinetic profiles of the three drugs following administration (ClinicalTrials.gov, 
329 NCT03230916).
330 In August 2013, Naeja Pharmaceutical Inc. were granted a patent for a promising series of 
331 novel C2 N-(hydroxy)amide and hydrazide DABCOs (Maiti, 2013), subsequently in-licensed to 
332 Fedora Pharmaceuticals (Inc., 2012). Lead compounds identified within this series included FPI-1459, 
333 FPI-1465, FPI-1523 and FPI-1602 and, unlike previous DABCOs, they were found to have multiple 
334 modes of action; in addition to their BLI activities, they act directly as antibacterial agents through 
335 inhibiting penicillin-binding protein 2 and also as potentiators of their accompanying antibiotics in the 
336 absence of β-lactamases (Morinaka et al., 2015, King et al., 2016, Bush & Page, 2017, Bush, 2018). 
337 Meiji Seika Pharma and Fedora Pharmaceuticals partnered with F. Hoffmann la Roche in January 
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338 2015 (Philippidis, 2015) to further develop FPI-1459, renamed nacubactam (RO7079901, previously 
339 OP0595, RG6080). In separate papers, Morinaka and co-workers investigated the ability of 
340 nacubactam to resensitise CTX-M-15 positive E. coli, KPC-positive K. pneumoniae and AmpC-
341 derepressed P. aeruginosa to piperacillin, meropenem and cefepime both in vitro and in vivo; they 
342 found 4 μg mL-1 of nacubactam sufficient to achieve mean MICs of <0.03 in vitro for all three β-
343 lactams in the E. coli and K. pneumoniae strains tested (Morinaka et al., 2016). At this concentration, 
344 only the cefepime combination achieved a mean MIC below 2 μg mL-1 in the P. aeruginosa strains 
345 tested, indicating cefepime to be the optimal β-lactam partner for nacubactam (Morinaka et al., 2017). 
346 Nacubactam was also observed to retain its β-lactam enhancer effect in Enterobacteriaceae possessing 
347 nacubactam-resistant metallo-β-lactamases (Livermore et al., 2016). Having completed a phase I trial 
348 in 2014 to assess safety and tolerability in adult Caucasian males (ClinicalTrials.gov, NCT02134834), 
349 nacubactam (Table 1) has since been involved in a number of other phase I trials and appears to be 
350 being developedin  development in combination with meropenem for the treatment of meropenem-
351 resistant Gram-negative infections (ClinicalTrials.gov, NCT03182504, NCT03174795, 
352 NCT02972255 & NCT02975388).
353 Previously known as WCK 5107, zidebactam (Table 1) is in development by Wockhardt Ltd 
354 (Bush & Page, 2017) and was originally patented in 2013 (Patel, 2013). Zidebactam inhibits class A, 
355 C and select class D β-lactamases (Khande, 2016) and, like nacubactam, possesses both direct activity 
356 against MDR Gram-negative bacteria (Deshpande, 2016) and the capability to augment the activity of 
357 β-lactams in the absence of β-lactamases (Livermore, 2016) in a number of species including A. 
358 baumannii (Moya et al., 2017) and P. aeruginosa (Moya et al., 2017). A combination with cefepime, 
359 also known as WCK 5222 and FED-ZID, was shown to be effective in vitro against a global 
360 collection of 7,876 clinical isolates from 2015, consisting of Enterobacteriaceae, P. aeruginosa and 
361 Acinetobacter spp.; in a 1:1 ratio, the combination achieved MICs below or equal to 4 μg mL-1 in 
362 99.9% of Enterobacteriaceae isolates and MICs below or equal to 8 μg mL-1 in 99.5% of P. 
363 aeruginosa isolates (Sader et al., 2017). These results are in concurrence with a subsequent, smaller 
364 scale study conducted by Sader and co-workers (Sader et al., 2017). However, a separate study by 
365 Livermore and co-workers found cefepime-zidebactam to be ineffective (over 32 μg mL-1) against 
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366 Proteeae, Serratia spp. and select strains of E. coli, Klebsiella spp., Enterobacter spp. and Citrobacter 
367 spp. (Livermore et al., 2017). A number of phase I clinical trials have been completed investigating 
368 the safety, tolerability and pharmacokinetics of zidebactam, both alone (ClinicalTrials.gov, 
369 NCT02674347) and in combination with cefepime (ClinicalTrials.gov, NCT02532140 & 
370 NCT02707107) (Preston et al., 2019).
371 Also in development by Wockhardt Ltd is WCK 5153 (Table 1), a close structural analogue 
372 of WCK 5107 differing only in the nature of the aliphatic ring of the side arm moiety (a 3-subsituted 
373 piperidine in WCK 5107, a 3-subsituted pyrrolidine in WCK 5153). WCK 5153 inhibits class A, C 
374 and some class D β-lactamases, with increased potency versus class C enzymes compared to both 
375 avibactam and relebactam (Papp-Wallace et al., 2018). As for WCK 5107, WCK 5153 shows a β-
376 lactam enhancer effect against A. baumannii (Moya et al., 2017) and P. aeruginosa (Moya et al., 
377 2017), with the combination of cefepime and WCK 5107 achieving MICs of 0.06-4 μg mL-1 in a 
378 panel of P. aeruginosa strains including porin mutants (Moya et al., 2017).
379 Another DABCO in development by Wockhardt Ltd. is WCK 4234 (Table 1). Like 
380 zidebactam, it is active against class A, C and some class D β-lactamases (Patil, 2016). A combination 
381 with meropenem, known as WCK 5999, has been shown to be superior to meropenem monotherapy 
382 against MDR clinical isolates of A. baumannii (Huband, 2016), including OXA-23- and OXA-24-
383 producing strains (Castanheira, 2016, Mushtaq et al., 2017), K. pneumoniae (Castanheira, 2016) and 
384 P. aeruginosa (Huband, 2016).
385 An effort by Entasis Therapeutics towards the rational design of analogues of avibactam with 
386 improved Gram-negative penetration and better activity against class D β-lactamases led to the 
387 discovery of ETX2514 (Figure 3), a DABCO analogue with class A, C and broad class D β-lactamase 
388 inhibitory activity (Durand-Reville et al., 2017). In particular, activity against the class D enzymes 
389 OXA-10, OXA-23 and OXA-24 is significantly improved in ETX2514 versus avibactam (Shapiro et 
390 al., 2017). Rate constants of time-dependent β-lactamase inhibition for ETX2514 (compared to 
391 avibactam) were approximately 100-fold higher for class A and C enzymes and approximately 1000-
392 fold higher for class D β-lactamases. ETX2514 was also observed to be an inhibitor of penicillin 
393 binding protein 2 in E. coli and A. baumannii, helping explain its direct antibacterial activity against 
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394 wider Enterobacteriaceae including mcr-1-positive E. coli (MIC90 1 μg mL-1, 10 strains), K. 
395 pneumoniae (MIC90 4 μg mL-1, 20 strains), Enterobacter cloacae (MIC90 1 μg mL-1, 10 strains), 
396 Stenotrophomonas maltophilia (MIC90 16 μg mL-1, 18 strains), Citrobacter spp. (MIC90 2 μg mL-1, 55 
397 strains) and class B β-lactamase-positive and -negative CRE (MIC90 8 μg mL-1, 32 strains). The 
398 compound was well tolerated up to 2 g kg-1 in both rats and dogs in separate 14-day toxicological 
399 studies (Durand-Reville et al., 2017).
400 Imipenem, meropenem, ceftazidime and aztreonam were combined individually with 
401 ETX2514 (4 μg mL-1) against panels of 202 random E. coli clinical isolates and 202 random P. 
402 aeruginosa clinical isolates, respectively; MIC90 values for all four combinations against the E. coli 
403 panel were below 0.06 μg mL-1, whereas imipenem was the most effective β-lactam partner versus P. 
404 aeruginosa (MIC90 2 μg mL-1). In a similar manner, the same four β-lactams and sulbactam were 
405 trialled with ETX2514 against 198 random K. pneumoniae clinical isolates; in this case, sulbactam 
406 was the most effective partner (MIC90 4 μg mL-1). The sulbactam-ETX2514 combination was further 
407 tested against 1,131 A. baumannii clinical isolates, including MDR, meropenem-resistant and colistin-
408 resistant phenotypes, and improved upon sulbactam monotherapy 16-fold (64 – 4 μg mL-1) (Durand-
409 Reville et al., 2017). McLeod et al. investigated the frequency of spontaneous resistance to 
410 sulbactam-ETX2514 in four different A. baumannii clinical isolates and found it to be low (<9.0 × 
411 10−10 frequency at 4x MIC of combination) with no ETX2514-resistant β-lactamases detected in 
412 resistant mutants (McLeod et al., 2018). ETX2514 has completed an open-label, phase I study 
413 (Rodvold et al., 2018) in 30 healthy adults in combination with sulbactam and a 124-person trial both 
414 alone and in combination with sulbactam compared with imipenem/cilastatin and a placebo to 
415 evaluate its safety, tolerability and pharmacokinetic profile (ClinicalTrials.gov, NCT02971423). As of 
416 April 2018, the combination is undergoing a phase I trial in 30 patients with varying degrees of renal 
417 impairment (ClinicalTrials.gov, NCT03310463) and phase II trial in 80 patients with complicated 
418 urinary tract infections (ClinicalTrials.gov, NCT03445195).
419 Also in development by Entasis Therapeutics is the DABCO ETX0282, an oral prodrug of 
420 ETX1317 (structures not yet disclosed). ETX1317, in line with other members of this class of BLI, 
421 enjoys activity against class A, C and D β-lactamases. Like ETX2514, it is an inhibitor of penicillin 
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422 binding protein 2 in E. coli, affording the compound intrinsic antimicrobial activity. Based on testing 
423 in combination against a SHV-18, OXA-2 and OKP-6 positive strain of K. pneumoniae, cefpodoxime 
424 was selected as the optimal partner for ETX1317 at 4 μg mL-1 of the latter (Durand-Réville, 2017). 
425 Pharmacokinetic studies in both rats and dogs showed both the prodrug and active form to have high 
426 bioavailabilities (>90%) and similar elimination half-lives to cefpodoxime. The combination of 
427 ETX0282 and cefpodoxime was effective at the three concentrations of BLI tested (10, 25 and 100 mg 
428 kg-1; cefpodoxime proxetil fixed at 50 mg kg-1) against E. coli ARC2687 in a neutropenic murine 
429 thigh infection model and against CRE K. pneumoniae ARC5118 at 200 and 400 mg kg-1 BLI 
430 concentrations (O’Donnell, 2017). In addition, the combination of cefpodoxime and 4 μg mL-1 
431 ETX1317 was active against 33 of a 35 isolate panel of KPC and/or MBL-positive Enterobacteriaceae 
432 (MICs <0.5 μg mL-1), outperforming ceftazidime and 4 μg mL-1 avibactam (McLeod, 2017). 
433 ETX0282 is currently undergoing a phase I clinical trial in healthy volunteers to evaluate 
434 pharmacokinetics and safety (ClinicalTrials.gov, NCT03491748).
435 Originally developed by LegoChem Biosciences (South Korea) as LCB18 0055, as of 
436 September 2017 Geom Therapeutics have secured a worldwide license excluding South Korea to 
437 further develop this DABCO, renamed GT-055 (Table 1), in combination with the novel siderophore-
438 conjugated cephalosporin GT-1 (also developed by LegoChem Biosciences and subsequently licensed 
439 to Geom Therapeutics) (AdisInsight, 2017). GT-055 is active against class A, C, D and some class B 
440 β-lactamases, has intrinsic activity against some Enterobacteriaceae and is reported to potentiate GT-1 
441 against MDR strains of A. baumannii and P. aeruginosa (Thye, 2018). Against a panel of 334 
442 Enterobacteriaceae clinical isolates, GT-055 was observed to increase GT-1 activity against MBL-
443 positive E. coli and K. pneumoniae strains (MIC50/90 4/8 μg mL-1 for both), including porin/efflux 
444 mutant strains (16-fold lower MIC90, from 64 μg mL-1 to 4 μg mL-1) (Sader, 2018). The combination 
445 was found to improve upon GT-1 alone in a K. pneumoniae murine infection model (Oh, 2018). The 
446 combination showed activity against the biothreat pathogen Yersinia pestis, both in vitro (MIC range 
447 <0.03-2 μg mL-1) and in mice (90% survival at 30 days post-challenge, dosing 200 mg kg-1 GT-1 and 
448 300 mg kg-1 GT-055) (Zumbrun, 2018). GT-055 has also been shown to potentiate GT-1 in strains of 
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449 E. coli with ESBLs that afford greater protection against the latter, such as CTX-M-15, and in strains 
450 of K. pneumoniae with DHA-1 AmpC (Phuong, 2018).
451 Boronic acid transition state inhibitors (BATSIs) are a novel class of BLIs with activity 
452 against serine β-lactamases. BATSIs are characterised by the presence of a boronic acid functionality, 
453 cyclic or acyclic, within the molecule; the electrophilic nature of the boron atom imitates the 
454 electrophilic carbonyl centre of a β-lactam ring, but nucleophilic attack by the catalytic serine residue 
455 of a β-lactamase generates a tetrahedral enzyme-BATSI adduct, inhibiting the enzyme in a 
456 competitive, reversible manner (Rojas et al., 2016).
457 Of the BATSIs, vaborbactam (RPX7009; developed by Rempex Pharmaceuticals, Inc., A 
458 Subsidiary of The Medicines Company; Figure 4) is currently the furthest advanced with respect to 
459 clinical development. Hecker et al. report that it shows inhibition of a broad spectrum of class A, C 
460 and D enzymes, including KPC, CTX-M, SHV, and CMY, and improves upon both clavulanic acid 
461 and tazobactam against KPC-2, P99 and CMY-2 (Hecker et al., 2015). Originally partnered with the 
462 carbapenem biapenem (RPX2003, also developed by Rempex Pharmaceuticals) (Livermore & 
463 Mushtaq, 2013), Goldstein and co-workers found the combination improved upon biapenem 
464 monotherapy against select anaerobic Gram-negative bacteria (Bacteroides fragilis, Bacteroides 
465 ovatus and Fusobacterium mortiferum) but not significantly for any anaerobic Gram-positive bacteria 
466 tested (Goldstein et al., 2013). Livermore and Mushtaq found vaborbactam itself to lack any direct 
467 antibacterial activity, but found the biapenem-vaborbactam combination to improve upon biapenem 
468 alone against a panel of 145 KPC-positive Enterobacteriaceae isolates (94.4% of isolate MICs below 
469 1 μg mL-1 for combination vs. 5.5% for biapenem alone) at a vaborbactam concentration of 8 μg mL-1 
470 (Livermore & Mushtaq, 2013). A combination with the cephalosporin cefepime at 4 μg mL-1 
471 vaborbactam was active in vitro against a panel of 13 Enterobacteriaceae expressing class A, C and D 
472 β-lactamases, showing 2 - 256-fold potentiation of cefepime across the panel, and vaborbactam also 
473 potentiated the carbapenems biapenem, meropenem, ertapenem and imipenem up to 512-fold versus a 
474 panel of 11 Enterobacteriaceae expressing class A carbapenemases (Hecker et al., 2015).
475 Lapuebla and co-workers evaluated the meropenem-vaborbactam combination 
476 (Carbavance®) at 8 μg mL-1 vaborbactam in vitro against a collection of 4,500 Gram-negative clinical 
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477 isolates from 11 New York City hospitals and found it to be highly active against KPC-producing 
478 Enterobacteriaceae including E. coli, Enterobacter spp. and K. pneumoniae. 98.5% of KPC-producing 
479 Enterobacteriaceae strains showed MICs below 1 μg mL-1, but vaborbactam did not potentiate 
480 meropenem against A. baumannii and P. aeruginosa. In addition, K. pneumoniae isolates with 
481 reduced expression of genes ompK35 and ompK36 were less susceptible to the combination (Lapuebla 
482 et al., 2015). A number of subsequent studies (Castanheira et al., 2016, Castanheira et al., 2017, 
483 Lomovskaya et al., 2017, Hackel et al., 2018, Pfaller et al., 2018) were in agreement with these 
484 findings; together, they note a number of additional factors that contribute to increased MICs for 
485 meropenem-vaborbactam in K. pneumoniae isolates, including possession of metallo-β-lactamases, 
486 reduced expression of ompK37, increased expression of the AcrAB-TolC efflux system (Castanheira 
487 et al., 2016) and possession of class B or D carbapenemases (Lomovskaya et al., 2017). Sun and co-
488 workers found the frequency of spontaneous resistance to the combination to be <1 × 10-8 in 77.8% of 
489 a panel of KPC-producing K. pneumoniae strains at 8 μg mL-1 of both meropenem and vaborbactam 
490 (Sun et al., 2017). Reports by Weiss et al. and Sabet et al. demonstrated that the combination is active 
491 in a murine pyelonephritis model (Weiss et al., 2018), an in vitro hollow fibre model (Sabet et al., 
492 2018) and murine thigh and lung infection models (Sabet et al., 2018), respectively.
493 Vaborbactam has completed a number of phase I clinical trials alone (Griffith et al., 2016) 
494 and in combination with biapenem (ClinicalTrials.gov, NCT01772836) and meropenem 
495 (ClinicalTrials.gov, NCT02073812) (Rubino et al., 2018, Rubino et al., 2018). The meropenem-
496 vaborbactam has completed two phase III trials, evaluating its use against complicated urinary tract 
497 infections (Kaye et al., 2018) and infections of carbapenem-resistant Enterobacteriaceae (Wunderink 
498 et al., 2018), and the FDA approved the combination for the former indication in August 2017 
499 (McCarthy & Walsh, 2017). Meropenem-vaborbactam is currently being evaluated for treatment of 
500 hospital-acquired and ventilator-associated bacterial pneumonia in a TANGO III trial 
501 (ClinicalTrials.gov, NCT03006679).
502 Other notable work in the field of BATSIs includes that of VenatoRx Pharmaceuticals, who 
503 are developing the BATSI VNRX-5133 (Figure 4) (Docquier, 2018). Patented in 2016 (Burns, 2016), 
504 VNRX-5133 inhibits class A, C and D serine β-lactamases and VIM/NDM class B metallo-β-
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505 lactamases in both carbapenem-resistant Enterobacteriaceae and P. aeruginosa. X-ray crystallography 
506 conducted on VNRX-5133 bound to the class A serine ESBL CTX-M-15 found the compound to bind 
507 the enzyme at the catalytic serine residue via the boron atom, which was sp3 hybridised. Similar 
508 experiments with VIM-2 found that the boron adopted the same hybridisation state, with its hydroxyl 
509 group interacting with Zn1 and the Asn233 residue and the cyclic oxygen atom interacting with Zn2 
510 (Docquier, 2018). Steady state inhibition studies confirmed VNRX-5133 to be a potent competitive 
511 VIM-2 inhibitor (Daigle, 2018). A combination with cefepime appears promising; of two panels, one 
512 of 1,120 recent Enterobacteriaceae isolates and another of 155 NDM- or OXA-positive 
513 Enterobacteriaceae isolates, 99% and 81% were inhibited at or below the cefepime breakpoint, 
514 respectively (Hackel, 2018, Kazmierczak, 2018). Cefepime activity was also restored to below 
515 breakpoint (8 μg mL-1) in 93.1% of 245 clinical CRE isolates (Tyrrell, 2018), 70% of 817 isolates of 
516 P. aeruginosa resistant to cefepime, meropenem or both (Estabrook, 2018) and 90% of 29 ESBL- and 
517 carbapenemase-producing P. aeruginosa isolates (Donnelly, 2018). 98.3% of 1,066 
518 Enterobacteriaceae urinary tract infection isolates resistant to co-amoxiclav and levofloxacin were 
519 susceptible to the combination (Hackel, 2018). Potentiation of cefepime between 8 and over 2048-fold 
520 by VNRX-5133 against individual Enterobacteriaceae strains possessing CTX-M-15, KPC, VIM-1, 
521 NDM-1 and OXA-48 enzymes has also been reported (C. Hamrick, 2018). The combination has 
522 proved effective in murine bacteremia (Weiss, 2018), lung (Weiss, 2018), urinary tract (Weiss, 2018) 
523 and neutropenic thigh infection models (Georgiou, 2018), has completed a phase I study in healthy 
524 volunteers (ClinicalTrials.gov, NCT02955459) and is currently undergoing a phase I drug-drug 
525 interaction study (ClinicalTrials.gov, NCT03332732).
526 Very few effective inhibitors of metallo-β-lactamases (MBLs) have been discovered to date, 
527 with none in clinical use currently. Unlike the serine β-lactamases, MBLs achieve hydrolysis of β-
528 lactam antibiotics via a divalent metal cofactor, often zinc (Davies & Abraham, 1974, Wommer et al., 
529 2002). These enzymes are of special concern because of their activity against penicillins, 
530 cephalosporins and carbapenems (covering both widely used and last-resort antibiotics) and their 
531 resistance to the actions of all BLIs in current clinical use (Palzkill, 2013).
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532 A potential clinically useful MBL inhibitor is aspergillomarasmine A, a natural fungal 
533 product that has shown efficacy against the MBLs NDM-1 and VIM-2 and has been shown to 
534 resensitise MBL-positive strains of Pseudomonas spp., Acinetobacter spp. and Enterobacteriaceae to 
535 meropenem. Aspergillomarasmine A restored meropenem activity in CD1 mice infected with NDM-
536 1-producing K. pneumoniae (>95% survival rate after 5 days, single dose of aspergillomarasmine A 
537 and meropenem combination). It is thought to act as a Zn2+ ion chelator, achieving demetallation and 
538 thus inactivation of MBLs (King et al., 2014).
539 Discovered in Japan by Meiji Seika Kaisha Ltd., ME1071 is a maleic acid derivative 
540 (Yamada et al., 2013) and selective MBL inhibitor capable of potentiating carbapenems and 
541 ceftazidime against MBL-positive P. aeruginosa (Ishii et al., 2010). Work by Livermore et al. 
542 demonstrates that, regardless of partner carbapenem, ME1071 achieved its greatest levels of 
543 potentiation against strains possessing IMP-type MBLs and its lowest levels against NDM-type MBLs 
544 (Livermore et al., 2013). Combined with biapenem, ME1071 significantly prolonged the survival of 
545 mice infected with MBL-positive P. aeruginosa compared with both control and biapenem 
546 monotherapy groups (P < 0.05) (Yamada et al., 2013).
547 The metal chelating agents 1,4,7-triazacyclononane-1,4,7-triacetic acid and 1,4,7,10-
548 tetraazacyclod-odecane-1,4,7,10-tetraacetic acid have been reported by Somboro et al. to inhibit 
549 NDM, VIM, and IMP-type MBLs (Somboro et al., 2015, Zhang et al., 2018).
550 Wang et al. have reported that a number of Bi(III)-containing compounds, including colloidal 
551 bismuth subcitrate (CBS), inhibit a large variety of B1 MBLs (at 32 μg mL-1, CBS potentiated 
552 meropenem 16-fold against NDM-1-positive Citrobacter freundii, 64-fold against VIM-2-positive E. 
553 coli BL21 and 8-fold against IMP-4-positive E. coli BL21). IC50 values against NDM-1, VIM-2 and 
554 IMP-4 for CBS were 2.81 ± 0.34 μM, 3.55 ± 0.78 μM and 0.70 ± 0.08 μM, respectively. The study 
555 concluded that such compounds achieve MBL (NDM-1) inhibition through binding to a cysteine 
556 residue (shown to be Cys208 in NDM-1 via a C208A mutant), leading to release of Zn(II) from the 
557 enzyme. CBS was also observed to suppress resistance mutations in NDM-1-positive bacteria; when 
558 added to meropenem (½ MIC concentration) against the NDM-1-positive E. coli strains NDM-HK, 
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559 CBS reduced the mutation frequency from approximately 4 × 10−7 (no CBS) to 1 × 10−10 (256 μg mL-1 
560 CBS) (Wang et al., 2018).
561 Recent studies by Spyrakis et al. and Cain et al. have demonstrated in silico screening as a 
562 possible method of MBL inhibitory discovery and development. Spyrakis and co-workers docked a 
563 commercially available library of compounds with available crystal structures for NDM-1 (protein 
564 data bank ID 3Q6X and 3SPU) to identify a number of non-β-lactam compounds with MBL-
565 inhibitory activity (compound 1 Ki 0.72 ± 0.014 μM) (Spyrakis et al., 2018). In contrast, Cain et al. 
566 used the de novo molecular design program SPROUT to generate possible ligands for a crystal 
567 structure of NDM-1 (protein data bank ID 3Q6X) and found 2-(mercaptomethyl)benzoic acid as a 
568 putative NDM-1 substrate-competitive inhibitor. Further modification of this scaffold resulted in a 
569 number of analogues with potent B1 MBL inhibitory activities (compound 5; NDM-1 IC50 0.31 ± 0.05 
570 μM, VIM-2 IC50 0.07 ± 0.05 μM, IMP-1 IC50 0.14 ± 0.05 μM) (Cain et al., 2018).
571 Two other novel classes of BLI being developed are O-acyl and O-phosphyl hydroxamates. 
572 Tilvawala and Pratt assessed the effectiveness of N-phenylcarbonyl and N-tertbutoxycarbonyl 
573 derivatives of the cyclic O-acyl-hydroxamic acid, 3H-benzo[d][1,2]oxazine-1,4-dione. These 
574 compounds are prodrugs with no BLI activity which spontaneously hydrolyse in aqueous solution to 
575 produce O-phthaloyl hydroxamic acids with serine-β-lactamase inhibitor activity, and both can 
576 subsequently and reversibly cyclise in solution to form phthalic anhydride, another BLI. For both 
577 derivatives, both the O-phthaloyl hydroxamic acid and phthalic anhydride forms can react to form 
578 covalent phthaloyl-enzyme complexes and it was found that incubation of either compound with P99 
579 β-lactamase resulted in inhibition of the enzyme (t1/2 for turnover of CENTA™ (50 µM) by enzyme 
580 (1.0 nM) alone (100s), in presence of phthalic anhydride (500s at 30 mM) and in presence of O-
581 phthaloyl hydroxamic acids (>1500s for both at 10 mM phthalic anhydride, 10 mM hydroxamic 
582 acid)). Inhibition was observed to be transient; this was ascribed to hydrolysis of the phthaloyl-
583 enzyme complexes leading to reactivation of the β-lactamase (Tilvawala & Pratt, 2013).
584 Cyclobutanone derivatives of β-lactams have received attention as potential serine- and 
585 metallo-β-lactamase inhibitory compounds (Johnson et al., 2008, Devi & Rutledge, 2017). Johnson 
586 and co-workers tested a number of such compounds against representative β-lactamases from classes 
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587 A-D (KPC-2, IMP-1, GC1 and OXA-10, respectively); micromolar inhibitory activity was observed 
588 against KPC-2 and GC1, with activity against IMP-1 and OXA-10 less pronounced (Johnson et al., 
589 2010).
590
591 3.1.2. Aminoglycoside-Modifying Enzyme Inhibitors
592 The aminoglycosides are a family of bacterial protein synthesis inhibitors that bind to the A site of the 
593 prokaryotic 70S ribosome and possess bactericidal activity (Doi & Arakawa, 2007). Aminoglycoside 
594 resistance is a major concern because of the several important uses of aminoglycoside antibiotics, 
595 including treatment of infections of Mycobacterium tuberculosis. While the initial treatment for M. 
596 tuberculosis infections usually consists of a combination regimen including rifampicin, ethambutol, 
597 pyrazinamide and isoniazid, streptomycin is a suitable alternative when isoniazid resistance has been 
598 established or if the patient has any tolerability issues with the initial regimen. Amikacin is a suitable 
599 second-line option when there are further issues with resistance or side effects caused by the first-line 
600 drugs (Rojano et al., 2019).
601 Resistance to aminoglycosides may arise through several different mechanisms, including 
602 extrusion by efflux pumps, reduced outer membrane permeability, target modification and enzymatic 
603 inactivation. Target modification may occur by methylation of specific nucleotides within the 16S 
604 rRNA. This resistance mechanism was initially identified in aminoglycoside-producing species such 
605 as Streptomyces spp., providing them with intrinsic resistance against the antibiotics they produce. 
606 This mechanism was subsequently identified in several strains of clinically relevant bacteria such as 
607 P. aeruginosa (Doi & Arakawa, 2007). However, the most prevalent aminoglycoside resistance 
608 mechanism is enzymatic inactivation. As with the β-lactamases, these modifying enzymes may be 
609 further subdivided into several groups, members of which achieve the same effects through slightly 
610 different mechanisms. The three groups of aminoglycoside modifying enzymes are the 
611 aminoglycoside acetyltransferases (AACs), aminoglycoside nucleotidyltransferases (ANTs) and 
612 aminoglycoside phosphotransferases (APHs). AACs function by catalysing the acetylation of primary 
613 amine groups within the aminoglycoside molecules, using acetyl coenzyme A as a donor substrate. 
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614 ANTs are responsible for mediating the transfer of an adenosine monophosphate group to a hydroxyl 
615 group in the aminoglycoside molecule, using ATP as a donor substrate, while APHs catalyse the 
616 transfer of a phosphate group to the aminoglycoside molecule (Ramirez & Tolmasky, 2010). Several 
617 promising inhibitors of these enzymes have been developed, but none have yet entered clinical use.
618 In 1997, Hon and co-workers reported that APH(3’) enzymes (EC 2.3.1.81) show unusually 
619 high structural similarity to eukaryotic protein kinases despite minimal sequence homology (Hon et 
620 al., 1997). This inspired the testing of protein kinase inhibitors as inhibitors of APHs. Selective 
621 inhibition is an important requirement for any such repurposed compound, since the inhibitor must be 
622 able to distinguish between eukaryotic protein kinases and APHs. Stogios et al. identified 
623 pyrazolopyrimidine compounds with selective inhibitory activity against the enzyme APH(3’)-Ia, 
624 which plays a large role in Gram-negative resistance against aminoglycoside antibiotics, and 
625 suggested that these can be further developed to provide a new option for combatting aminoglycoside 
626 resistance (Stogios et al., 2013).
627 Another strategy is the use of bisubstrate analogues, consisting of the aminoglycoside 
628 antibiotic and coenzyme A (CoA). This strategy was successfully carried out with gentamicin; the 
629 bisubstrate showed inhibitory activity in vitro (but not in vivo) towards the enzyme AAC(3)-I. It was 
630 suggested that this was due to poor compound influx into Gram-negative bacterial cells (Williams & 
631 Northrop, 1979). Since this discovery, several aminoglycoside-CoA conjugates have been 
632 synthesised, with varying functional groups. It was found that amide-linked bisubstrates that 
633 contained sulfoxide and sulfone functionalities showed effective inhibition of AAC(6)-Ii (EC 
634 2.3.1.82) at nanomolar concentrations (Gao et al., 2008).
635 Boehr et al. screened several antimicrobial peptides against the aminoglycoside-modifying 
636 enzymes APH(3’)-IIIa (EC 2.7.1.95), AAC(6’)-Ii and AAC(6’)-APH(2″) (EC 2.3.1.81). The bovine 
637 peptide indolicidin (primary sequence H-ILPWKWPWWPWRR-NH2) and its analogues CP11CN (H-
638 ILKKWPWWPWRRK-NH2) and CP10A (H- ILAWKWAWWAWRR-NH2) were all demonstrated to 
639 inhibit AAC(6’)-Ii, with IC50 values of 13, 23 and 4.4 μM respectively, and APH(3’)-IIIa, with IC50 
640 values of 11, 51 and 11 μM respectively (Boehr et al., 2003).
641
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642 3.2. Membrane Permeabilisers
643 Gram-negative bacteria are intrinsically resistant to several antibiotic classes because of the presence 
644 of a second, outer membrane compared to Gram-positive bacteria which these antibiotics cannot 
645 penetrate. The Gram-negative bacterial envelope consists of three components; an inner membrane 
646 which surrounds the organelles, an outer membrane (OM) and a periplasmic region between the two 
647 membranes containing a peptidoglycan layer (Silhavy et al., 2010). The OM consists mainly of 
648 lipopolysaccharides (LPS), which are made up of three parts; a polysaccharide referred to as the O-
649 antigen, a core domain consisting of an oligosaccharide component and a lipid region referred to as 
650 lipid A (Raetz & Whitfield, 2002). This LPS layer is stabilised by cross-linking, enabled by divalent 
651 cations such as Mg2+ and Ca2+ (Zabawa et al., 2016). The OM contains porins, water-filled protein 
652 channels that facilitate entry of hydrophilic molecules into the bacterial cell; mutations in Gram-
653 negative bacteria resulting in reduced porin expression can reduce influx of hydrophilic drugs into 
654 these bacteria. This method of antibacterial resistance has been confirmed in several clinically 
655 relevant bacterial species, such as P. aeruginosa (Fernandez & Hancock, 2012).
656 Besides directly damaging the cell membrane, various other methods have been suggested to 
657 increase rates of antibiotic influx in bacterial cells, such as the use of liposomal drug preparations 
658 (Torres et al., 2012). However, it is the use of membrane permeabilisers, compounds that make the 
659 Gram-negative outer membrane more permeable to facilitate increased antibiotic influx, that will be 
660 reviewed herein. Membrane permeabilisers can function by chelating and removing divalent cations 
661 from the OM and/or (in the case of permeabilisers with a net cationic charge) associating with the 
662 negatively charged OM to disrupt it, causing a breakdown of OM structure (Zabawa et al., 2016). The 
663 effectiveness of putative membrane permeabilisers can be assessed by measuring the level of uptake 
664 of substances that would not normally be able to penetrate the Gram-negative outer membrane, such 
665 as a hydrophobic probe. The fluorescent dye N-phenyl-1-napthylamine (NPN) is used for this 
666 purpose; an increase in fluorescence indicates increased incorporation of NPN into the outer 
667 membrane of the pathogen and thus increased outer membrane permeability (Lee et al., 2004). 
668 Besides enabling increased influx of antibiotics, membrane permeabilisation alone can be sufficient to 
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669 cause bacterial lysis; as such, several of the compounds mentioned in this section also have direct 
670 antibacterial activity (Zabawa et al., 2016).
671
672 3.2.1. The Polymyxins
673 Polymyxins (see Figure 5 and Table 2), including polymyxin B and polymyxin E (colistin), are 
674 antibiotics that function through disruption of the Gram-negative OM. First reported in 1947 
675 (Ainsworth et al., 1947, Benedict & Langlykke, 1947, Stansly et al., 1947), the polymyxins are 
676 pentacationic lipopeptides consisting of a cyclic peptide attached to a long fatty acid chain. Colistin 
677 itself was available for treatment of Gram-negative bacterial infections from 1959 (Ross et al., 1959), 
678 though clinical use decreased from the 1970s to the 1990s because of reports of neurotoxicity and 
679 nephrotoxicity (Vaara, 1992, Li et al., 2005, Falagas & Kasiakou, 2006). While Falagas and Kasiakou 
680 report that adverse events related to current polymyxin use are less frequent than reported in older 
681 literature, possibly due to better understanding of appropriate dosing regimen and the avoidance of 
682 simultaneous administration of nephrotoxic and/or neurotoxic drugs (Falagas & Kasiakou, 2006), 
683 increased colistin use in recent years has been primarily driven by the onset of resistance to β-lactams, 
684 aminoglycosides and quinolones in Gram-negatives (Livermore, 2002). Polymyxins interact 
685 electrostatically with the OM to displace Mg2+ and Ca2+ cations from their binding sites to disrupt 
686 membrane integrity, causing cell damage and also facilitating the influx of other molecules, including 
687 other antibiotics (Landman et al., 2008). Lin et al. found that azithromycin, ineffective against Gram-
688 negative rods, showed synergy with colistin; the combination was effective against MDR-isolates of 
689 P. aeruginosa, K. pneumoniae and A. baumannii (Lin et al., 2015). Synergistic combinations of 
690 colistin with other drugs have also been reported; Lee and co-workers found that the combination of 
691 colistin and rifampicin at clinically-relevant concentrations was additive or synergistic against MDR 
692 strains of A. baumannii and suppressed the emergence of colistin resistance (Lee et al., 2013).
693 The membrane permeabilising effects of colistin towards pandrug-resistant Gram-negative 
694 bacteria have been investigated. Pandrug-resistant bacteria refers to bacteria that are resistant to all 
695 anti-pseudomonal drugs (penicillins, cephalosporins, carbapenems, monobactams, quinolones, 
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696 aminoglycosides) except the polymyxins, although some commentators include the polymyxins in this 
697 definition. Mohamed et al. measured the effect of 50 μg mL-1 of colistin on the cytoplasmic 
698 membranes of four pandrug-resistant clinical isolates (A. baumannii A182, P. aeruginosa P103, K. 
699 pneumoniae K103 and E. coli E9). This concentration of colistin was far in excess of the MICs for the 
700 isolates (range 0.625-1.25 μg mL-1) and resulted in net membrane leakage in all four isolates. The 
701 haemolytic effect of colistin on human red blood cells was also assessed; at a concentration of 12.5 μg 
702 mL-1, colistin caused approximately 1.3% haemolysis, confirming its selectivity towards bacterial 
703 membranes (Mohamed et al., 2016).
704
705 3.2.2. Polymyxin Derivatives
706 Increasing levels of polymyxin resistance globally (Cannatelli et al., 2016, Lee et al., 2016, Liu et al., 
707 2016, Rapoport et al., 2016, Skov & Monnet, 2016, Kluytmans, 2017, Haeili et al., 2018) necessitate 
708 the development of novel alternatives. Efforts to develop polymyxin derivatives as ARBs to potentiate 
709 the actions of antibiotics have been spearheaded in recent decades by Prof. Martti Vaara and co-
710 workers. Chihara et al. first described in 1972 the production of a novel, truncated form of polymyxin 
711 B, later termed polymyxin B nonapeptide (PMBN; Table 2) (Vaara, 1988). PMBN lacks the fatty acid 
712 and terminal diaminobutyric acid moieties of polymyxin B required for bactericidal activity (Vaara, 
713 1988), but it does retain the OM permeabilising character of the latter, a fact first demonstrated by 
714 Vaara in 1983 (Vaara & Vaara, 1983). Together with subsequent work, they showed it capable of 
715 enhancing penetration of hydrophobic antibiotics, including erythromycin, clindamycin, rifampicin, 
716 fusidic acid, novobiocin and cloxacillin, in most polymyxin-susceptible Gram-negative bacteria, 
717 including MDR E. coli, K. pneumoniae and P. aeruginosa (Viljanen & Vaara, 1984). Ofek et al. 
718 tested several polymyxin-susceptible strains of E. coli, K. pneumoniae, P. aeruginosa and Salmonella 
719 typhimurium with PMBN and found that it sensitised the majority of them to six different antibiotics 
720 (ampicillin, erythromycin, lincomycin, nafcillin, novobiocin and vancomycin). The exceptions were a 
721 single strain of P. aeruginosa resistant to nafcillin, one E. coli strain and two K. pneumoniae strains 
722 resistant to vancomycin; it was suggested that these strains possess resistance mechanisms unrelated 
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723 to permeability (Ofek et al., 1994). Zabawa et al. posit that development of PMBN ultimately stalled 
724 because of similar levels of nephrotoxicity to polymyxin B in rats (Zabawa et al., 2016).
725 Many membrane permeabilising agents require a net positive charge to exert their effects. 
726 However, in a second generation of polymyxin B derivatives, Vaara et al. showed that analogues with 
727 a reduced number of positive charges display a concomitant reduction in nephrotoxicity. The 
728 derivatives, which contain only three positive charges at physiological conditions instead of the usual 
729 five, had a lower affinity for rat kidney border brush membranes than polymyxin B. Antibacterial 
730 activity was not necessarily compromised; MICs of one derivative, NAB739, were comparable to 
731 those of polymyxin B against 17 different E. coli strains (range 0.5-1 μg mL-1 for NAB739, range 
732 0.25-1 μg mL-1 for polymyxin B) and were 2-8 fold higher than the corresponding polymyxin B MICs 
733 for strains of Klebsiella oxytoca, K. pneumoniae, E. cloacae, C. freundii, A. baumannii and P. 
734 aeruginosa. Furthermore, at sub-MIC concentrations, NAB739 potentiated the activity of several 
735 antibiotic drugs against A. baumannii, including rifampicin, vancomycin and clarithromycin (Vaara et 
736 al., 2008).
737 Another second generation derivative, NAB741 (Table 2), showed strong synergism with 
738 rifampin and clarithromycin against resistant strains of E. coli, K. pneumoniae, E. cloacae and A. 
739 baumannii and sensitised E. coli and E. cloacae strains to azithromycin, mupirocin, fusidic acid and 
740 vancomycin (Vaara et al., 2010). Further studies detailed reduced cytotoxicity in NAB741 versus 
741 polymyxin B, with the former found to have 32-fold cytotoxicity towards LLC-PK1 cells than the 
742 latter (Mingeot-Leclercq et al., 2012). These second generation derivatives were patented by Vaara, 
743 Vaara and Northern Antibiotic Ltd (Vaara & Vaara, 2009) in 2009 and subsequently licensed to Spero 
744 Therapeutics, where NAB741 was given the code SPR741. Corbett et al. reported that 8 μg mL-1 of 
745 SPR741 was sufficient to potentiate thirteen antibiotics (azithromycin, clarithromycin, dalfopristin, 
746 erythromycin, fidaxomicin, fosfomycin, fusidic acid, mupirocin, novobiocin, ramoplanin, 
747 retapamulin, rifampicin and telithromycin) between 32 and 8,192-fold against E. coli ATCC 25922 
748 (Corbett et al., 2017). At 16 μg mL-1, SPR741 potentiated ten antibiotics (azithromycin, 
749 clarithromycin, erythromycin, fusidic acid, mupirocin, novobiocin, retapamulin, rifampicin, 
750 telithromycin and vancomycin) between 32 and 128-fold against K. pneumoniae ATCC 43816, and 
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751 eight antibiotics (clarithromycin, dalfopristin, erythromycin, fusidic acid, ramoplanin, retapamulin, 
752 rifampicin and teicoplanin) between 32 and 128-fold against A. baumannii NCTC 12156 (Corbett et 
753 al., 2017). Further work by Zurawski and co-workers using a panel of 28 extensively drug-resistant 
754 strains of A. baumannii found that a combination of 1 μg mL-1 rifampicin combined with 4 μg mL-1 
755 SPR741 was sufficient to inhibit growth in 27 of the strains (96%). The exception, strain AB3927, 
756 was significantly more resistant to rifampicin (MIC >256 μg mL-1) compared to the other strains 
757 (MIC range 2-16 μg mL-1) (Zurawski et al., 2017). As of December 2017, SPR741 has completed two 
758 phase I clinical trials; a 64-person, first-in-man study to assess safety and tolerability 
759 (ClinicalTrials.gov, NCT03022175) and a 27-person trial evaluating separate combinations of 
760 SPR741 and ceftazidime, piperacillin/tazobactam and aztreonam (ClinicalTrials.gov, NCT03376529).
761
762 3.2.3. Other Permeabilisers
763 Antimicrobial peptides (AMPs), an umbrella term encompassing a diverse array of compounds 
764 produced by a variety of organisms to combat infections of pathogenic microorganisms, have been 
765 investigated for use as ARBs. The temporins, the first 10 members of which were isolated from the 
766 skins secretions of the European common frog Rana temporaria, are a notable example; Giacometti et 
767 al. investigated the activity of temporin A against Enterococcus faecalis and reported both direct 
768 activity and synergism with imipenem and co-amoxiclav (Simmaco et al., 1996, Giacometti et al., 
769 2005). LL-37, a cathelicidin class antimicrobial peptide found in humans, was found by Lin and 
770 colleagues to potentiate the macrolide antibiotic azithromycin and the combination to be synergistic at 
771 sub-MIC concentrations against MDR strains of P. aeruginosa, K. pneumoniae and A. baumannii (Lin 
772 et al., 2015). Synthetic AMPs appear equally attractive ARB candidates; Lainson et al. have described 
773 synergy between a novel bivalent peptide, ASU014, and the narrow spectrum β-lactam oxacillin 
774 against MRSA at sub-MIC concentrations of both compounds both in vitro and in a skin infection 
775 model (Lainson et al., 2017). A more thorough discussion of antimicrobial peptides in this capacity 
776 can be found in previous summaries (Kosikowska & Lesner, 2016).
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777 Peptidomimetics are synthetic compounds that mimic the membrane permeabilization 
778 mechanism of action of antimicrobial peptides, but are stable to enzymatic degradation. A 
779 peptidomimetic library was designed by Radzishevsky et al. with alternating acyl chains and cationic 
780 amino acids, called oligo-acyl-lysyls, with the purpose of avoiding the formation of undesirable 
781 secondary structures. Compound C12K-7α8 exhibited significant antimicrobial activity against several 
782 Gram-negative bacteria, including Klebsiella spp. and Pseudomonas spp., and showed no increase in 
783 MICs after several subcultures, indicating a low probability of resistance emerging. Furthermore, 
784 C12K-7α8 showed minimal haemolytic activity up to at least 156 μM, a concentration 100-fold higher 
785 than its MIC for several bacteria (Radzishevsky et al., 2007). A subsequent study from the same 
786 group found that C12K-7α8 at ½ MIC concentration was capable of potentiating several cytoplasm-
787 targeting antibiotics (erythromycin, clarithromycin and tetracycline) up to 256-fold versus four MDR 
788 E. coli clinical isolates, but was far less efficient at potentiating periplasm-targeting compounds such 
789 as β-lactams. The authors concluded that C12K-7α8 synergises with efflux-afflicted antibiotics to 
790 increase their influx into the bacterial cell, thereby circumventing this resistance mechanism (Livne et 
791 al., 2010). Further work has established the ability of macromolecular assemblies of C12K-7α8 to 
792 potentiate erythromycin in male ICR mice infected with MDR E. coli (Sarig et al., 2011). Another 
793 oligo-acyl-lysyl, C12(ω7)X, has been demonstrated to reduce the MIC of rifampicin against E. coli, K. 
794 pneumoniae, P. aeruginosa and Salmonella enterica (Jammal et al., 2015).
795 Li and co-workers have demonstrated that cholic acid derivatives are suitable alternatives to 
796 polymyxins as ARBs. The derivatives were designed to include structural elements present in the 
797 polymyxins, including three primary amine groups and associated hydrophobic chains. Of the 
798 derivatives assessed, compound 5 showed particular promise for use as an ARB; while it showed 
799 weak direct antibiotic activity against P. aeruginosa, E. coli and K. pneumoniae strains (MIC range 
800 20-50 μg mL-1), it showed synergism with erythromycin, novobiocin and rifampicin at concentrations 
801 as low as 0.16-5.3 μg mL-1 against the aforementioned strains (strains were resistant to all three 
802 antibiotics in monotherapy) (Li et al., 1999). A further advantage of cholic acid derivatives is their 
803 activity against Gram-positive cocci and fungi. Compound 5 had MICs of 3.3, 2.0 and 4.2 μg mL-1 
804 against E. faecalis, S. aureus, and Streptococcus pyogenes, respectively, and had an MIC of 14 μg 
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805 mL-1 against Candida albicans, improving on polymyxin B by over four-fold in all cases. However, 
806 commercial development of this compound may be complicated because of its significant haemolytic 
807 activity (100 μg mL-1).
808 Another example of a permeabiliser is ethylenediaminetetraacetic acid, a chaotropic agent 
809 that has been shown to release a large proportion of LPS from the OM. It functions by chelating the 
810 divalent cations present in the LPS layer, thereby compromising the integrity and stability of the OM 
811 (Vaara, 1992). Polyethyleneimine, a cationic polymer, has also shown membrane permeabilising 
812 effects. However, instead of releasing LPS, it functions by intercalating into the OM (Helander et al., 
813 1997, Helander et al., 1998). Alakomi et al. assessed NPN uptake for several membrane 
814 permeabilisers, including ethylenediaminetetraacetic acid and polyethyleneimine, and found that both 
815 caused increased NPN uptake in Pseudomonas sp. and Stenotrophomonas nitritireducens strains. The 
816 clinical benefits of polyethyleneimine have been investigated; it was shown in a susceptibility study to 
817 induce an increased susceptibility of a Pseudomonas sp. strain to erythromycin, novobiocin and 
818 fusidin. However, susceptibilities of S. nitritireducens and Sinorhizobium morelense strains to the 
819 same antibiotics did not show similar improvements (Alakomi et al., 2006).
820 Plant-derived phenolic compounds, a group of secondary metabolites abundant in fruit, 
821 vegetables and berries, have been shown to possess membrane permeabilising activity. The effect of 
822 berry-derived phenolic compounds on the OM permeability of Salmonella species was studied by 
823 Alakomi et al. It was shown that several of these compounds, such as 3-phenylpropionic acid, 
824 efficiently permeabilised the membrane as indicated by an increased NPN uptake. Their destabilising 
825 effect on the OM, acting on the divalent cations, was confirmed by the addition of MgCl2 which 
826 partially abolished this effect. The same study also found that the use of organic acids present in 
827 berries, such as sorbic and benzoic acid, also resulted in an increased NPN uptake and LPS release. 
828
829 3.3. Efflux Pump Inhibitors
830 Bacterial efflux pumps act to decrease intracellular concentrations of antibiotics by pumping 
831 antibiotics out of bacterial cells, thereby reducing their effectiveness. The presence of efflux systems 
832 has been confirmed in prokaryotic species, archaea and both inferior and superior eukaryotic species 
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833 (Van Bambeke et al., 2003). Their main function is the extrusion of undesirable compounds from 
834 cells; these include heavy metals (Nies, 2003), organic solvents (Ramos et al., 2002), dyes such as 
835 ethidium bromide (Kaatz et al., 1993), amphiphilic detergents (Ma et al., 1994), biocides (Costa et al., 
836 2013), quorum sensing molecules (Pearson et al., 1999) and metabolites (Van Dyk et al., 2004) in 
837 addition to antibiotics. The presence of efflux pumps and their clinical significance in contributing 
838 towards AMR has been confirmed in many bacteria, including M. tuberculosis (Ainsa et al., 1998) 
839 and P. aeruginosa. The latter species possesses the tripartite RND systems MexAB-OprM, MexXY-
840 OprM, MexCD-OprJ and MexEF-OprN, which together can extrude fluoroquinolones, tetracycline, 
841 chloramphenicol and some β-lactams to achieve a multidrug resistant phenotype (Piddock, 2006). 
842 Efflux systems have also been implicated in biofilm formation in a number of different bacterial 
843 species; a more detailed discussion of this area can be found in previous reviews on the subject (Alav 
844 et al., 2018).
845 Prokaryotic efflux systems can be categorised into a number of superfamilies according to 
846 their energy source, substrates they can act on, composition and membrane-spanning regions. These 
847 include the resistance-nodulation-division (RND) family, the major facilitator superfamily (MFS), the 
848 ATP-binding cassette (ABC) superfamily, the small multidrug resistance (SMR) family and the 
849 multidrug and toxic compound extrusion (MATE) family (Sun et al., 2014). Substrate specificity 
850 varies between different pumps; some are drug-specific while others act on multiple drugs. Genes for 
851 multidrug-extruding pumps are usually found on chromosomes, while drug-specific efflux systems 
852 are located on mobile gene elements which can be transferred between different bacteria via 
853 horizontal gene transfer (Poole, 2007).
854 A popular approach to combatting bacterial efflux systems has been the development of 
855 efflux pump inhibitor (EPI) compounds. A diverse array of EPI compounds have been reported to 
856 date (Stavri et al., 2007, Mahmood et al., 2016), both from natural product screening, de novo 
857 synthetic efforts and in the form of repurposed previously-approved drugs, and these are detailed in 
858 Table 3. However, at the time of writing no discrete EPI compound has been approved for clinical 
859 use. While unacceptable toxicities would appear to be the most touted explanation, this position may 
860 not be unilaterally correct (Lomovskaya, 2018, Opperman, 2018). Most EPIs investigated thus far 
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861 adhere to a ‘cork-in-bottle’ method of blocking pumps, serving to physically obstruct passage of 
862 substrate molecules through the transporter. But in the absence of compounds able to covalently 
863 modify their target pumps, this approach allows for a degree of competition for pump binding 
864 between the substrate antibiotic and the inhibitor, with the result that levels of potentiation observed 
865 are typically modest (Figure 6).
866 Two alternative interpretations of the EPI paradigm could address this problem. The design of 
867 agents, either small molecule or biologic in nature, capable of selectively binding the promoter 
868 regions of the genes encoding efflux transporters could allow for the efflux problem to be 
869 circumvented entirely by preventing pump expression. Jeon and Zhang employed peptide nucleic 
870 acids, synthetic DNA-mimicking polymers, to this end and achieved decreased expression of the 
871 RND-type CmeABC efflux pump in Campylobacter jejuni, sensitising it to ciprofloxacin and 
872 erythromycin. Addition of the peptide nucleic acid, CmeA-PNA, at a concentration of 1 µM resulted 
873 in a 2-fold reduction of the MICs of both antibiotics, while at a concentration of 2 µM it caused 8- and 
874 4-fold reductions in the MICs of ciprofloxacin and erythromycin, respectively (Jeon & Zhang, 2009). 
875 Alternatively, covalently modified antibiotics with EPI character could provide a conventional pump 
876 blocking agent free of the aforementioned competitive binding disadvantage and thus be better able to 
877 improve upon the parent antibiotic (Laws et al., 2017).
878
879 4. Future Perspective and Conclusion
880 Antibiotic resistance is increasing at an alarming rate and is now widely recognised as a global issue 
881 that requires urgent attention. Despite several strategies being deployed, resistance levels are still of 
882 huge concern, and antibiotic resistance breakers (ARBs) represent a promising avenue of research to 
883 counter this. Yet as things stand, the only class of ARBs to make a significant impact in the clinic is 
884 the β-lactamase inhibitors; factors underpinning both the successes of enzyme inhibitors and the 
885 failures of efflux pump inhibitors and membrane permeabilisers as adjunct therapies must be 
886 appreciated if a more complete suite of clinically-approved ARBs is to be realised.
Page 84 of 123
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
34
887 The conventional ARB approach – that of using discrete antibiotic and ARB compounds in 
888 combination to enhance the action of the former – deserves re-examining. Undoubtedly it has 
889 advantages, chiefly an inherent flexibility in the nature of the combined agents and the possibility of 
890 synergy between the two drugs. But these are offset by a number of problems, including the increased 
891 regulatory burden resulting from combining two drugs and a caveat that the pharmacokinetic profiles 
892 of the combined drugs be similar (Gonzalez-Bello, 2017). The latter has suited development of β-
893 lactam-BLI combinations since BLIs necessarily resemble β-lactam antibiotics in structure, but likely 
894 poses more of a challenge in the cases of membrane permeabilisers and efflux pump inhibitors where 
895 the ARBs will likely not structurally resemble the antibiotic they potentiate. This hurdle may be 
896 circumvented by embracing other methodologies, such as covalent modification of substrate 
897 antibiotics to introduce additional ARB character (Laws et al., 2017).
898 Further research within the field must aim for derivatives with improved toxicological 
899 profiles, since several of the compounds mentioned herein are unsuitable for further clinical 
900 development for this reason (Zabawa et al., 2016, Lomovskaya, 2018). In this regard, the 
901 investigation of less nephrotoxic derivatives of polymyxin B (Corbett et al., 2017, Zurawski et al., 
902 2017) (ClinicalTrials.gov, NCT03022175 & NCT03376529) and continued refinement of existing 
903 efflux pump inhibitor scaffolds (Opperman et al., 2014, Vargiu et al., 2014, Aron & Opperman, 2016, 
904 Opperman, 2018) is encouraging. Another option here, as noted by David Brown in his 2015 review 
905 on the subject, is the repurposing of previously-approved drugs for use as ARBs or their use as hit 
906 scaffolds in ARB development (Brown, 2015). This would presumably serve to expedite the market 
907 entry of any resulting therapies and is an attractive option.
908 De novo techniques must play a role in ARB development; an area which will likely drive 
909 development of future ARBs through enhancing understanding of ARB mechanisms of action is 
910 computational modelling of specific biological targets and systems. This is particularly true in the 
911 case of efflux inhibition, where in the absence of crystal structures (due to the complex, 
912 transmembrane nature of prokaryotic efflux transporters), use of computer processing power to 
913 develop a mechanistic understanding of efflux inhibition is critical (Ramaswamy et al., 2016, 
914 Jamshidi et al., 2018). The current state of technology necessitates a compromise between accuracy 
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915 and computational burden; systems on the protein scale are modelled using coarse grain molecular 
916 dynamics simulations, with more accurate and resource-intensive quantum mechanical simulations 
917 reserved only for small areas therein (Chaskar et al., 2017). However, with increasing interest and 
918 investment in much-vaunted quantum computing technology (Preskill, 2018), the gains in processor 
919 power required for quantum mechanical simulations to be applied to protein-sized systems may soon 
920 be within reach. Such advances could conceivably allow a more accurate suite of in silico modelling 
921 tools to drive new generations of both antibiotic and ARB compounds towards the clinic.
922 The scientific community can also look beyond small-molecules to biologics and related 
923 technologies in order to realise the next generation of ARBs. Researchers need to further explore the 
924 use of biologics in targeted delivery to overcome resistance and reduce the selection pressure 
925 associated with non-targeting broad-spectrum antibiotics. The success of antibody-drug conjugates as 
926 cancer therapies has led to research into antibiotic-antibody conjugates using bacteria-specific 
927 antibodies (Mariathasan & Tan, 2017) and there has been some early success at the pre-clinical level 
928 to treat intracellular S. aureus (Lehar et al., 2015). Phage therapy, which uses viruses that specifically 
929 infect bacterial cells, also deserves mention; though its discovery and first use predates that of modern 
930 antibiotics, doubts surrounding the efficacy of phage preparations led to their supersession by the 
931 latter (Sulakvelidze et al., 2001). Phage therapy is not widely used currently and is approved in few 
932 countries (Sulakvelidze et al., 2001), but previous data shows its potential for treating infections of E. 
933 coli (Smith & Huggins, 1982), P. aeruginosa, A. baumannii (Soothill, 1992) and K. pneumoniae 
934 (Bogovazova et al., 1991) in mice and several phage preparations have undergone phase I/II clinical 
935 trials, including a topical preparation for E. coli and P. aeruginosa infections in burn wounds (Gill et 
936 al., 2015).
937 The use of nucleic acid-based aptamers is another promising direction and can be used for the 
938 specific recognition of infectious agents as well as for blocking their functions. Systematic evolution 
939 of ligands by exponential enrichment (SELEX) technologies are being employed to identify aptamers 
940 that can detect specific pathogens (Alizadeh et al., 2017). Aptamers could be used to develop nucleic 
941 acid-based detection systems that can detect bacteria directly in a real complex matrix without 
942 preliminary concentration, which is often a limiting factor in developing rapid diagnostics. Aptamers 
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943 able to detect and often block critical function have already been reported for S. enterica, S. aureus 
944 and M. tuberculosis and this represents an important development towards the realisation of such 
945 diagnostic platforms (Alizadeh et al., 2017).
946 A novel delivery platform using nanocarriers could be used to overcome the permeability 
947 barrier encountered in Gram-negative bacteria. Nanocarriers can also be used to selectively deliver 
948 high concentrations of antibiotics locally, thus avoiding systemic side effects. Several strategies have 
949 been studied in order to deliver antibiotics such as the use of antimicrobial polymers, nanoparticles 
950 and liposomes. Success with these strategies has been limited, but it is expected that with more 
951 research and advancement of technology, nanodelivery can become an important tool to overcome 
952 bacterial resistance (Gao et al., 2014).
953 The BLIs in the clinic today were, by their very nature, developed after their partner 
954 antibiotics. However, the fact that the majority of BLIs have arrived on the clinical scene many 
955 decades after their partner β-lactams were first approved (Drawz & Bonomo, 2010) likely reflects the 
956 relatively recent drive to address the problem of antimicrobial resistance. This typifies the current 
957 reactive nature of antibiotic research and development, ‘patching up’ a failing arsenal as it declines. 
958 Going forward, we hope that a new wave of funding schemes such as non-profit private-public 
959 partnerships (such as CARB-X) and government-funded programmes (such as the EU-backed 
960 Innovative Medicines Initiative) can drive a change in this methodology. A more proactive, 
961 diagnostics-driven approach to ARB development would allow the lifespans of current antibiotics to 
962 be maximised when practised in combination with wider efforts such as antimicrobial stewardship and 
963 increased public awareness of AMR.
964
Page 87 of 123
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
37
965 Funding
966 This work was supported by the Biotechnology and Biological Sciences Research Council [grant 
967 number BB/M015033/1].
968
969 Competing Interests
970 The authors declare no competing interests.
971
Page 88 of 123
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
38
972 References
973 Abee T, Kovacs AT, Kuipers OP & van der Veen S (2011) Biofilm formation and dispersal in Gram-
974 positive bacteria. Curr Opin Biotechnol 22: 172-179.
975 AdisInsight (2017) Research programme: beta lactamase inhibitors - LegoChem Biosciences/Geom 
976 Therapeutics. Vol. 2018 p.^pp. Adis Insight.
977 Ainsa JA, Blokpoel MC, Otal I, Young DB, De Smet KA & Martin C (1998) Molecular cloning and 
978 characterization of Tap, a putative multidrug efflux pump present in Mycobacterium fortuitum and 
979 Mycobacterium tuberculosis. J Bacteriol 180: 5836-5843.
980 Ainsworth GC, Brown AM & Brownlee G (1947) Aerosporin, an antibiotic produced by Bacillus 
981 aerosporus Greer. Nature 159: 263.
982 Alakomi HL, Paananen A, Suihko ML, Helander IM & Saarela M (2006) Weakening effect of cell 
983 permeabilizers on gram-negative bacteria causing biodeterioration. Appl Environ Microbiol 72: 4695-
984 4703.
985 Alakomi HL, Puupponen-Pimia R, Aura AM, Helander IM, Nohynek L, Oksman-Caldentey KM & 
986 Saarela M (2007) Weakening of salmonella with selected microbial metabolites of berry-derived 
987 phenolic compounds and organic acids. J Agric Food Chem 55: 3905-3912.
988 Alanis AJ (2005) Resistance to antibiotics: are we in the post-antibiotic era? Arch Med Res 36: 697-
989 705.
990 Alav I, Sutton JM & Rahman KM (2018) Role of bacterial efflux pumps in biofilm formation. J 
991 Antimicrob Chemother 73: 2003-2020.
992 Alizadeh N, Memar MY, Moaddab SR & Kafil HS (2017) Aptamer-assisted novel technologies for 
993 detecting bacterial pathogens. Biomed Pharmacother 93: 737-745.
994 Ambler RP (1980) The structure of beta-lactamases. Philos Trans R Soc Lond B Biol Sci 289: 321-331.
995 Aron Z & Opperman TJ (2016) Optimization of a novel series of pyranopyridine RND efflux pump 
996 inhibitors. Curr Opin Microbiol 33: 1-6.
997 Aronoff SC, Jacobs MR, Johenning S & Yamabe S (1984) Comparative activities of the beta-lactamase 
998 inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin. 
999 Antimicrob Agents Chemother 26: 580-582.
1000 Benedict RG & Langlykke AF (1947) Antibiotic activity of Bacillus polymyxa. J Bacteriol 54: 24.
1001 Bodey GP, Miller P & Ho DH (1989) In vitro assessment of sulbactam plus cefoperazone in the 
1002 treatment of bacteria isolated from cancer patients. Diagn Microbiol Infect Dis 12: 209S-214S.
1003 Boehr DD, Draker KA, Koteva K, Bains M, Hancock RE & Wright GD (2003) Broad-spectrum peptide 
1004 inhibitors of aminoglycoside antibiotic resistance enzymes. Chem Biol 10: 189-196.
1005 Bogovazova GG, Voroshilova NN & Bondarenko VM (1991) [The efficacy of Klebsiella pneumoniae 
1006 bacteriophage in the therapy of experimental Klebsiella infection]. Zh Mikrobiol Epidemiol 
1007 Immunobiol 5-8.
1008 Brown D (2015) Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery 
1009 void? Nat Rev Drug Discov 14: 821-832.
1010 Bryan LE & Kwan S (1981) Mechanisms of aminoglycoside resistance of anaerobic bacteria and 
1011 facultative bacteria grown anaerobically. J Antimicrob Chemother 8 Suppl D: 1-8.
1012 Burns CJ, Daigle, D., Liu, B., McGarry, D., Pevear, D. C., Trout, R. E. L. (2016) BETA-LACTAMASE 
1013 INHIBITORS. p.^pp. VenatoRx Pharmaceuticals, Inc., USA.
1014 Bush K (1988) Beta-lactamase inhibitors from laboratory to clinic. Clin Microbiol Rev 1: 109-123.
1015 Bush K (2015) A resurgence of beta-lactamase inhibitor combinations effective against multidrug-
1016 resistant Gram-negative pathogens. Int J Antimicrob Agents 46: 483-493.
1017 Bush K (2018) Game Changers: New beta-Lactamase Inhibitor Combinations Targeting Antibiotic 
1018 Resistance in Gram-Negative Bacteria. ACS Infect Dis 4: 84-87.
1019 Bush K & Jacoby GA (2010) Updated functional classification of beta-lactamases. Antimicrob Agents 
1020 Chemother 54: 969-976.
Page 89 of 123
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
39
1021 Bush K & Page MGP (2017) What we may expect from novel antibacterial agents in the pipeline with 
1022 respect to resistance and pharmacodynamic principles. J Pharmacokinet Phar 44: 113-132.
1023 C. Hamrick JC, Chatwin, C. L., John, K. J., Pevear, D. C., Burns, C. J., and Xerri, L. (2018) The ability of 
1024 broad-spectrum β-lactamase inhibitor VNRX-5133 to restore bactericidal activity of cefepime in 
1025 Enterobacteriaceae- and P. aeruginosa-expressing Ambler class A, B, C and D enzymes is 
1026 demonstrated using time-kill kinetics. p.^pp. Madrid, Spain.
1027 Cain R, Brem J, Zollman D, et al. (2018) In Silico Fragment-Based Design Identifies Subfamily B1 
1028 Metallo-beta-lactamase Inhibitors. J Med Chem 61: 1255-1260.
1029 Cannatelli A, Giani T, Antonelli A, Principe L, Luzzaro F & Rossolini GM (2016) First Detection of the 
1030 mcr-1 Colistin Resistance Gene in Escherichia coli in Italy. Antimicrob Agents Chemother 60: 3257-
1031 3258.
1032 Castanheira M, Mendes RE & Sader HS (2017) Low Frequency of Ceftazidime-Avibactam Resistance 
1033 among Enterobacteriaceae Isolates Carrying blaKPC Collected in U.S. Hospitals from 2012 to 2015. 
1034 Antimicrob Agents Chemother 61.
1035 Castanheira M, Rhomberg PR, Flamm RK & Jones RN (2016) Effect of the beta-Lactamase Inhibitor 
1036 Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing 
1037 Enterobacteriaceae. Antimicrob Agents Chemother 60: 5454-5458.
1038 Castanheira M, Huband MD, Mendes RE & Flamm RK (2017) Meropenem-Vaborbactam Tested 
1039 against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including 
1040 Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant 
1041 Enterobacteriaceae. Antimicrob Agents Chemother 61.
1042 Castanheira M, Mills JC, Costello SE, Jones RN & Sader HS (2015) Ceftazidime-avibactam activity 
1043 tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of 
1044 beta-lactamase-producing strains. Antimicrob Agents Chemother 59: 3509-3517.
1045 Castanheira M, Rhomberg, P. R., Lindley, J. M., Jones, R. N., Sader, H. S. (2016) Activity of the New 
1046 Carbapenem/β-Lactamase Inhibitor Combination WCK 5999 against Gram-Negative Isolates 
1047 Producing Oxacillinases (OXAs). p.^pp. American Society for Microbiology, Boston, Massachusetts, 
1048 USA.
1049 Castanheira M, Rhomberg, P. R., Schaefer, B. A., Jones, R. N., Sader, H. S. (2016) In vitro Activity of 
1050 WCK 5999, a Carbapenem/β-lactamase Inhibitor Combination Tested against Contemporary KPC-
1051 producing Enterobacteriaceae. p.^pp. American Society for Microbiology, Boston, Massachusetts, 
1052 USA.
1053 Chalhoub H, Tunney M, Elborn JS, Vergison A, Denis O, Plesiat P, Kahl BC, Van Bambeke F & Tulkens 
1054 PM (2015) Avibactam confers susceptibility to a large proportion of ceftazidime-resistant 
1055 Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients. J Antimicrob Chemother 
1056 70: 1596-1598.
1057 Chaskar P, Zoete V & Rohrig UF (2017) On-the-Fly QM/MM Docking with Attracting Cavities. J Chem 
1058 Inf Model 57: 73-84.
1059 Cho JC, Fiorenza MA & Estrada SJ (2015) Ceftolozane/Tazobactam: A Novel Cephalosporin/beta-
1060 Lactamase Inhibitor Combination. Pharmacotherapy 35: 701-715.
1061 Coates AR, Halls G & Hu Y (2011) Novel classes of antibiotics or more of the same? Br J Pharmacol 
1062 163: 184-194.
1063 Corbett D, Wise A, Langley T, et al. (2017) Potentiation of Antibiotic Activity by a Novel Cationic 
1064 Peptide: Potency and Spectrum of Activity of SPR741. Antimicrob Agents Chemother 61.
1065 Costa SS, Viveiros M, Amaral L & Couto I (2013) Multidrug Efflux Pumps in Staphylococcus aureus: an 
1066 Update. Open Microbiol J 7: 59-71.
1067 Crader MF & Bhimji SS (2018) Preoperative Antibiotic Prophylaxis. StatPearls,p.^pp. Treasure Island 
1068 (FL).
1069 Crandon JL & Nicolau DP (2015) In Vitro Activity of Cefepime/AAI101 and Comparators against 
1070 Cefepime Non-susceptible Enterobacteriaceae. Pathogens 4: 620-625.
Page 90 of 123
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
40
1071 Crandon JL & Nicolau DP (2015) In vivo activities of simulated human doses of cefepime and 
1072 cefepime-AAI101 against multidrug-resistant Gram-negative Enterobacteriaceae. Antimicrob Agents 
1073 Chemother 59: 2688-2694.
1074 Crandon JL, Schuck VJ, Banevicius MA, Beaudoin ME, Nichols WW, Tanudra MA & Nicolau DP (2012) 
1075 Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-
1076 avibactam against Pseudomonas aeruginosa. Antimicrob Agents Chemother 56: 6137-6146.
1077 Crandon JL, Nicolau, D. (2014) Comparative potency of cefepime and cefepime/AAI101 against 
1078 highly resistant Enterobacteriaceae. p.^pp. Washington, DC.
1079 Cullmann W & Stieglitz M (1990) Antibacterial activity of piperacillin and tazobactam against beta-
1080 lactamase-producing clinical isolates. Chemotherapy 36: 356-364.
1081 Daigle DM, Pevear, D. C., Burns, C. J. (2018) Kinetic mechanism and parameters of inhibition of 
1082 serine KPC-2, CTX-M15, p99 AmpC and metallo VIM-2 by the broad-spectrum β-lactamase inhibitor 
1083 VNRX-5133. p.^pp. Madrid, Spain.
1084 Davies RB & Abraham EP (1974) Metal Cofactor Requirements of Beta-Lactamase Ii. Biochemical 
1085 JournalBiochem J 143: 129-135.
1086 Deshpande PK, Bhavsar, S. B., Joshi, S. N., Pawar, S. S., Kale, R. P., Mishra, A., Jadhav, S. B., Pavase, L. 
1087 S., Gupta, S. V., Yeole, R. D., Rane, V. P., Ahirrao, V. K., Bhagwat, S. S., Patel, M. V. (2016) WCK 5107 
1088 (Zidebactam, Zid): structure activity relationship (Sar) of novel bicyclo acyl hydrazide (Bch) 
1089 pharmacophore active against Gram-negatives including Pseudomonas (Pa). p.^pp. American Society 
1090 for Microbiology, Boston, Massachusetts, USA.
1091 Devi P & Rutledge PJ (2017) Cyclobutanone Analogues of beta-Lactam Antibiotics: beta-Lactamase 
1092 Inhibitors with Untapped Potential? Chembiochem 18: 338-351.
1093 Docquier JD, Luzzaro F, Amicosante G, Toniolo A & Rossolini GM (2001) Multidrug-resistant 
1094 Pseudomonas aeruginosa producing PER-1 xtended-spectrum serine-beta-lactamase and VIM-2 
1095 metallo-beta-lactamase. Emerg Infect Dis 7: 910-911.
1096 Docquier JD, De Luca, F., Benvenuti, M., Pozzi, C., Daigle, D. M., Pevear, D. C., Burns, C. J., and 
1097 Mangani, S. (2018) Structural basis for serine- and metallo-β-lactamase inhibition by VNRX-5133, a 
1098 new β-lactamase inhibitor (BLI) in clinical development. p.^pp. Madrid, Spain.
1099 Doi Y & Arakawa Y (2007) 16S ribosomal RNA methylation: emerging resistance mechanism against 
1100 aminoglycosides. Clin Infect Dis 45: 88-94.
1101 Donlan RM (2002) Biofilms: microbial life on surfaces. Emerg Infect Dis 8: 881-890.
1102 Donnelly R, Kloezen, W., Goldman, M., Van Mil, A. C., Lagarde, C. M., Meletiadis, J., and Mouton, J. 
1103 W. (2018) In vitro activity of cefepime alone and in combination with the broad-spectrum β-
1104 lactamase inhibitor VNRX-5133 against ESBL and carbapenamases harbouring Enterobacteriaceae 
1105 and Pseudomonas spp. p.^pp. Madrid, Spain.
1106 Drawz SM & Bonomo RA (2010) Three decades of beta-lactamase inhibitors. Clin Microbiol Rev 23: 
1107 160-201.
1108 Drlica K & Perlin D (2011) Antibiotic resistance : understanding and responding to an emerging crisis. 
1109 FT Press, Upper Saddle River, N.J.
1110 Durand-Réville T (2017) ETX0282, a Novel Oral Agent Against Multidrug-Resistant 
1111 Enterobacteriaceae. p.^pp. American Society for Microbiology, New Orleans, Louisiana, USA.
1112 Durand-Reville TF, Guler S, Comita-Prevoir J, et al. (2017) ETX2514 is a broad-spectrum beta-
1113 lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including 
1114 Acinetobacter baumannii. Nat Microbiol 2: 17104.
1115 ECDC (2015) Summary of the latest data on antibiotic consumption in the European Union: ESAC-Net 
1116 surveillance data. p.^pp. European Centre for Disease Prevention and Control, Stockholm.
1117 Elander RP (2003) Industrial production of beta-lactam antibiotics. Appl Microbiol Biotechnol 61: 
1118 385-392.
1119 Eliopoulos GM, Klimm K, Ferraro MJ & Moellering RC, Jr. (1989) In vitro activity of cefoperazone-
1120 sulbactam combinations against cefoperazone-resistant clinical bacterial isolates. Eur J Clin Microbiol 
1121 Infect Dis 8: 624-626.
Page 91 of 123
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
41
1122 English AR, Retsema JA, Girard AE, Lynch JE & Barth WE (1978) CP-45,899, a beta-lactamase inhibitor 
1123 that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization. 
1124 Antimicrob Agents Chemother 14: 414-419.
1125 Estabrook M, Hackel, M., Sahm, D. (2018) In vitro activity of cefepime in combination with VNRX-
1126 5133 against meropenem and/or cefepime resistant clinical isolates of Pseudomonas aeruginosa. 
1127 p.^pp. Madrid, Spain.
1128 Falagas ME & Kasiakou SK (2006) Toxicity of polymyxins: a systematic review of the evidence from 
1129 old and recent studies. Crit Care 10: R27.
1130 Fernandez L & Hancock RE (2012) Adaptive and mutational resistance: role of porins and efflux 
1131 pumps in drug resistance. Clin Microbiol Rev 25: 661-681.
1132 Fisher JF, Meroueh SO & Mobashery S (2005) Bacterial resistance to beta-lactam antibiotics: 
1133 compelling opportunism, compelling opportunity. Chem Rev 105: 395-424.
1134 Flamm RK, Farrell DJ, Sader HS & Jones RN (2014) Ceftazidime/avibactam activity tested against 
1135 Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract 
1136 infections in US medical centres (2012). J Antimicrob Chemother 69: 1589-1598.
1137 Gao F, Yan X, Zahr O, Larsen A, Vong K & Auclair K (2008) Synthesis and use of sulfonamide-, 
1138 sulfoxide-, or sulfone-containing aminoglycoside-CoA bisubstrates as mechanistic probes for 
1139 aminoglycoside N-6'-acetyltransferase. Bioorg Med Chem Lett 18: 5518-5522.
1140 Gao W, Thamphiwatana S, Angsantikul P & Zhang L (2014) Nanoparticle approaches against bacterial 
1141 infections. Wiley Interdiscip Rev Nanomed Nanobiotechnol 6: 532-547.
1142 Garber K (2015) A beta-lactamase inhibitor revival provides new hope for old antibiotics. Nat Rev 
1143 Drug Discov 14: 445-447.
1144 Georgiou PC, Siopi, M., Tsala, M., Lagarde, C., Kloezen, W., Donnelly, R., Meletiadis, J., and Mouton, 
1145 J. W. (2018) VNRX-5133, a novel broad-spectrum β-lactamase inhibitor, enhances the activity of 
1146 cefepime against Enterobacteriaceae and P. aeruginosa isolates in a neutropenic mouse-thigh 
1147 infection model. p.^pp. Madrid, Spain.
1148 Giacometti A, Cirioni O, Kamysz W, D'Amato G, Silvestri C, Del Prete MS, Licci A, Lukasiak J & Scalise 
1149 G (2005) In vitro activity and killing effect of temporin A on nosocomial isolates of Enterococcus 
1150 faecalis and interactions with clinically used antibiotics. J Antimicrob Chemother 55: 272-274.
1151 Gilbert P, Collier PJ & Brown M (1990) Influence of growth rate on susceptibility to antimicrobial 
1152 agents: biofilms, cell cycle, dormancy, and stringent response. Antimicrobial agents and 
1153 chemotherapy 34: 1865.
1154 Gill EE, Franco OL & Hancock RE (2015) Antibiotic adjuvants: diverse strategies for controlling drug-
1155 resistant pathogens. Chem Biol Drug Des 85: 56-78.
1156 Goldstein EJ, Citron DM, Tyrrell KL & Merriam CV (2013) In vitro activity of Biapenem plus RPX7009, 
1157 a carbapenem combined with a serine beta-lactamase inhibitor, against anaerobic bacteria. 
1158 Antimicrob Agents Chemother 57: 2620-2630.
1159 Gonzalez-Bello C (2017) Antibiotic adjuvants - A strategy to unlock bacterial resistance to antibiotics. 
1160 Bioorg Med Chem Lett 27: 4221-4228.
1161 Griffith DC, Loutit JS, Morgan EE, Durso S & Dudley MN (2016) Phase 1 Study of the Safety, 
1162 Tolerability, and Pharmacokinetics of the beta-Lactamase Inhibitor Vaborbactam (RPX7009) in 
1163 Healthy Adult Subjects. Antimicrob Agents Chemother 60: 6326-6332.
1164 Hackel MA, Lomovskaya O, Dudley MN, Karlowsky JA & Sahm DF (2018) In Vitro Activity of 
1165 Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae. Antimicrob 
1166 Agents Chemother 62.
1167 Hackel MaS, D. (2018) Antimicrobial activity of cefepime in combination with VNRX-5133 against a 
1168 global collection of clinical isolates. p.^pp. Madrid, Spain.
1169 Haeili M, Kafshdouz M & Feizabadi MM (2018) Molecular Mechanisms of Colistin Resistance Among 
1170 Pandrug-Resistant Isolates of Acinetobacter baumannii with High Case-Fatality Rate in Intensive Care 
1171 Unit Patients. Microb Drug Resist.
Page 92 of 123
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
42
1172 Hecker SJ, Reddy KR, Totrov M, et al. (2015) Discovery of a Cyclic Boronic Acid beta-Lactamase 
1173 Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases. J Med Chem 58: 3682-3692.
1174 Helander IM, Latva-Kala K & Lounatmaa K (1998) Permeabilizing action of polyethyleneimine on 
1175 Salmonella typhimurium involves disruption of the outer membrane and interactions with 
1176 lipopolysaccharide. Microbiology 144 ( Pt 2): 385-390.
1177 Helander IM, Alakomi HL, Latva-Kala K & Koski P (1997) Polyethyleneimine is an effective 
1178 permeabilizer of gram-negative bacteria. Microbiology 143 ( Pt 10): 3193-3199.
1179 Hon WC, McKay GA, Thompson PR, Sweet RM, Yang DS, Wright GD & Berghuis AM (1997) Structure 
1180 of an enzyme required for aminoglycoside antibiotic resistance reveals homology to eukaryotic 
1181 protein kinases. Cell 89: 887-895.
1182 Huband MD, Farrell, D. J., Flamm, R. K., Jones, R. N., Sader, H. S. (2016) In Vitro Activity of WCK 5999 
1183 against Acinetobacter baumannii and Pseudomonas aeruginosa isolates from a Worldwide 
1184 Surveillance Program (2015). p.^pp. American Society for Microbiology, Boston, Massachusetts, USA.
1185 Inc. FP (2012) Fedora Pharmaceuticals In-licenses Intellectual Property from NAEJA Pharmaceuticals 
1186 and Incorporates. Vol. 2018 p.^pp. Fedora Pharmaceuticals Inc., Edmonton, Alberta.
1187 Ishii Y, Eto M, Mano Y, Tateda K & Yamaguchi K (2010) In vitro potentiation of carbapenems with 
1188 ME1071, a novel metallo-beta-lactamase inhibitor, against metallo-beta-lactamase- producing 
1189 Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 54: 3625-3629.
1190 Jammal J, Zaknoon F, Kaneti G, Goldberg K & Mor A (2015) Sensitization of Gram-negative bacteria 
1191 to rifampin and OAK combinations. Sci Rep 5: 9216.
1192 Jamshidi S, Sutton JM & Rahman KM (2018) Mapping the Dynamic Functions and Structural Features 
1193 of AcrB Efflux Pump Transporter Using Accelerated Molecular Dynamics Simulations. Sci Rep 8: 
1194 10470.
1195 Jeon B & Zhang Q (2009) Sensitization of Campylobacter jejuni to fluoroquinolone and macrolide 
1196 antibiotics by antisense inhibition of the CmeABC multidrug efflux transporter. J Antimicrob 
1197 Chemother 63: 946-948.
1198 Johnson JW, Gretes M, Goodfellow VJ, Marrone L, Heynen ML, Strynadka NC & Dmitrienko GI (2010) 
1199 Cyclobutanone analogues of beta-lactams revisited: insights into conformational requirements for 
1200 inhibition of serine- and metallo-beta-lactamases. J Am Chem Soc 132: 2558-2560.
1201 Johnson JW, Evanoff DP, Savard ME, Lange G, Ramadhar TR, Assoud A, Taylor NJ & Dmitrienko GI 
1202 (2008) Cyclobutanone mimics of penicillins: effects of substitution on conformation and hemiketal 
1203 stability. J Org Chem 73: 6970-6982.
1204 Kaatz GW, Seo SM & Ruble CA (1993) Efflux-mediated fluoroquinolone resistance in Staphylococcus 
1205 aureus. Antimicrob Agents Chemother 37: 1086-1094.
1206 Kalan L & Wright GD (2011) Antibiotic adjuvants: multicomponent anti-infective strategies. Expert 
1207 Rev Mol Med 13: e5.
1208 Kaye KS, Bhowmick T, Metallidis S, et al. (2018) Effect of Meropenem-Vaborbactam vs Piperacillin-
1209 Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract 
1210 Infection: The TANGO I Randomized Clinical Trial. JAMA 319: 788-799.
1211 Kazmierczak K, Hackel, M., and Sahm, D. (2018) In vitro activity of cefepime in combination with 
1212 VNRX-5133 when tested against cephalosporin and carbapenem resistant β-lactamase producing 
1213 gram-negative isolates. p.^pp. Madrid, Spain.
1214 Khande HN, Joshi, P. R., Palwe, S. R., Bhagwat, S. S., Patel, M. V. (2016) WCK 5222 [cefepime (FEP)-
1215 WCK 5107 (zidebactam, ZID)]: activity against ESBL, class C, and KPC-expressing enterics and 
1216 Pseudomonas (PA) expressing AmpC (PA AmpC) or OXA β-lactamases (PA OXA). p.^pp. American 
1217 Society for Microbiology, Boston, Massachusetts, USA.
1218 King AM, Reid-Yu SA, Wang W, King DT, De Pascale G, Strynadka NC, Walsh TR, Coombes BK & 
1219 Wright GD (2014) Aspergillomarasmine A overcomes metallo-beta-lactamase antibiotic resistance. 
1220 Nature 510: 503-506.
Page 93 of 123
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
43
1221 King AM, King DT, French S, et al. (2016) Structural and Kinetic Characterization of 
1222 Diazabicyclooctanes as Dual Inhibitors of Both Serine-beta-Lactamases and Penicillin-Binding 
1223 Proteins. ACS Chem Biol 11: 864-868.
1224 Kluytmans J (2017) Plasmid-encoded colistin resistance: mcr-one, two, three and counting. Euro 
1225 Surveill 22.
1226 Kosikowska P & Lesner A (2016) Antimicrobial peptides (AMPs) as drug candidates: a patent review 
1227 (2003-2015). Expert Opin Ther Pat 26: 689-702.
1228 Lainson JC, Daly SM, Triplett K, Johnston SA, Hall PR & Diehnelt CW (2017) Synthetic Antibacterial 
1229 Peptide Exhibits Synergy with Oxacillin against MRSA. ACS Med Chem Lett 8: 853-857.
1230 Landman D, Georgescu C, Martin DA & Quale J (2008) Polymyxins revisited. Clin Microbiol Rev 21: 
1231 449-465.
1232 Lapuebla A, Abdallah M, Olafisoye O, Cortes C, Urban C, Quale J & Landman D (2015) Activity of 
1233 Meropenem Combined with RPX7009, a Novel beta-Lactamase Inhibitor, against Gram-Negative 
1234 Clinical Isolates in New York City. Antimicrob Agents Chemother 59: 4856-4860.
1235 Laws M, Jamshidi S, Nahar K, Sutton M & Rahman KM (2017) Antibiotic Resistance Breakers. p.^pp. 
1236 UK.
1237 Lee DL, Powers JP, Pflegerl K, Vasil ML, Hancock RE & Hodges RS (2004) Effects of single D-amino 
1238 acid substitutions on disruption of beta-sheet structure and hydrophobicity in cyclic 14-residue 
1239 antimicrobial peptide analogs related to gramicidin S. J Pept Res 63: 69-84.
1240 Lee HJ, Bergen PJ, Bulitta JB, Tsuji B, Forrest A, Nation RL & Li J (2013) Synergistic activity of colistin 
1241 and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro 
1242 pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 57: 3738-3745.
1243 Lee JY, Park YK, Chung ES, Na IY & Ko KS (2016) Evolved resistance to colistin and its loss due to 
1244 genetic reversion in Pseudomonas aeruginosa. Sci Rep 6: 25543.
1245 Leflon-Guibout V, Speldooren V, Heym B & Nicolas-Chanoine M (2000) Epidemiological survey of 
1246 amoxicillin-clavulanate resistance and corresponding molecular mechanisms in Escherichia coli 
1247 isolates in France: new genetic features of bla(TEM) genes. Antimicrob Agents Chemother 44: 2709-
1248 2714.
1249 Legrand P, Soussy CJ, Orsoni A, Brickley X & Duval J (1988) [Activity of 9 beta-lactam antibiotics 
1250 combined with clavulanic acid or sulbactam against the strains of broad-spectrum beta-lactamase 
1251 (CTX-1) producing Enterobacteriaceae isolated at the Henri Mondor Hospital]. Pathol Biol (Paris) 36: 
1252 425-429.
1253 Lehar SM, Pillow T, Xu M, et al. (2015) Novel antibody-antibiotic conjugate eliminates intracellular S. 
1254 aureus. Nature 527: 323-328.
1255 Li C, Lewis MR, Gilbert AB, Noel MD, Scoville DH, Allman GW & Savage PB (1999) Antimicrobial 
1256 activities of amine- and guanidine-functionalized cholic acid derivatives. Antimicrob Agents 
1257 Chemother 43: 1347-1349.
1258 Li J, Nation RL, Milne RW, Turnidge JD & Coulthard K (2005) Evaluation of colistin as an agent against 
1259 multi-resistant in Gram-negative bacteria. Int J Antimicrob Ag 25: 11-25.
1260 Limansky AS, Mussi MA & Viale AM (2002) Loss of a 29-kilodalton outer membrane protein in 
1261 Acinetobacter baumannii is associated with imipenem resistance. J Clin Microbiol 40: 4776-4778.
1262 Lin L, Nonejuie P, Munguia J, et al. (2015) Azithromycin Synergizes with Cationic Antimicrobial 
1263 Peptides to Exert Bactericidal and Therapeutic Activity Against Highly Multidrug-Resistant Gram-
1264 Negative Bacterial Pathogens. EBioMedicine 2: 690-698.
1265 Ling J, Kam KM, Lam AW & French GL (1988) Susceptibilities of Hong Kong isolates of multiply 
1266 resistant Shigella spp. to 25 antimicrobial agents, including ampicillin plus sulbactam and new 4-
1267 quinolones. Antimicrob Agents Chemother 32: 20-23.
1268 Liu YY, Wang Y, Walsh TR, et al. (2016) Emergence of plasmid-mediated colistin resistance 
1269 mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological 
1270 study. Lancet Infect Dis 16: 161-168.
Page 94 of 123
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
44
1271 Livermore DM (2002) Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: 
1272 our worst nightmare? Clin Infect Dis 34: 634-640.
1273 Livermore DM & Mushtaq S (2013) Activity of biapenem (RPX2003) combined with the boronate 
1274 beta-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae. J Antimicrob 
1275 Chemother 68: 1825-1831.
1276 Livermore DM, Warner M, Mushtaq S & Woodford N (2016) Interactions of OP0595, a Novel Triple-
1277 Action Diazabicyclooctane, with beta-Lactams against OP0595-Resistant Enterobacteriaceae 
1278 Mutants. Antimicrob Agents Chemother 60: 554-560.
1279 Livermore DM, Mushtaq S, Warner M, Vickers A & Woodford N (2017) In vitro activity of 
1280 cefepime/zidebactam (WCK 5222) against Gram-negative bacteria. J Antimicrob Chemother 72: 
1281 1373-1385.
1282 Livermore DM, Mushtaq S, Warner M, Turner SJ & Woodford N (2018) Potential of high-dose 
1283 cefepime/tazobactam against multiresistant Gram-negative pathogens. J Antimicrob Chemother 73: 
1284 126-133.
1285 Livermore DM, Mushtaq S, Morinaka A, Ida T, Maebashi K & Hope R (2013) Activity of carbapenems 
1286 with ME1071 (disodium 2,3-diethylmaleate) against Enterobacteriaceae and Acinetobacter spp. with 
1287 carbapenemases, including NDM enzymes. J Antimicrob Chemother 68: 153-158.
1288 Livermore DM, Mushtaq, S., Warner, M., Vickers, A., Woodford, N. (2016) Activity of combinations of 
1289 cefepime with zidebactam (WCK 5107), a novel triple-action diazabicyclooctane. p.^pp. American 
1290 Society for Microbiology, Boston, Massachusetts, USA.
1291 Livne L, Epand RF, Papahadjopoulos-Sternberg B, Epand RM & Mor A (2010) OAK-based cochleates 
1292 as a novel approach to overcome multidrug resistance in bacteria. FASEB J 24: 5092-5101.
1293 Lomovskaya O (2018) Antibiotics and Gram Negative Membranes: the Ins and Outs. p.^pp. American 
1294 Society for Microbiology, Atlanta, Georgia, USA.
1295 Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson K, Tsivkovski R, Griffith DC & Dudley MN (2017) 
1296 Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on 
1297 Activity in Enterobacteriaceae. Antimicrob Agents Chemother 61.
1298 Ma D, Cook DN, Hearst JE & Nikaido H (1994) Efflux pumps and drug resistance in gram-negative 
1299 bacteria. Trends Microbiol 2: 489-493.
1300 Mahmood HY, Jamshidi S, Sutton JM & Rahman KM (2016) Current Advances in Developing 
1301 Inhibitors of Bacterial Multidrug Efflux Pumps. Curr Med Chem 23: 1062-1081.
1302 Maiti SN, Nguyen, D., Khan, J., Ling, R., (2013) NEW BICYCLIC COMPOUNDS AND THEIR USE AS 
1303 ANTIBACTERIAL AGENTS AND BETA-LACTAMASE INHIBITORS (Office UPaT, ed.) p.^pp. NAEJA 
1304 PHARMACEUTICAL INC., Edmonton, California, USA.
1305 Mangion IK, Ruck RT, Rivera N, Huffman MA & Shevlin M (2011) A concise synthesis of a beta-
1306 lactamase inhibitor. Org Lett 13: 5480-5483.
1307 Mariathasan S & Tan MW (2017) Antibody-Antibiotic Conjugates: A Novel Therapeutic Platform 
1308 against Bacterial Infections. Trends Mol Med 23: 135-149.
1309 McCarthy MW & Walsh TJ (2017) Meropenem/vaborbactam fixed combination for the treatment of 
1310 patients with complicated urinary tract infections. Drugs Today (Barc) 53: 521-530.
1311 McLeod S, Hackel, M., Badal, R., Shapiro, A., Mueller, J., Tommasi, R., and Miller, A. (2017) The 
1312 Antibacterial Activity of Cefpodoxime and the Novel beta-lactamase Inhibitor ETX1317 Against 
1313 Recent Clinical Isolates of beta-lactamase-producing Enterobacteriaceae. p.^pp. American Society 
1314 for Microbiology, New Orleans, Louisiana, USA.
1315 McLeod SM, Shapiro AB, Moussa SH, Johnstone M, McLaughlin RE, de Jonge BLM & Miller AA (2018) 
1316 Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel beta-
1317 Lactamase Inhibitor ETX2514 in Clinical Isolates of Acinetobacter baumannii. Antimicrob Agents 
1318 Chemother 62.
1319 Melchior NH & Keiding J (1991) In-vitro evaluation of ampicillin/brobactam and comparison with 
1320 other beta-lactam antibiotics. J Antimicrob Chemother 27: 29-40.
Page 95 of 123
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
45
1321 Mena A, Plasencia V, Garcia L, Hidalgo O, Ayestaran JI, Alberti S, Borrell N, Perez JL & Oliver A (2006) 
1322 Characterization of a large outbreak by CTX-M-1-producing Klebsiella pneumoniae and mechanisms 
1323 leading to in vivo carbapenem resistance development. J Clin Microbiol 44: 2831-2837.
1324 Mingeot-Leclercq MP, Tulkens PM, Denamur S, Vaara T & Vaara M (2012) Novel polymyxin 
1325 derivatives are less cytotoxic than polymyxin B to renal proximal tubular cells. Peptides 35: 248-252.
1326 Mohamed YF, Abou-Shleib HM, Khalil AM, El-Guink NM & El-Nakeeb MA (2016) Membrane 
1327 permeabilization of colistin toward pan-drug resistant Gram-negative isolates. Braz J Microbiol 47: 
1328 381-388.
1329 Mohanty S, Singhal R, Sood S, Dhawan B, Das BK & Kapil A (2005) Comparative in vitro activity of 
1330 beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria. Indian J Med Res 
1331 122: 425-428.
1332 Morinaka A, Tsutsumi Y, Yamada M, et al. (2015) OP0595, a new diazabicyclooctane: mode of action 
1333 as a serine beta-lactamase inhibitor, antibiotic and beta-lactam 'enhancer'. J Antimicrob Chemother 
1334 70: 2779-2786.
1335 Morinaka A, Tsutsumi Y, Yamada K, et al. (2016) In Vitro and In Vivo Activities of OP0595, a New 
1336 Diazabicyclooctane, against CTX-M-15-Positive Escherichia coli and KPC-Positive Klebsiella 
1337 pneumoniae. Antimicrob Agents Chemother 60: 3001-3006.
1338 Morinaka A, Tsutsumi Y, Yamada K, et al. (2017) In vitro and in vivo activities of the 
1339 diazabicyclooctane OP0595 against AmpC-derepressed Pseudomonas aeruginosa. J Antibiot (Tokyo) 
1340 70: 246-250.
1341 Mosley JF, 2nd, Smith LL, Parke CK, Brown JA, Wilson AL & Gibbs LV (2016) Ceftazidime-Avibactam 
1342 (Avycaz): For the Treatment of Complicated Intra-Abdominal and Urinary Tract Infections. P T 41: 
1343 479-483.
1344 Moya B, Barcelo IM, Bhagwat S, Patel M, Bou G, Papp-Wallace KM, Bonomo RA & Oliver A (2017) 
1345 Potent beta-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter 
1346 baumannii, Including Carbapenemase-Producing Clinical Isolates. Antimicrob Agents Chemother 61.
1347 Moya B, Barcelo IM, Bhagwat S, Patel M, Bou G, Papp-Wallace KM, Bonomo RA & Oliver A (2017) 
1348 WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "beta-Lactam 
1349 Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-beta-
1350 Lactamase-Producing High-Risk Clones. Antimicrob Agents Chemother 61.
1351 Munita JM & Arias CA (2016) Mechanisms of Antibiotic Resistance. Microbiol Spectr 4.
1352 Mushtaq S, Vickers A, Woodford N & Livermore DM (2017) WCK 4234, a novel diazabicyclooctane 
1353 potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class 
1354 A, C and D beta-lactamases. J Antimicrob Chemother 72: 1688-1695.
1355 Mushtaq S, Chaudhry, A., Adkin, R., Woodford, N., Benedict, N., Pypstra, R., Shapiro, S. (2014) In-
1356 vitro activity of diverse β-lactam/AAI101 combinations vs. multidrug-resistant Gram-negative clinical 
1357 strains, abstr P452. p.^pp. Barcelona, Spain.
1358 Nies DH (2003) Efflux-mediated heavy metal resistance in prokaryotes. FEMS Microbiol Rev 27: 313-
1359 339.
1360 Nikaido H (2009) Multidrug resistance in bacteria. Annu Rev Biochem 78: 119-146.
1361 Nordmann P, Girlich, D., Benedict, N., Pypstra, R., Shapiro, S. (2014) Characterization of β-lactamase 
1362 inhibition by AAI101. p.^pp. Barcelona, Spain.
1363 O’Donnell J, Chen, A., Tanudra, A., Mueller, J., Tommasi, R., Miller, A., Carter, N., McLeod, S., Comita-
1364 Prevoir, J., and Durand-Réville, T. (2017) Cefpodoxime proxetil/ETX0282: A novel oral β-lactam/β-
1365 lactamase inhibitor combination to treat the emerging threat of multi-drug resistant 
1366 Enterobacteriaceae. p.^pp. American Society for Microbiology, New Orleans, Louisiana, USA.
1367 O’Neill J (2014) Review on Antimicrobial Resistance. Antimicrobial Resistance: Tackling a Crisis for 
1368 the Health and Wealth of Nations. p.^pp.
1369 Ofek I, Cohen S, Rahmani R, Kabha K, Tamarkin D, Herzig Y & Rubinstein E (1994) Antibacterial 
1370 synergism of polymyxin B nonapeptide and hydrophobic antibiotics in experimental gram-negative 
1371 infections in mice. Antimicrob Agents Chemother 38: 374-377.
Page 96 of 123
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
46
1372 Oh SH, Lee, J. H., Han, H. W., Cho, Y. L., Oh, K. M., Kwak, J. H. (2018) Activity of Novel Siderophore 
1373 Cephalosporin GT-1 and ß-lactamase Inhibitor GT-055 Against Resistant K. pneumoniae in Time-Kill 
1374 and Murine Thigh Infection Studies. p.^pp. American Society for Microbiology, Atlanta, Georgia, 
1375 USA.
1376 Opperman TJ (2018) MBX-4191, A Novel Pyranopyridine RND Efflux Pump Inhibitor. p.^pp. American 
1377 Society for Microbiology, Atlanta, Georgia, USA.
1378 Opperman TJ, Kwasny SM, Kim HS, Nguyen ST, Houseweart C, D'Souza S, Walker GC, Peet NP, 
1379 Nikaido H & Bowlin TL (2014) Characterization of a novel pyranopyridine inhibitor of the AcrAB efflux 
1380 pump of Escherichia coli. Antimicrob Agents Chemother 58: 722-733.
1381 Palzkill T (2013) Metallo-beta-lactamase structure and function. Ann N Y Acad Sci 1277: 91-104.
1382 Papp-Wallace KM, Endimiani A, Taracila MA & Bonomo RA (2011) Carbapenems: past, present, and 
1383 future. Antimicrob Agents Chemother 55: 4943-4960.
1384 Papp-Wallace KM, Nguyen NQ, Jacobs MR, et al. (2018) Strategic Approaches to Overcome 
1385 Resistance against Gram-Negative Pathogens Using beta-Lactamase Inhibitors and beta-Lactam 
1386 Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and 
1387 WCK 4234. J Med Chem 61: 4067-4086.
1388 Papp-Wallace KM, Bethel, C. R., Barnes, M. D., Rutter, J. D., Taracila, M. A., Bajaksouzian, S., Jacobs, 
1389 M. R., Bonomo, R. A. (2017) AAI101, a Novel β-Lactamase Inhibitor: Microbiological and Enzymatic 
1390 Profiling p.^pp. San Diego, California, USA.
1391 Patel MV, Deshpande, P. K., Bhawasar, S., Bhagwat, S., Jafri, M. A., Mishra, A., Pavase, L., Gupta, S., 
1392 Kale, R., Joshi, S. (2013) Nitrogen containing compound 1,6-diazabicyclo[3,2,1]octan-7-one 
1393 derivatives and their use in the treatment of bacterial infections. p.^pp. Wockhardt Limited, India.
1394 Paterson DL & Bonomo RA (2005) Extended-spectrum beta-lactamases: a clinical update. Clin 
1395 Microbiol Rev 18: 657-686.
1396 Patil VJ, Tadiparthi, R., Birajdar, S. S., Dond, B. D., Shaikh, M. U., Dekhane, D. V., Pawar, M. J., 
1397 Bhagwat, S. S., Patel, M. V. (2016) WCK 4234: synthesis and structure-activity relationship (SAR) 
1398 identifying a novel β-lactamase inhibitor active against Acinetobacter expressing OXA-
1399 carbapenemases (Ab-Oxa). p.^pp. American Society for Microbiology, Boston, Massachusetts, USA.
1400 Payne DJ, Cramp R, Winstanley DJ & Knowles DJ (1994) Comparative activities of clavulanic acid, 
1401 sulbactam, and tazobactam against clinically important beta-lactamases. Antimicrob Agents 
1402 Chemother 38: 767-772.
1403 Pearson JP, Van Delden C & Iglewski BH (1999) Active efflux and diffusion are involved in transport of 
1404 Pseudomonas aeruginosa cell-to-cell signals. J Bacteriol 181: 1203-1210.
1405 Penwell WF, Shapiro AB, Giacobbe RA, et al. (2015) Molecular mechanisms of sulbactam 
1406 antibacterial activity and resistance determinants in Acinetobacter baumannii. Antimicrob Agents 
1407 Chemother 59: 1680-1689.
1408 Pfaller MA, Huband MD, Mendes RE, Flamm RK & Castanheira M (2018) In vitro activity of 
1409 meropenem-vaborbactam and characterization of carbapenem resistance mechanisms among 
1410 carbapenem-resistant Enterobacteriaceae from the 2015 meropenem-vaborbactam surveillance 
1411 program. Int J Antimicrob Agents.
1412 Philippidis A (2015) Roche Licenses Infectious Disease Candidate from Meiji, Fedora Vol. 2018 p.^pp. 
1413 Genetic Engineering and Biotechnology News.
1414 Phuong NL, Pinto, N. A., Vu, T. N., Cho, Y. L., Byun, J. H., D’Souza, R., Yong, D., and Lee, K. (2018) In 
1415 Vitro Activity of Novel Siderophore-cephalosporin, GT-1, and β-lactamase Inhibitor, GT-055, against 
1416 KPC- or OXA-type Carbapenemase- and ESBL- Producing E. coli, K. pneumoniae Clinical Isolates from 
1417 a Characterized MDR Panel. p.^pp. American Society for Microbiology, Atlanta, Georgia, USA.
1418 Piddock LJ (2006) Clinically relevant chromosomally encoded multidrug resistance efflux pumps in 
1419 bacteria. Clin Microbiol Rev 19: 382-402.
1420 Poole K (2007) Efflux pumps as antimicrobial resistance mechanisms. Ann Med 39: 162-176.
1421 Preskill J (2018) Quantum Computing in the NISQ era and beyond. p.^pp.
Page 97 of 123
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
47
1422 Preston RA, Mamikonyan G, DeGraff S, et al. (2019) Single-Center Evaluation of the 
1423 Pharmacokinetics of WCK 5222 (Cefepime-Zidebactam Combination) in Subjects with Renal 
1424 Impairment. Antimicrob Agents Chemother 63.
1425 Queenan AM & Bush K (2007) Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 20: 
1426 440-458.
1427 Radzishevsky IS, Rotem S, Bourdetsky D, Navon-Venezia S, Carmeli Y & Mor A (2007) Improved 
1428 antimicrobial peptides based on acyl-lysine oligomers. Nat Biotechnol 25: 657-659.
1429 Raetz CR & Whitfield C (2002) Lipopolysaccharide endotoxins. Annu Rev Biochem 71: 635-700.
1430 Rafailidis PI, Ioannidou EN & Falagas ME (2007) Ampicillin/sulbactam: current status in severe 
1431 bacterial infections. Drugs 67: 1829-1849.
1432 Ramaswamy VK, Cacciotto P, Malloci G, Ruggerone P & Vargiu AV (2016) Multidrug Efflux Pumps and 
1433 Their Inhibitors Characterized by Computational Modeling. Efflux-Mediated Antimicrobial Resistance 
1434 in Bacteria,(Z. LX, C. E & H. Z, eds.), p.^pp. Adis, Cham.
1435 Ramirez MS & Tolmasky ME (2010) Aminoglycoside modifying enzymes. Drug Resist Updat 13: 151-
1436 171.
1437 Ramos JL, Duque E, Gallegos MT, Godoy P, Ramos-Gonzalez MI, Rojas A, Teran W & Segura A (2002) 
1438 Mechanisms of solvent tolerance in gram-negative bacteria. Annu Rev Microbiol 56: 743-768.
1439 Rapoport M, Faccone D, Pasteran F, Ceriana P, Albornoz E, Petroni A, Group MCR & Corso A (2016) 
1440 First Description of mcr-1-Mediated Colistin Resistance in Human Infections Caused by Escherichia 
1441 coli in Latin America. Antimicrob Agents Chemother 60: 4412-4413.
1442 Reading C, Farmer T & Cole M (1983) The beta-lactamase stability of amoxycillin with the beta-
1443 lactamase inhibitor, clavulanic acid. J Antimicrob Chemother 11: 27-32.
1444 Rice LB (2008) Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no 
1445 ESKAPE. J Infect Dis 197: 1079-1081.
1446 Rodriguez-Martinez JM, Poirel L & Nordmann P (2009) Molecular epidemiology and mechanisms of 
1447 carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 53: 4783-4788.
1448 Rodvold KA, Gotfried MH, Isaacs RD, O'Donnell JP & Stone E (2018) Plasma and Intrapulmonary 
1449 Concentrations of ETX2514 and Sulbactam following Intravenous Administration of ETX2514SUL to 
1450 Healthy Adult Subjects. Antimicrob Agents Chemother 62.
1451 Rojano B, Caminero JA & Hayek M (2019) Curving Tuberculosis: Current Trends and Future Needs. 
1452 Ann Glob Health 85.
1453 Rojas LJ, Taracila MA, Papp-Wallace KM, Bethel CR, Caselli E, Romagnoli C, Winkler ML, Spellberg B, 
1454 Prati F & Bonomo RA (2016) Boronic Acid Transition State Inhibitors Active against KPC and Other 
1455 Class A beta-Lactamases: Structure-Activity Relationships as a Guide to Inhibitor Design. Antimicrob 
1456 Agents Chemother 60: 1751-1759.
1457 Ross S, Puig JR & Zaremba EA (1959) Colistin: some preliminary laboratory and clinical observations 
1458 in specific gastroenteritis in infants and children. Antibiot Annu 7: 89-100.
1459 Rubino CM, Bhavnani SM, Loutit JS, Lohse B, Dudley MN & Griffith DC (2018) Single-Dose 
1460 Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal 
1461 Impairment. Antimicrob Agents Chemother 62.
1462 Rubino CM, Bhavnani SM, Loutit JS, Morgan EE, White D, Dudley MN & Griffith DC (2018) Phase 1 
1463 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and 
1464 in Combination following Single and Multiple Doses in Healthy Adult Subjects. Antimicrob Agents 
1465 Chemother 62.
1466 Sabet M, Tarazi Z, Nolan T, Parkinson J, Rubio-Aparicio D, Lomovskaya O, Dudley MN & Griffith DC 
1467 (2018) Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing 
1468 Carbapenem-Resistant Enterobacteriaceae. Antimicrob Agents Chemother 62.
1469 Sabet M, Tarazi Z, Rubio-Aparicio D, Nolan TG, Parkinson J, Lomovskaya O, Dudley MN & Griffith DC 
1470 (2018) Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against 
1471 Carbapenem-Resistant Enterobacteriaceae in an In Vitro Hollow-Fiber Model. Antimicrob Agents 
1472 Chemother 62.
Page 98 of 123
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
48
1473 Sader HS, Castanheira M, Huband M, Jones RN & Flamm RK (2017) WCK 5222 (Cefepime-
1474 Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected 
1475 Worldwide in 2015. Antimicrob Agents Chemother 61.
1476 Sader HS, Rhomberg PR, Flamm RK, Jones RN & Castanheira M (2017) WCK 5222 
1477 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing 
1478 clinically relevant beta-lactamases. J Antimicrob Chemother 72: 1696-1703.
1479 Sader HS, Castanheira M, Mendes RE, Flamm RK, Farrell DJ & Jones RN (2015) Ceftazidime-avibactam 
1480 activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 
1481 and 2013. Antimicrob Agents Chemother 59: 3656-3659.
1482 Sader HS, Duncan, L. R., Thompson, J., Cho, Y. L., Biek, D., Flamm, R. K. (2018) Antimicrobial Activity 
1483 of the Novel Siderophore Cephalosporin GT-1 Tested Alone and Combined with the β-Lactamase 
1484 Inhibitor GT-055 against Molecularly Characterized Enterobacteriaceae Clinical Isolates. p.^pp. 
1485 American Society for Microbiology, Atlanta, Georgia, USA.
1486 Santos Costa S, Viveiros M, Rosato AE, Melo-Cristino J & Couto I (2015) Impact of efflux in the 
1487 development of multidrug resistance phenotypes in Staphylococcus aureus. BMC Microbiol 15: 232.
1488 Sarig H, Ohana D, Epand RF, Mor A & Epand RM (2011) Functional studies of cochleate assemblies of 
1489 an oligo-acyl-lysyl with lipid mixtures for combating bacterial multidrug resistance. FASEB J 25: 3336-
1490 3343.
1491 Schaechter M, Engleberg NC, DiRita VJ & Dermody T (2007) Schaechter's mechanisms of microbial 
1492 disease. Lippincott Williams & Wilkins, Philadelphia.
1493 Shapiro AB, Gao N, Jahic H, Carter NM, Chen A & Miller AA (2017) Reversibility of Covalent, Broad-
1494 Spectrum Serine beta-Lactamase Inhibition by the Diazabicyclooctenone ETX2514. ACS Infect Dis 3: 
1495 833-844.
1496 Shields RK, Chen L, Cheng S, et al. (2017) Emergence of Ceftazidime-Avibactam Resistance Due to 
1497 Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella 
1498 pneumoniae Infections. Antimicrob Agents Chemother 61.
1499 Shlaes DM (2013) New beta-lactam-beta-lactamase inhibitor combinations in clinical development. 
1500 Ann N Y Acad Sci 1277: 105-114.
1501 Silhavy TJ, Kahne D & Walker S (2010) The bacterial cell envelope. Cold Spring Harb Perspect Biol 2: 
1502 a000414.
1503 Simmaco M, Mignogna G, Canofeni S, Miele R, Mangoni ML & Barra D (1996) Temporins, 
1504 antimicrobial peptides from the European red frog Rana temporaria. Eur J Biochem 242: 788-792.
1505 Skov RL & Monnet DL (2016) Plasmid-mediated colistin resistance (mcr-1 gene): three months later, 
1506 the story unfolds. Euro Surveill 21: 30155.
1507 Smith HW & Huggins MB (1982) Successful treatment of experimental Escherichia coli infections in 
1508 mice using phage: its general superiority over antibiotics. J Gen Microbiol 128: 307-318.
1509 Somboro AM, Tiwari D, Bester LA, Parboosing R, Chonco L, Kruger HG, Arvidsson PI, Govender T, 
1510 Naicker T & Essack SY (2015) NOTA: a potent metallo-beta-lactamase inhibitor. J Antimicrob 
1511 Chemother 70: 1594-1596.
1512 Soothill JS (1992) Treatment of experimental infections of mice with bacteriophages. J Med 
1513 Microbiol 37: 258-261.
1514 Spyrakis F, Celenza G, Marcoccia F, Santucci M, Cross S, Bellio P, Cendron L, Perilli M & Tondi D 
1515 (2018) Structure-Based Virtual Screening for the Discovery of Novel Inhibitors of New Delhi Metallo-
1516 beta-lactamase-1. ACS Med Chem Lett 9: 45-50.
1517 Stachyra T, Pechereau MC, Bruneau JM, Claudon M, Frere JM, Miossec C, Coleman K & Black MT 
1518 (2010) Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam 
1519 beta-lactamase inhibitor. Antimicrob Agents Chemother 54: 5132-5138.
1520 Stansly PG, Shepherd RG & White HJ (1947) Polymyxin: a new chemotherapeutic agent. Bull Johns 
1521 Hopkins Hosp 81: 43-54.
1522 Stavri M, Piddock LJ & Gibbons S (2007) Bacterial efflux pump inhibitors from natural sources. J 
1523 Antimicrob Chemother 59: 1247-1260.
Page 99 of 123
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
49
1524 Stogios PJ, Spanogiannopoulos P, Evdokimova E, Egorova O, Shakya T, Todorovic N, Capretta A, 
1525 Wright GD & Savchenko A (2013) Structure-guided optimization of protein kinase inhibitors reverses 
1526 aminoglycoside antibiotic resistance. Biochem J 454: 191-200.
1527 Sukkar E (2013) Why are there so few antibiotics in the research and development pipeline? The 
1528 Pharmaceutical Journal 291: 520.
1529 Sulakvelidze A, Alavidze Z & Morris JG, Jr. (2001) Bacteriophage therapy. Antimicrob Agents 
1530 Chemother 45: 649-659.
1531 Sun D, Rubio-Aparicio D, Nelson K, Dudley MN & Lomovskaya O (2017) Meropenem-Vaborbactam 
1532 Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-
1533 Producing Klebsiella pneumoniae. Antimicrob Agents Chemother 61.
1534 Sun J, Deng Z & Yan A (2014) Bacterial multidrug efflux pumps: mechanisms, physiology and 
1535 pharmacological exploitations. Biochem Biophys Res Commun 453: 254-267.
1536 Sutherland R, Croydon EA & Rolinson GN (1970) Flucloxacillin, a new isoxazolyl penicillin, compared 
1537 with oxacillin, cloxacillin, and dicloxacillin. Br Med J 4: 455-460.
1538 Teillant A, Gandra S, Barter D, Morgan DJ & Laxminarayan R (2015) Potential burden of antibiotic 
1539 resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: a literature review 
1540 and modelling study. Lancet Infect Dis 15: 1429-1437.
1541 Thye D (2018) A Novel Siderophore Cephalosporin for MDR Gram-Negative Pathogens - as 
1542 Monotherapy and in Combination with GT-055, a Novel Beta-Lactamase Inhibitor. p.^pp. American 
1543 Society for Microbiology, Atlanta, Georgia, USA.
1544 Tilvawala R & Pratt RF (2013) Kinetics of action of a two-stage pro-inhibitor of serine beta-
1545 lactamases. Biochemistry 52: 7060-7070.
1546 Torres IM, Bento EB, Almeida Lda C, de Sa LZ & Lima EM (2012) Preparation, characterization and in 
1547 vitro antimicrobial activity of liposomal ceftazidime and cefepime against Pseudomonas aeruginosa 
1548 strains. Braz J Microbiol 43: 984-992.
1549 Tyrrell JM, Wali, M., Daigle, D. M., Aboklaish, A. F., Kurepina, N., Kreiswirth, B., Walsh, T. R., Pevear, 
1550 D. C., and Xerri, L. (2018) Susceptibility to cefepime / VNRX-5133 in 298 carbapenem-resistant 
1551 Enterobacteriaceae producing serine- and metallo-β-lactamases. p.^pp. Madrid, Spain.
1552 Vaara M (1988) Analytical and preparative high-performance liquid chromatography of the papain-
1553 cleaved derivative of polymyxin B. J Chromatogr 441: 423-430.
1554 Vaara M (1992) Agents that increase the permeability of the outer membrane. Microbiol Rev 56: 
1555 395-411.
1556 Vaara M & Vaara T (1983) Sensitization of Gram-negative bacteria to antibiotics and complement by 
1557 a nontoxic oligopeptide. Nature 303: 526-528.
1558 Vaara M & Vaara T (2009) SHORT FATTY ACID TAIL POLYMYXIN DERIVATIVES AND USES THEREOF   
1559 p.^pp. Northern Antibiotics, Finland.
1560 Vaara M, Fox J, Loidl G, Siikanen O, Apajalahti J, Hansen F, Frimodt-Moller N, Nagai J, Takano M & 
1561 Vaara T (2008) Novel polymyxin derivatives carrying only three positive charges are effective 
1562 antibacterial agents. Antimicrob Agents Chemother 52: 3229-3236.
1563 Vaara M, Siikanen O, Apajalahti J, Fox J, Frimodt-Moller N, He H, Poudyal A, Li J, Nation RL & Vaara T 
1564 (2010) A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive 
1565 charges has strong synergism with agents excluded by the intact outer membrane. Antimicrob 
1566 Agents Chemother 54: 3341-3346.
1567 Van Bambeke F, Michot JM & Tulkens PM (2003) Antibiotic efflux pumps in eukaryotic cells: 
1568 occurrence and impact on antibiotic cellular pharmacokinetics, pharmacodynamics and 
1569 toxicodynamics. J Antimicrob Chemother 51: 1067-1077.
1570 Van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA & Laxminarayan R (2014) 
1571 Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. 
1572 Lancet Infect Dis 14: 742-750.
1573 Van Dyk TK, Templeton LJ, Cantera KA, Sharpe PL & Sariaslani FS (2004) Characterization of the 
1574 Escherichia coli AaeAB efflux pump: a metabolic relief valve? J Bacteriol 186: 7196-7204.
Page 100 of 123
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
50
1575 Vargiu AV, Ruggerone P, Opperman TJ, Nguyen ST & Nikaido H (2014) Molecular mechanism of 
1576 MBX2319 inhibition of Escherichia coli AcrB multidrug efflux pump and comparison with other 
1577 inhibitors. Antimicrob Agents Chemother 58: 6224-6234.
1578 Ventola CL (2015) The antibiotic resistance crisis: part 1: causes and threats. P T 40: 277-283.
1579 Viljanen P & Vaara M (1984) Susceptibility of gram-negative bacteria to polymyxin B nonapeptide. 
1580 Antimicrob Agents Chemother 25: 701-705.
1581 Wang R, Lai TP, Gao P, Zhang H, Ho PL, Woo PC, Ma G, Kao RY, Li H & Sun H (2018) Bismuth 
1582 antimicrobial drugs serve as broad-spectrum metallo-beta-lactamase inhibitors. Nat Commun 9: 439.
1583 Weiss WJ, Pulse ME, Nguyen P, Peterson K, Silva J, Simecka JW, Valtierra D, Sabet M & Griffith DC 
1584 (2018) Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a 
1585 Murine Model of Pyelonephritis. Antimicrob Agents Chemother 62.
1586 Weiss WJ, Pulse, M. E., Nguyen, P., Valtierra, D., Peterson, K., Carter, K., Pevear, D. C., and Burns, C. 
1587 J. (2018) Efficacy of Cefepime Combined with VNRX-5133, A Novel Broad-Spectrum β-Lactamase 
1588 Inhibitor, against A Cephalosporin-Resistant Esbl E. coli in A Murine Uti Model. p.^pp. American 
1589 Society for Microbiology, Atlanta, Georgia, USA.
1590 Weiss WJ, Pulse, M. E., Nguyen, P., Valtierra, D., Peterson, K., Carter, K., Pevear, D. C., Burns, C. J., 
1591 and Xerri, L. (2018) Efficacy of cefepime / VNRX-5133, a novel β-lactamase inhibitor, against 
1592 cephalosporin-resistant, ESBL-producing K. pneumoniae in a murine lung-infection model. p.^pp. 
1593 Madrid, Spain.
1594 Weiss WJ, Pulse, M. E., Nguyen, P., Valtierra, D., Pevear, D. C., Burns, C. J., and Xerri, L. (2018) 
1595 Efficacy of cefepime / VNRX-5133, a novel broad-spectrum β-lactamase inhibitor (BS-BLI), in a 
1596 murine bacteremia infection model with carbapenem-resistant Enterobacteriaceae (CREs). p.^pp. 
1597 Madrid, Spain.
1598 Wenzel RP (1992) Preoperative Antibiotic-Prophylaxis. New Engl J Med 326: 337-339.
1599 Wiegand I, Hilpert K & Hancock RE (2008) Agar and broth dilution methods to determine the minimal 
1600 inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc 3: 163-175.
1601 Wilke MS, Lovering AL & Strynadka NC (2005) Beta-lactam antibiotic resistance: a current structural 
1602 perspective. Curr Opin Microbiol 8: 525-533.
1603 Williams JW & Northrop DB (1979) Synthesis of a tight-binding, multisubstrate analog inhibitor of 
1604 gentamicin acetyltransferase I. J Antibiot (Tokyo) 32: 1147-1154.
1605 Wise R, O'Sullivan N, Johnson J & Andrews JM (1992) Pharmacokinetics and tissue penetration of 
1606 ampicillin and brobactam following oral administration of 2085P. Antimicrob Agents Chemother 36: 
1607 1002-1004.
1608 Wommer S, Rival S, Heinz U, Galleni M, Frere JM, Franceschini N, Amicosante G, Rasmussen B, Bauer 
1609 R & Adolph HW (2002) Substrate-activated zinc binding of metallo-beta -lactamases: physiological 
1610 importance of mononuclear enzymes. J Biol Chem 277: 24142-24147.
1611 Wood TK, Knabel SJ & Kwan BW (2013) Bacterial persister cell formation and dormancy. Appl Environ 
1612 Microbiol 79: 7116-7121.
1613 Wright AJ (1999) The penicillins. Mayo Clin Proc 74: 290-307.
1614 Wright GD (2005) Bacterial resistance to antibiotics: enzymatic degradation and modification. Adv 
1615 Drug Deliv Rev 57: 1451-1470.
1616 Wright GD (2016) Antibiotic Adjuvants: Rescuing Antibiotics from Resistance. Trends Microbiol.
1617 Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et al. (2018) Effect and Safety of Meropenem-
1618 Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant 
1619 Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial. Infect Dis Ther 7: 439-455.
1620 Yamada K, Yanagihara K, Kaku N, et al. (2013) In vivo efficacy of biapenem with ME1071, a novel 
1621 metallo-beta-lactamase (MBL) inhibitor, in a murine model mimicking ventilator-associated 
1622 pneumonia caused by MBL-producing Pseudomonas aeruginosa. Int J Antimicrob Agents 42: 238-
1623 243.
1624 Zabawa TP, Pucci MJ, Parr TR, Jr. & Lister T (2016) Treatment of Gram-negative bacterial infections 
1625 by potentiation of antibiotics. Curr Opin Microbiol 33: 7-12.
Page 101 of 123
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
51
1626 Zhanel GG, Lawrence CK, Adam H, et al. (2018) Imipenem-Relebactam and Meropenem-
1627 Vaborbactam: Two Novel Carbapenem-beta-Lactamase Inhibitor Combinations. Drugs 78: 65-98.
1628 Zhang E, Wang MM, Huang SC, Xu SM, Cui DY, Bo YL, Bai PY, Hua YG, Xiao CL & Qin S (2018) NOTA 
1629 analogue: A first dithiocarbamate inhibitor of metallo-beta-lactamases. Bioorg Med Chem Lett 28: 
1630 214-221.
1631 Zumbrun SD, Halasohoris, S. A., Lemmon, M. M., Desai, P., Miller, L., Int Veldt, S., Huang, Z., Hannah, 
1632 B., Biek, D., and Panchal, R. G. (2018) GT-1, A Novel Siderophore Cephalosporin, with Potent Activity 
1633 against Select Biothreat Pathogens Either Alone Or in Combination with A Beta-Lactamase Inhibitor 
1634 (GT-055). p.^pp. American Society for Microbiology, Atlanta, Georgia, USA.
1635 Zurawski DV, Reinhart AA, Alamneh YA, Pucci MJ, Si Y, Abu-Taleb R, Shearer JP, Demons ST, Tyner SD 
1636 & Lister T (2017) SPR741, an Antibiotic Adjuvant, Potentiates the In Vitro and In Vivo Activity of 
1637 Rifampin against Clinically Relevant Extensively Drug-Resistant Acinetobacter baumannii. Antimicrob 
1638 Agents Chemother 61.
1639
Page 102 of 123
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Room FWB 5.80
Franklin Wilkins Building
150 Stamford Street
London SE1 9NH
Telephone 020 7848 1891
Fax 020 7848 4781
Faculty of Life Sciences & 
Medicine
at Guy’s, King’s College
and St Thomas’ Hospitals
School of Cancer & Pharmaceutical 
Science
Dr Khondaker Miraz Rahman
Reader in Medicinal Chemistry
Re:  Antibiotic Resistance Breakers: Current Approaches and Future Directions
Mark Laws, Ali Shaaban and Khondaker Miraz Rahman
Manuscript ID: FEMSRE-19-02-0007
Response to the reviewers’ comments (Original comments in black and our response in blue)
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Comments to the Author
This review explores the area of antibiotic resistance breakers (ARBs). Current ARBs are discussed 
including enzyme inhibitors, particularly beta-lactamase inhibitors, membrane permeabilizers, and 
efflux pump inhibitors.
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1. Lines 111-112, it states that high level resistance is rarely caused by single mutations. This is 
not true as there are several examples of single step, high level resistant mutants, particularly when 
a single target is involved.
Our response: We agree with the comment made by the reviewer. Although this is not true for all 
antibiotic classes, there are indeed several examples in the literature involving beta lactamase 
inhibitors in which a single mutation has been associated with high level resistance. We have 
therefore deleted the sentence from the review to avoid confusion. 
2. In regard to bacteria in biofilms, their dormant state where they are not actively growing also 
contributes to their resisting killing by antibiotics.
Our response: We thank the reviewer for his/her comments. We agree with the comment and have 
added the following sentence and two relevant references in the revised manuscript. 
“The bacterial population within the biofilm can also enter into a dormant state where they are not 
actively growing, and this can also contribute to antibiotic resistance(Gilbert et al., 1990, Wood et al., 
2013).”
3. Line 178 should state “aminoglycoside-modifying enzyme inhibitors”.
Our response: We have changed the sentence in the revised manuscript and added “inhibitors” after 
“aminoglycoside-modifying enzyme”. 
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5. Lines 346-347, it is preferable to state “appears to be in development” versus “appears to be 
being developed”.
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6. Lines 890-891, BLI similarity in structure to beta-lactam antibiotics does not necessarily mean 
that their PK profiles should be similar.
Our response: Structurally similar compounds typically have similar pharmacokinetic profiles. 
Although there are exceptions, there is significant support for this in the literature. More 
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lactam inhibitors (Please see references 1 & 2 below). We acknowledge that compounds with similar 
structures do not always give similar pharmacokinetic profiles. However, we think the statement is 
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address the comment. 
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Bacterial Resistance Mechanisms to Antibiotics. 1) Increased drug efflux; 2) Decreased drug uptake; 3) Drug 
modification/destruction; 4) Target modification (Munita & Arias, 2016). 
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. Classic β-Lactamase Inhibitors. Structures of clavulanic acid (top), sulbactam (middle left), tazobactam 
(middle right), brobactam (bottom left) and AAI101 (bottom right) (English et al., 1978, Reading et al., 
1983, Aronoff et al., 1984, Wise et al., 1992, Mushtaq, 2014, Nordmann, 2014). 
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The Diazabicyclooctanes (DABCOs). General structure of DABCOs (left) and structure of ETX2514 (right) 
(Mangion et al., 2011, Durand-Reville et al., 2017). 
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The Boronic Acid Transition State Inhibitors (BATSIs). Structure of vaborbactam (left) and VNRX-5133 
(right) (Hecker et al., 2015, Docquier, 2018). 
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The Polymyxins. General structure of the polymyxins (Velkov et al., 2010). 
56x49mm (300 x 300 DPI) 
Page 110 of 123
ScholarOne Support 1-434/964-4100
FEMS Microbiology Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Figure 6. Efflux Substrate Competition. Competition for pump binding between discrete efflux pump inhibitor 
(EPI) and antibiotic molecules. 
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Figure 1. Bacterial Resistance Mechanisms to Antibiotics. 1) Increased drug efflux; 2) Decreased 
drug uptake; 3) Drug modification/destruction; 4) Target modification (Munita & Arias, 2016).
Figure 2. Classic β-Lactamase Inhibitors. Structures of clavulanic acid (top), sulbactam (middle left), 
tazobactam (middle right), brobactam (bottom left) and AAI101 (bottom right) (English et al., 1978, 
Reading et al., 1983, Aronoff et al., 1984, Wise et al., 1992, Mushtaq, 2014, Nordmann, 2014).
Figure 3. The Diazabicyclooctanes (DABCOs). General structure of DABCOs (left) and structure of 
ETX2514 (right) (Mangion et al., 2011, Durand-Reville et al., 2017).
Figure 4. The Boronic Acid Transition State Inhibitors (BATSIs). Structure of vaborbactam (left) and 
VNRX-5133 (right) (Hecker et al., 2015, Docquier, 2018).
Figure 5. The Polymyxins. General structure of the polymyxins (Velkov et al., 2010).
Figure 6. Efflux Substrate Competition. Competition for pump binding between discrete efflux pump 
inhibitor (EPI) and antibiotic molecules.
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Table 1.
Structures of DABCOs currently in clinical use/in development (Mangion et al., 2011, Maiti, 2013, 
Garber, 2015, Patil, 2016, AdisInsight, 2017, Bush & Page, 2017, Papp-Wallace et al., 2018).
Name R group Name R group
Bicyclic urea core H Zidebactam
HN
H
N
OO
N
H
Avibactam
H2N
O
WCK 5153
HN
H
N
OOHN
Relebactam
H
N
O
HN WCK 4234 N
Nacubactam
H2N
O
H
N
O
GT-055
NO
H3N
NH2
.TFA
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Table 2.
Structures of the polymyxins and their derivatives (Vaara, 1988, Vaara et al., 2010, Velkov et al., 
2010).
Name R1 group R2 group
Polymyxin B1 HN
O
N
H
H
N
O
OH
O
NH2
N
H
O
NH2
Ph
Polymyxin B2 HN
O
N
H
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H
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H
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H
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iPr
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H
H
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OH
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Table 3.
Major classes of EPIs investigated to date.
EPI Class Biological Activity Profile Structure
Natural Sources
Catechin gallates Obtained from green tea extracts, catechin gallates have been shown to reverse β-lactam resistance in MRSA, 
with epicatechin gallate more effective than epigallocatechin gallate. The former managed to reduce the MIC 
of oxacillin from 64-512 μg mL-1 to ≤0.5-1 μg mL-1 in three different isolates (Stapleton et al., 2004). When 
incorporated at a concentration of 20 μg mL-1, both were able to cause a 4-fold decrease in the MIC of 
norfloxacin in isolates of S. aureus and S. epidermis. Both compounds were found to possess a weak 
inhibitory action towards the NorA transporter, with epicatechin gallate being the more potent of the two 
(Gibbons et al., 2004). Epigallocatechin gallate also reversed tetracycline resistance in Tet(K)-expressing S. 
aureus and S. epidermis strains (Sudano Roccaro et al., 2004).
O
O
O
OH
OH
OH
OH
OH
OH
HO
R
R = H ; Epicatechin gallate
R = OH ; Epigallocatechin gallate
Abietane diterpines Isolated from the herb Rosmarinus officinalis, carnosic acid and carnosol act as potentiators of erythromycin 
and tetracycline against S. aureus strains containing Msr(A) and Tet(k) pumps. At concentrations of 10 µg 
mL-1, both compounds achieved 2- and 4-fold reductions in the MIC of tetracycline, respectively. Carnosic 
acid showed synergism with erythromycin, causing an 8-fold reduction in its MIC (Oluwatuyi et al., 2004).
OH OH
HO HO
HO2C
H
O
O
H
    Carnosic acid           Carnosol
Methoxylated 
flavones and 
isoflavones
Baicalein, isolated from the leaves of Thymus vulgaris, displays weak antibacterial activity alone (MIC 100 
µg mL-1) but can reduce the MICs of tetracycline and some β-lactams, including ampicillin and oxacillin, 
against certain MRSA isolates (Fujita et al., 2005). The flavones have shown activity against Gram-positive 
bacteria, but few reports have been made on their interaction with Gram-negative bacteria (Mahmood et al., 
2016).
O
OOH
HO
HO
Baicalein
Microbial 
fermentation products
Compounds EA-371α and EA-371δ were originally isolated from Streptomyces fermentation extracts. At 
0.625 µg mL-1, both compounds caused a 4-fold decrease in the MIC of levofloxacin against a strain of P. 
aeruginosa overexpressing the MexAB-OprM efflux system (Lee et al., 2001).
 
X
Y
O OH
HO
OHOOH
O
S
HO
HO OH
EA-371α ; X-Y = CH-CH
EA-371δ ; X-Y = C=C
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EPI Class Biological Activity Profile Structure
Hetereocyclic 
macrocycles
Porphyrin pheophorbide A, extracted from Berberis spp., can sensitize S. aureus to berberine, also extracted 
from the same plant, and works against the NorA pump. However, several issues including potential toxicity 
have limited clinical development of this compound and any potential derivatives (Zechini & Versace, 2009). N HN
NNH
O
O
HO
O
O
Pheophorbide A
Homoisoflavonoids Bonducellin, a homoisoflavonoid purified from the roots of Caesalpinia digyna, is another compound that has 
shown potential for use as an EPI. At a concentration of 62.5 µg mL-1, bonducellin showed synergistic activity 
with ethidium bromide against drug-resistant Mycobacterium smegmatis, decreasing its MIC 8-fold (Roy et 
al., 2013).
OHO
O
O
Bonducellin
Flavolignans The flavolignan 5’-methoxyhydnocarpin, extracted from Berberis spp., has been identified as an inhibitor of 
the NorA pump and shows synergism with the fluoroquinolones. Addition of 5’-methoxyhydnocarpin at 10 µg 
mL-1 reduced the MIC of norfloxacin against a wild-type S. aureus strain by 4-fold, from 1 µg mL-1 to 0.25 µg 
mL-1 (Stermitz et al., 2000).
OHO
OH O
O
O
O
OH
OH
O
5’-methoxyhydnocarpin
Alkaloids Reserpine, an indole plant alkaloid extracted from the roots of Rauvolfia serpentina and Rauvolfia vomitoria, 
has been shown to be effective in inhibiting the highly homologous (Kaatz et al., 1993) NorA and Bmr efflux 
pumps in S. aureus and Bacillus subtilis, respectively, although Neyfakh et al. reported that 2-4-fold greater 
concentrations of reserpine were required to achieve the same extent of inhibition for the former compared to 
the latter pump (Neyfakh et al., 1993). The primary issue with reserpine, in common with many other EPIs, is 
its toxicity to mammalian cells. Reserpine has been observed to cause central nervous system disturbances 
(Pfeifer et al., 1976), limiting its potential for use as an ARB in the clinic. Other alkaloids shown to have EPI 
character include piperine, obtained from Piper nigrum and Piper longum (Khan et al., 2006), and berberine, 
found in a variety of plants including Berberis spp. (Aghayan et al., 2017). Piperine has been demonstrated to 
restore ciprofloxacin susceptibility in certain S. aureus strains, causing a 4-fold MIC reduction when used at a 
concentration of 50 µg mL-1 (Khan et al., 2006). Su and Wang found berberine to potentiate the activity of 
imipenem in vitro against P. aeruginosa through inhibiting the tripartite MexXY-OprM efflux pump (Su & 
Wang, 2018).
N
H
O
N
H
H
H
O
O
O
O
O
O
O
O
Reserpine
N
O
O
O
Piperine
Acyclic sesquiterpene 
alcohols
Farnesol, an acyclic sesquiterpene alcohol found as a metabolite in both plants and animals, was investigated 
by Jin and co-workers due to previous reports that it was capable of potentiating antimicrobial agents against 
strains of both S. aureus and E. coli. They demonstrated that farnesol is both capable of potentiating the action 
of ethidium bromide in Mycobacterium smegmatis through blocking its efflux and possesses greater intrinsic 
activity (64 µg mL-1) towards M. smegmatis than some other EPIs (reserpine 256 µg mL-1; verapamil 300 µg 
mL-1) (Jin et al., 2010).
OH
Farnesol
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Synthetic Sources
Peptidomimetics Arguably the most widely studied, PAβN is a broad-spectrum EPI capable of combatting fluoroquinolone 
resistance in P. aeruginosa. A C-terminal amide dipeptide, Lomovskaya and co-workers showed that at 40 µg 
mL-1 PAβN caused an 8-fold decrease in the MIC of levofloxacin against wild type P. aeruginosa strain 
PAM1020, while a 64-fold reduction was achieved in three strains overexpressing the MexAB-OprM tripartite 
efflux system (Lomovskaya et al., 2001). However, the cytotoxic nature of this compound led Lomovskaya 
and colleagues at Microcide Pharmaceuticals, Inc. to develop improved analogs between 1995 and 1998, 
culminating in MC-004124, an EPI with minimised cytotoxicity and acute toxicity and lower serum free drug 
clearance (Lomovskaya, 2018). Recent computational work conducted by Jamshidi et al. investigating the 
PAβN mode of inhibition in AdeB in A. baumannii revealed that it occupies the hydrophobic distal binding 
pocket to keep the binding monomer in the binding configuration, thus preventing the pump from progressing 
through the series of conformational changes required to achieve substrate efflux (Jamshidi et al., 2017).
H2N
O
H
N
N
H
NH
NH2
N
H
O
PAβN
Quinoline derivatives Quinoline compounds and their derivatives have been shown able to inhibit efflux of various antibiotics in 
MDR isolates of Klebsiella aerogenes (previously Enterobacter aerogenes). Compound 814 was reported to 
potentiate chloramphenicol 16-fold (512 µg mL-1 to 32 µg mL-1) and norfloxacin 8-fold (128 µg mL-1 to 16 µg 
mL-1) against the MDR strain EA3 (Mahamoud et al., 2006).
N
HN
N
O2N
Compound 814
Pyridoquinoline 
derivatives
Pyridoquinoline derivatives have been found to restore fluoroquinolone activity in K. aerogenes. Compound 
2a was demonstrated to potentiate both norfloxacin and ciprofloxacin 8-fold (128 µg mL-1 to 16 µg mL-1 and 
32 µg mL-1 to 4 µg mL-1, respectively) against the MDR strain EA3 (Chevalier et al., 2001).
N
S
N
S
NN
Compound 2a
Arylpiperazine 
derivatives
1-(1-Naphthylmethyl)-piperazine inhibits both the AcrAB and AcrEF efflux pumps in E. coli, increasing 
levofloxacin susceptibility (among other antibacterial agents) in E. coli clinical isolates. It also potentiated 
antimicrobial activity in several Enterobacteriaceae species, including K. pneumoniae, K. aerogenes, A. 
baumannii, and Vibrio cholera (Bohnert & Kern, 2005, Pannek et al., 2006, Schumacher et al., 2006, Bina et 
al., 2009). However, because of their serotonin agonist properties, compounds in this class are considered 
unsuitable for use as EPIs in humans (Zechini & Versace, 2009).
N
HN
1-(1-Naphthylmethyl)-piperazine
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Pyridopyrimidine 
derivatives
Developed by Daiichi Pharmaceutical Co., lead compound D13-9001 binds to and inhibits AcrB in E. coli and 
MexB in P. aeruginosa by preventing the conformational changes required for the pump to successfully 
extrude its bound substrates (Nakashima et al., 2013). No clinical evaluation of D13-9001 has been published 
yet (Mahmood et al., 2016).
N
N N
O
O
N
N
H
O
O
N N
N
H
NO
N
H
ON
S
D13-9001
Pyranopyridine 
derivatives
Compound MBX-2319, found through a high-throughput screen for small molecule potentiators of 
ciprofloxacin in E. coli, has shown activity against AcrAB in E. coli and increases the activity of drugs that 
are known substrates of AcrAB (Aron & Opperman, 2016). Although the compound does not show any 
bactericidal activity itself, it was found to cause 2-, 4- and 8-fold decreases in the MICs of ciprofloxacin, 
levofloxacin and piperacillin, respectively, when used at a concentration of 12.5 µM (Opperman et al., 2014, 
Vargiu et al., 2014). Based on structure-activity relationship analysis, a second generation of pyranopyridines 
was developed, including MBX-3796. Aron and Opperman report that MBX-3796 is ‘well tolerated at 10 mg 
kg-1 IV and [exhibits] a promising PK profile with an AUC ~10,000 and a CL < 1000 mL hr-1 kg-1’ (Aron & 
Opperman, 2016). As of 2018, the current lead compound in the series is MBX-4191, and is reported to have 
no intrinsic antibiotic activity (MIC ≥ 100 μM), potent potentiation of antibacterials in Enterobacteriaceae but 
less effect in non-fermenting Gram-negatives due to poor outer membrane penetration (Opperman, 2018).
O N
N
S
O
CN
N
H
N
H
N
NN
MBX-4191
Biricodar, timcodar Biricodar (formerly VX 710) and timcodar (formerly VX 853) were originally developed by Vertex 
Pharmaceuticals as anticancer agents, but have more recently found applications in prokaryotic efflux 
inhibition. Mullin et al. found both compounds capable of enhancing the activities of ethidium bromide, 
ciprofloxacin, tetracycline and gentamicin (amongst others) against S. aureus (Mullin et al., 2004). Further 
work by Grossman revealed that timcodar can synergise with the antituberculous drugs rifampicin, 
moxifloxacin, and bedaquiline against M. tuberculosis (Grossman et al., 2015).
O
O
O
O
O
N
O
O
N
N
Biricodar
Previously-Approved Drugs
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Trimethoprim and 
sertraline
The combination of trimethoprim, a dihydrofolate reductase inhibitor, and sertraline, a selective serotonin 
reuptake inhibitor (SSRI), is synergistic with three conventional antibiotics (levofloxacin, piperacillin and 
meropenem) against P. aeruginosa. As reported by Adamson et al., this synergism was not present in efflux-
deficient mutants of P. aeruginosa, indicating the efflux pump inhibitory nature of the two drugs together. 
Further in vivo evidence showed that trimethoprim and sertraline were of enhanced therapeutic benefit in P. 
aeruginosa-infected Galleria mellonella larvae when compared with antibiotic monotherapy (Adamson et al., 
2015).
N
N
NH2
H2N
O
O
O
Trimethoprim
Selective serotonin 
reuptake inhibitors
A subclass of SSRIs termed the phenylpiperidine SSRIs (p-SSRIs), including paroxetine, were first shown to 
be inhibitors of the S. aureus MFS-type NorA pump by Kaatz and co-workers, with a group of four P-SSRIs 
showing consistent potentiation of both ethidium bromide (2-8 fold at 20 µg mL-1) and norfloxacin (4-8 fold 
at 20 µg mL-1) (Kaatz et al., 2003). Subsequent structure-activity relationship work by Kaatz sought to 
rationalise the varying levels of potentiation achieved by the different P-SSRI analogs used (Wei et al., 2004). 
More recently, Nzakizwanayo and co-workers reported that the SSRI fluoxetine inhibits the Proteus mirabilis 
Bcr/CflA efflux system, determined via an ethidium bromide accumulation assay. Since this efflux system 
plays an important role in the formation of P. mirabilis biofilms, fluoxetine and related derivatives could 
prove useful as biofilm disrupting agents (Nzakizwanayo et al., 2017).
OO
O
H
N
F
Paroxetine
Proton pump 
inhibitors
Members of this class, including omeprazole and lansoprazole, have inhibitory activity towards NorA in S. 
aureus. Aeschlimann et al. reported 8-fold potentiation of both ciprofloxacin and norfloxacin by the 
aforementioned PPIs against the NorA-overexpressing S. aureus mutant strain SA 1199B (Aeschlimann et al., 
1999). N
H
N
O
S
O
N
O
Omeprazole
Calcium channel 
blockers
Verapamil, a drug used to treat cardiac disorders through inhibiting mammalian efflux transporters such as P-
glycoprotein, has also been shown to inhibit the ATP-dependent ABC-type prokaryotic efflux systems. It is 
capable of potentiating a number of antibiotics (including rifampicin, fluoroquinolones and macrolides) 
against strains of M. tuberculosis (Pule et al., 2016, Chien et al., 2017). The phenothiazines, including 
chlorpromazine and prochlorperazine, are marketed antipsychotic medications that have also been observed as 
a class to inhibit the MFS-type pump NorA in S. aureus (Kaatz et al., 2003).
O
O N
N
O
O
Verapamil
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